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Adverse drug reactions (ADRs) present a major concern for drug safety and are a ma-
jor obstacle in modern drug development. They account for about one-third of all
late-stage drug failures, and approximately 4% of all new chemical entities are with-
drawn from the market due to severe ADRs. Although off-target drug interactions are
considered to be the major causes of ADRs, the adverse reaction profile of a drug de-
pends on a wide range of factors such as specific features of drug chemical structures,
its ADME/PK properties, interactions with proteins, the metabolic machinery of the
cellular environment, and the presence of other diseases and drugs. Hence computa-
tional modeling for ADRs prediction is highly complex and challenging. We propose
a set of statistical learning models for effective ADRs prediction systematically from
multiple perspectives.
We first discuss available data sources for protein-chemical interactions and adverse
drug reactions, and how the data can be represented for effective modeling. We also
employ biological network analysis approaches for deeper understanding of the chem-
ical biological mechanisms underlying various ADRs. In addition, since protein-
chemical interactions are an important component for ADRs prediction, identifying
these interactions is a crucial step in both modern drug discovery and ADRs predic-
tion. The performance of common supervised learning methods for predicting protein-
chemical interactions have been largely limited by insufficient availability of binding
data for many proteins. We propose two multi-task learning (MTL) algorithms for
jointly predicting active compounds of multiple proteins, and our methods outperform
existing states of the art significantly. All these related data, methods, and preliminary
results are helpful for understanding the underlying mechanisms of ADRs and further
studies.
ADRs data are complex and noisy, and in many cases we do not fully understand the
molecular mechanisms of ADRs. Due to the noisy and heterogeneous data set avail-
able for some ADRs, we propose a sparse multi-view learning (MVL) algorithm for
predicting a specific ADR - drug-induced QT prolongation, a major life-threatening
adverse drug effect. It is crucial to predict the QT prolongation effect as early as
possible in drug development. MVL algorithms work very well when complex data
from diverse domains are involved and only limited labeled examples are available.
Unlike existing MVL methods that use !2-norm co-regularization to obtain a smooth
objective function, we propose an !1-norm co-regularized MVL algorithm for predict-
ing QT prolongation, reformulate the objective function, and obtain its gradient in the
analytic form. We optimize the decision functions on all views simultaneously and
achieve 3-4 fold higher computational speedup, comparing to previous !2-norm co-
regularized MVL methods that alternately optimizes one view with the other views
fixed until convergence. !1-norm co-regularization enforces sparsity in the learned
mapping functions and hence the results are expected to be more interpretable.
The proposed MVL method can only predict one ADR at a time. It would be ad-
vantageous to predict multiple ADRs jointly, especially when these ADRs are highly
related. Advanced modeling techniques should be investigated to better utilize ADR
data for more effective ADRs prediction. We study the quantitative relationship among
drug structures, drug-protein interaction profiles, and drug ADRs. We formalize the
modeling problem as a multi-view (drug structure data and drug-protein interaction
profile data) multi-task (one drug may cause multiple ADRs and each ADR is a task)
classification problem. We apply the co-regularized MVL on each ADR and use reg-
ularized MTL to increase the total sample size and improve model performance. Ex-
perimental studies on the ADR data set demonstrate the effectiveness of our MVMT
iv
algorithm. Cluster analysis and significant feature identification using the results of
our models reveal interesting hidden insight.
In summary, we use computational methods such as biological network analysis, multi-
task learning, multi-view learning, and inductive multi-view multi-task learning to
systematically investigate the modeling of various ADRs, and construct highly accu-
rate models for ADRs prediction. We also have significant contribution on proposing
novel supervised and semi-supervised learning algorithms, which con be applied to
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Adverse drug reactions (ADRs) are undesirable effects of drugs on human bodies occurring at
the proper drug doses for an appropriate indication. ADRs are a subset of more generally named
adverse drug events or side effects [Hammann et al., 2010], which have increasingly attracted broad
public concern on the danger to patients and major attention to the huge burden on national public
health care system in the past decades. An ADR is defined as serious in clinical studies if the
patient outcome is one or more of the following: death, life-threatening, hospitalization, disability,
congenital anomaly, and requiring intervention to prevent permanent impairment or damage [Med,
2010]. In general, each drug may have multiple adverse reactions, which may or may not be serious
ADRs.
Various studies have estimated that ADRs cause or contribute to a two-day increase in the
average length of hospitalization, and about 6.7% of all hospitalizations with a fatality rate of
0.32% [Eichelbaum et al., 2006, Lazarou et al., 1998], that is, ADRs affect over two million hos-
pitalized patients and cause about 100,000 deaths in U.S. annually. In addition, it is estimated
that over 350,000 ADRs occur in U.S. nursing homes each year [Gurwitz et al., 2000]. ADRs
are the fourth leading cause of death in U.S., following cancer and heart diseases, and cause more
deaths than pulmonary disease, diabetes, and AIDS. Other western countries show similar statis-
tics [van der Hooft et al., 2006,Leone et al., 2008]. Moreover, one out of five injuries or deaths per
1
year to hospitalized patients may be as a result of ADRs [Leape et al., 1991], and serious ADRs
account for 1.8-6.2% of all hospitalized cases at any age [Onder et al., 2002]. A two-fold greater
mean length of stay, cost and mortality has been reported for hospitalized patients experiencing an
ADR compared to a control group of patients without an ADR [Classen et al., 1997]. Consequen-
tially, in U.S. the total cost of drug-related morbidity and mortality is estimated to be $136 billion
annually [Johnson & Bootman, 1995], which is as much as the drug treatment itself [Eichelbaum
et al., 2006], and higher than that spent on cardiovascular or diabetic care [Johnson & Bootman,
1995].
Moreover, drug discovery and development is an expensive and lengthy process, for instance, a
successful drug generally costs $800 million and needs continuous investment and efforts for more
than 10 years [DiMasi et al., 2003]. Unexpected serious ADRs have been one of the major obsta-
cles in drug development and clinical applications, and hence a big nightmare to pharmaceutical
companies. They account for about one-third of all late-stage (phase 2 and 3 clinical trials) drug
failures [Kennedy, 1997], and approximately 4% of all new chemical entities are withdrawn from
the market due to serious ADRs [Moore et al., 2007]. For instance, the numbers of reported ADRs
and related deaths have increased both for about 2.6 times, and at least 34 drugs have been with-
drawn from the market during the period of 1998–2005 [Need et al., 2005]. Such late-stage failures
make clinical drugs unsafe for patients, and the cost associated with late-stage failures increases
exponentially as the development of a drug proceeds. Lasser et al. [Lasser et al., 2002] conducted
a detailed analysis of 548 new chemical entities approved during the period of 1975–1999, and
found that 56 drugs (10.2%) acquired a new black box warning or were withdrawn, of which 45
(8.2%) acquired one or more black box warnings, and 16 (2.9%) were withdrawn from the market
due to serious ADRs. Since 1993 seven drugs were approved, marketed and subsequently with-
drawn from the market, and over 1,000 deaths were reported to be associated with them [Lasser
et al., 2002]. DiMasi et al. [DiMasi, 2002] estimated that if the clinical success rate increases from
1/5 to 1/3, pharmaceutical companies can save $221 million on the drug development process and
$129 million for reducing 25% of the total development and regulatory review time.
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Therefore, it is of great importance to identify ADRs as early as possible in the drug discovery
and development pipeline to avoid further investing and even marketing drugs with serious ADRs.
However, the causes and molecular mechanisms underlying each ADR vary significantly. Drug
molecules are designed to bind to target proteins and change their bioactivities to achieve thera-
peutic effects, and hence drug targets and off-targets are involved into the generation of ADRs.
Some ADRs are also resulted from the interactions of a drug (or its metabolites) with other drugs
or cellular components which are important in normal cellular functions [Lin et al., 2008], in-
cluding the drug’s main therapeutic target, off-target proteins, nucleic acids, and etc. The adverse
reaction profile of a drug (i.e. the set of proteins that the drug binds to) depends not only on the
drug’s chemical structure and the ADME/PK properties, but also on the target protein structures,
the binding sites, the metabolic machinery of the cellular environment, the genetic makeup of the
cells, and etc.
In this thesis, we aim to establish a universally applicable and externally predictive ADRs mod-
eling framework incorporating ADR-related data from multiple diverse sources. The rest of this
thesis is organized as follows. We will discuss the background of modeling ADRs prediction as a
computational problem in Chapter 2 and review related work on ADRs prediction in Chapter 3. We
introduce the available data sources related to ADRs and a variety of feature extraction methods for
chemical compounds, and analyze data in PubChem with biological network approaches in Chap-
ter 4. Utilizing the protein-chemical interaction networks existing in PubChem, DrugBank and
other online databases, we propose novel network features for effectively predicting potential drug
targets in Chapter 5. In Chapter 6, we propose multi-task learning (MTL) approaches to jointly
predicts multiple interacting proteins for a given chemical simultaneously, which is important for
obtaining the interacting protein profiles for drugs.
We hypothesize that by integrating multiple sources of data related to ADRs such as drug struc-
tures and interacting protein profiles using advanced machine learning techniques, our proposed
multi-task and multi-view learning algorithms can significantly improve the performance of ADRs
prediction models, and provide critical clues for explaining causes of ADRs. In Chapter 7, we
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propose a sparse multi-view learning algorithm to effective predict a single ADR for a set of drugs,
and achieve much better model performance. Here MVL is an advanced semi-supervised learning
technique that learns multiple classifiers for the same data set with multiple views, one for a view.
We further develop a novel multi-view multi-task (MVMT) learning algorithm to learn multiple
related task jointly in Chapter 8, where each task has multi-view data. Outstanding performance
improvement is achieved using our MVMT methods on several benchmark data sets. In Chapter 9,
we apply the MVMT learning methods described in Chapter 8 to jointly predict multiple ADRs and





Although ADRs may not be preventable, they can be anticipated and predicted. Conventional ex-
perimental methods for ADRs identification first screen compounds in animal models, and conduct
a screening of preclinical drugs against a large number of enzymes and receptors in vitro, and are
hence expensive and time-consuming [Whitebread et al., 2005,Bass et al., 2004,MacDonald et al.,
2007]. Experimental methods can only enter the drug development pipeline at a relatively late
stage, not as early as possible. Computational approaches are hence indispensable, complemen-
tary tools to experimental methods with less time and expenses.
There are three knowledge sources of ADRs: toxicity studies on animal models, drug clinical
trials, and clinical reports in the ADR reporting systems. Animal testing and clinical trials are
widely used to evaluate ADRs during the pre-market phase of a drug. Results from animal models
may not be always generalizable to humans due to specie differences. Clinical trials are usually
conducted on a very limited population of patients (up to 2,000). Rare ADRs occurring less than 1
out of 100,000 patients often go undetected during clinical trials. Hence a continuous post-market
monitoring of ADRs is mandatory [Amery, 1999]. Once a drug is commercialized, Food and
Drug Administration (FDA) primarily uses a voluntary Adverse Event Report Systems (AERS),
combined with the literature to monitor ADRs. AERS is an information database designed to sup-
port the FDA’s post-marketing safety surveillance program for all approved drug and therapeutic
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biologic products. Voluntary ADR reporting systems, however, contain a large amount of ADR
information with errors, noisy, bias, and uncertainty (http://www.fda.gov/medwatch/). Con-
sequentially, it is highly challenging to employ theoretic and computational principles to enable
the effective ADR prediction for safe pharmaceutical care and achieve deeper understanding of the
underlying molecular mechanisms of ADRs.
Off-target drug interactions are generally considered to be the major causes of ADRs [Onder
et al., 2002]. However, the adverse reaction profile of a drug depends on a wide range of factors
such as specific features of drug chemical structures, its ADME/PK (Absorption, Distribution,
Metabolism, Excretion and Pharmacokinetics) properties, specific and non-specific interactions
with proteins, the metabolic machinery of the cellular environment, the genetic makeup of the
cells, the developmental stage of the hosts, and the presence of other diseases and drugs [Faulon
et al., 2008, Jacob & Vert, 2008, Onder et al., 2002]. The extraordinary complexity of modeling
and predicting ADRs presents serious challenges to existing data mining and machine learning
approaches.
Computationally predicting ADRs is a daunting routine. First, biological effects of compounds
are defined by their chemical structures, which are characterized by a large number of computed
chemical descriptors (features) for constructing QSAR models. Second, the data sets of drugs that
are reported to have a specific ADR are often rather small, but the additional data for related ADRs
may be available. The incorporation of data from related but distinct ADRs is attractive but needs
to be done with care. Third, the data for each ADR often come from multiple sources, and some of
which may be useless or even present contradictory information for ADRs prediction. Identifying
the right information sources is hence critical.
Several computational approaches have been proposed to predict adverse reactions of pre-
clinical and commercial drugs either using drug chemical structures [Yap et al., 2004, Li et al.,
2005, Bhavani et al., 2006] or using ligand-protein inverse docking by taking into account the tar-
get proteins and identifying non-therapeutic, alternative target proteins that are predicted to bind a
given drug [Rockey & Elcock, 2002,Ji et al., 2006,Xie et al., 2007]. These methods suffer from the
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limited availability of chemical data for drugs known to cause a particular ADRs, or lack of struc-
tural data on protein targets. Traditional in silico approaches employed for the prediction of chem-
ical effects in vivo typically either rely on the use of calculated physical properties or structural
features of chemicals (i.e., chemical descriptors) or attempt to relate the results of short term as-
says to predict the in vivo outcome of chemical exposure (in vitro - in vivo correlations). Although
both approaches have been somewhat successful, existing tools and models should be substantially
improved to enable their reliable application in ongoing drug discovery and drug safety regulation.
Recently chemogenomics approaches that integrate heterogeneous data from protein-chemical in-
teractions, chemical ADME properties, and gene-chemical interactions have attracted attention as
potential means of ADRs prediction [Faulon et al., 2008, Jacob & Vert, 2008]. So far there has
been no systematic effort to employ diverse informatics approaches toward rigorous prediction of
ADRs.
In this thesis we aim to systematically examine the relevant data and develop remedies for
effective modeling of ADRs. We posit that the ultimate success of computational ADRs models
depends on three major factors: (1) selection of the subset of ADRs for modeling and the quality of
primary data used for model development, (2) comprehensive development of a variety of learning
algorithms for modeling noisy and heterogeneous data to enable effective ADRs prediction, and
(3) rigorous evaluation of the learning algorithms on a wide range of data sets from a variety of
domains for continuous methodology improvements. Since the causes and molecular mechanisms
of different ADRs vary significantly, we need to refine a subset of ADRs with similar mechanisms
and develop appropriate models accordingly. Here we focus on those ADRs resulting from interac-
tions between drug chemicals and their desired targets or other related cellular proteins, and ADRs




In this chapter, we review computational methods in existing literature that have been utilized for
identifying ADRs. A straightforward way is to develop quantitative structure-activity relation-
ship (QSAR) models for an ADR using chemoinformatics, a rapidly emerging research discipline
that uniquely combines computational, statistical, and informational methodologies with key con-
cepts from chemistry. It is distinct from other computational modeling approaches in that it uses
unique representations of chemical structures in the form of multiple chemical descriptors, it has its
own metrics for defining chemical similarity and diversity in chemical compound libraries, and it
applies a wide array of statistical, data mining, and machine learning techniques to very large col-
lections of chemicals in order to establish robust relationships between chemical structures and its
physical or biological properties. Chemoinformatics tools have played a central role in the analysis
and interpretation of structure-property data collected by means of modern high throughput screen-
ing [Schneider et al., 2008]. QSAR models establish quantitative relationships between chemical
structures characterized by chemical descriptors and a target property, e.g., biological activity of
chemicals in specific biological assays. Validated and externally predictive models can be applied
to screen virtual chemical libraries to retrieve compounds with desired properties [Tropsha, 2010].
Some computational studies of ADRs have been mainly concerned with the prediction of in-
dividual adverse effects such as hERG inhibition [Nisius & Goller, 2009]. Chen et al. [Yap et al.,
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2004] applied support vector machine (SVM) classification to predict an important ADR - tor-
sade de pointes (TdP) from the linear salvation energy relationships (LSER) of compounds [Pip,
2010]. They extended their study to predict genotoxicity of chemical compounds using a set of
199 selected molecular descriptors [Li et al., 2005] with various statistical learning methods such
as SVM, probabilistic neural network (PNN), and k-nearest neighbors (KNN). Bhavani et al. [Bha-
vani et al., 2006] also conducted an SVM-based prediction of the TdP adverse effect with sophisti-
cated substructure-based feature extraction methods over a large diverse drug set, and yielded high
prediction accuracy. Overall, these approaches are ligand-based and predict ADRs only using drug
chemical structures. It is hard to generalize them to other ADRs due to lack of target information.
Approaches which take target structures into account have thereby been presented. One such
effort [Rockey & Elcock, 2002] employed a drug-docking algorithm named AutoDock to dis-
tinguish between the selectivity of different kinases for ADR virtual screening and showed very
high specificity and sensitivity. Ji et al. [Ji et al., 2006] utilized an inverse docking approach
(INVDOCK) to predict ADRs of 11 marketed anti-HIV drugs by searching for their interactions
with ADR-related proteins with 86-89% prediction accuracy achieved. Moreover, Xie and co-
workers [Xie et al., 2007] developed an integrated approach to studying protein-ligand interactions
on a structural proteome-wide scale by taking ADR-related information such as protein functional
sites, small molecule structures, and protein-ligand binding affinity profiles together into account.
They take a single drug molecule and look for how it might bind to as many of the proteins encoded
by the human proteome as possible in PDB with drug-target inverse docking. One limitation of
these structure-based approaches is that they usually employed a relatively small amount of data
due to the limited availability of the related data for each ADR. In addition, docking is an expen-
sive process due to the huge orientation space of proteins, and also not very accurate due to the
imperfection of current scoring functions.
Moreover, computational approaches for explaining ADRs at the molecular level have also
been proposed. Bender et al. [Bender et al., 2007] developed a systematic method to predict ADRs
and off-target effects using only drug chemical structures with a multi-category Bayes model. It is
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notable that features of the models are interpretable and back-projectable to chemical structures,
and hence new hypotheses linking targets and adverse effects can be proposed to rationally engi-
neer out those adverse effects. Scheiber et al. [Scheiber et al., 2009] analyzed a set of compounds
sharing a common toxicity and predicted the top 5 targets for each compound. By comparing the
pathways affected by toxic compounds with pathways modulated by nontoxic compounds, links
between toxicity and the pathways probably being responsible for it can be established.
There are some other methods that predict ADRs from a totally different perspective. Mushi-
roda et al. [Mushiroda et al., 2005] conducted genome-wide association studies to identify genetic
variations that might be associated with adverse cardiovascular events in 72 renal transplant recip-
ients using gene-based SNPs (single-nucleotide polymorphisms), and developed a scoring system
that was able to predict individual risks for cardiovascular toxicity. Lin et al. [Lin et al., 2008]
developed a tool which integrates drug and drug target knowledge bases, and built up drug-target
networks whose topological analysis can reveal drug interaction complexity for every ADR re-
port. This method can be used for the analysis and prediction on ADRs cases and also drug target
assessment in the early drug discovery process.
Although ligand-based and structure-based methods achieved good results for some ADR pre-
diction, a new trend is to integrate a variety of ADR-related information such as drug chemical
structures, protein functional sites, protein ligand binding profiles, cellular pathways, genotypic
information, and drug-target knowledge bases together, and more promising and generalized pre-
diction of ADRs has been obtained [Rockey & Elcock, 2002, Ji et al., 2006, Xie et al., 2007]. This
kind of strategy is somehow similar to the basic concepts in chemogenomics. Chemogenomics by
its definition is the investigation of classes of compounds (libraries) against families of function-
ally related proteins, and provides a systematic way of analyzing chemical-biological interactions
and discovering active and/or selective ligands for biological relevant targets. Here we borrow
this concept to describe that we utilize ADR-related information from both a drug and its targets
and off-targets to predict its ADR profile. The problem is then converted to how to measure the
similarity between two pairs of drugs and targets, e.g. (D1, P1) and (D2, P2), where D1, D2 are
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feature vectors from the two drugs, and P1, P2 are feature vectors from the two proteins. A typical
way is to measure the similarity of the two drugs and that of the two proteins separately using drug
kernels and protein kernels, say Kd(D1, D2), and Kp(P1, P2) respectively, and then multiply or sum
Kd and Kp to obtain the similarity between the two pairs of drugs and targets.
The existing methods that include target protein structures in ADR prediction usually focus on
one particular ADR class, and are often satisfied by some successful case studies. They lack a
global view of the ADR prediction problem, and their predictions of ADRs based on incompletely
included ADR-related information are hardly interpretable. Our understanding on ADR profiles
and the underlying molecular mechanisms is still ambiguous, and there is a critical gap between
the performance of current methods of ADR prediction and our goal of understanding ADRs more
deeply. Without understanding ADRs and the causing mechanisms at a molecular level, it is very
difficult to design more clinically safe drugs, guide lead compound identification and optimization
in rational drug development, and prevent potential ADRs from threatening the health of patients.
Therefore more sophisticated methods must be proposed to penetrate the gap of our knowledge on
ADRs.
Our proposed methods are novel since they integrate various ADR-related information using
chemogenomics concepts [Faulon et al., 2008, Jacob & Vert, 2008, Schneider et al., 2004] and
advanced data mining techniques to build statistical models for ADRs prediction at the molecular
level. We also realize that the ADRs associated with a drug are not independent, and some ADRs
may result from the same molecular mechanism. With complete implementation of our methods
using all these data mining techniques, we expect to draw a global picture of ADR prediction and
gain deeper understanding on the underlying molecular mechanisms of ADRs. Our sophisticated
experimental designs based on integrated ADR-related data will help understand molecular mech-
anisms of ADRs during the model construction process. By mining the associations of ADRs, we
might be able to identify the drug functional groups that cause the ADRs and hence guide lead
optimization. Finally, if some predicted side effects can be beneficial to patients, the purpose of
drug development can be changed to better fit the ADR profile of the drug.
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Chapter 4
Related Data, Methods and Preliminary
Results
In this chapter, we discuss how we collect and analyze data related to protein-chemical interactions
and adverse drug reactions, how to extract chemical features from raw data, how to select optimal
sets of descriptors to achieve best model performance, and eventually systematically analyze the
data in PubChem using biological network analysis. The basic concepts and methods in all these
works are indispensable and critical for further studies.
4.1 Related Data
Intense growth in drug development investment in the past decade has not yet produced significant
progress on the discovery of new drugs and the validation of new drug targets: the average number
of novel drugs entering the global market each year has remained roughly constant (approximately
26), along with only about 6-7 novel drug targets introduced annually [Adams & Brantner, 2006,
Yildirim et al., 2007, Cokol et al., 2005]. Moreover, the success rate of translating new drug
candidates into FDA-approved drugs significantly decreased [Kola & Landis, 2004], mainly due to
lack of efficacy or adverse drug reactions, each of which accounts for about 30% of late-stage drug
failures in clinical development [Kennedy, 1997]. The increasing rate of drug attrition challenges
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the traditional drug design paradigm and makes the current “one disease, one gene, one drug”
paradigm [Sams-Dodd, 2005] questionable.
One of the critical steps in drug discovery is the identification of chemical compounds with
desired and reproducible binding activity against a specific biomolecular target [Leach, 2001]. This
has become a significant challenge in the early stage of drug discovery, since any new drug must
not only produce the desired medical response to the disease, but should also minimize any side
effects [Wale et al., 2007]. Understanding and predicting the interactions between target proteins
and small molecules is hence of great importance in pharmaceutical industry. Our knowledge about
the interactions between chemical space and biological space, however, is very limited. Large
amounts of data related to the molecular and cellular activities of chemicals (including drugs)
were traditionally collected and analyzed only within the pharmaceutical industry. The landscape
of publicly available experimental data for pharmaceutical sciences has changed dramatically in
very recent years. The following are the three major sources for obtaining the data sets using
throughout this thesis.
4.1.1 PubChem
Under these circumstances, the National Health Institute (NIH) launched the Molecular Libraries
Initiative (MLI) in 2004 for identifying chemical probes to enhance the chemical biology un-
derstanding of therapeutically interesting genes and pathways [Austin et al., 2004]. The MLI
especially focused on genes in the “undruggable” part of human genome that has not been well
investigated in private sectors for identifying their functions and potential therapeutics. In 2005,
NIH launched the Molecular Libraries Probe Production Centers Network (MLPCN) project. The
goal of MLPCN is to profile chemicals at the molecular and cellular level such that molecules that
modulate biological networks could be identified [Austin et al., 2004]. All the results are being
made freely available to researchers in both public and private sectors via a web portal called Pub-
Chem (http://pubchem.ncbi.nlm.nih.gov/) [Zerhouni, 2003]. Tens of millions of chemicals
have been deposited into the PubChem Databases, but only a very small fraction (less than 2%)
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have their target protein information linked [Paolini et al., 2006].
PubChem is organized as a set of bioassays and is a good example of contemporary open ac-
cess databases. Each bioassay records screening results of a set of chemicals against a protein
or a cellular environment and each bioassay typically contains screening results of approximately
300,000 chemicals. The latest version of PubChem contains information for more than 50 mil-
lion chemicals, more than 20,000 bioassays, and links from chemicals to bioassay descriptions,
literature, and references. In our study to better predict drug ADRs, we combined data from
heterogeneous databases, primarily from PubChem but also including other chemical-protein in-
teraction databases. For each such database, we downloaded the data from the original databases
and removed possible duplicates by mapping chemicals to a unique id (PubChem Compound ID).
4.1.2 Literature and Other Online Databases
There are many other sources for obtaining protein-chemical binding data sets, including data used
in existing literature and other online databases such as DrugBank [Wishart et al., 2008, Wishart
et al., 2006] developed by colleagues. For instance, a widely used data set consisting of 279 Factor
Xa inhibitors and 156 inactives is taken from [Fontaine et al., 2005]. The following four data sets
include a number of inhibitors and approximately equal number of inactives to each of four target
proteins: 1) ACE; 2) COX2; 3) DHFR; and 4) THR [Sutherland et al., 2004]. Chemicals with IC50
< 10nM (pIC50 > 8 ) are defined as actives and > 1µM ( or pIC50 < 6) as inactives. Some other
data sets can also be extracted manually from the BindingDB database [Liu et al., 2007,Chen et al.,
2002a], which contains more than 450 target proteins and their binding chemicals. Two types of
binding activity parameters Ki and IC50 are provided, and both of them measure the inhibition
power of a chemical compound to a specific target protein [Chen et al., 2002b, Chen et al., 2001].
4.1.3 ADR Databases
For effective ADRs prediction, it is important to obtain a set of compounds that are known to cause
or contribute to some specific ADRs. Such data have very limited availability and the quality is
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somewhat unsatisfactory. For instance, a set of 142 compounds that are associated with drug-
induced QT prolongation effect are obtained from the home page of University of Arizona CERT
(http://www.azcert.org/) [Woosley, 2003] and the work by Ouillé et al. [Ouillé et al., 2011],
by merging these two data sets and removing redundant and/or inconsistent data samples. This
data set for the ADR of QT prolongation consists of 28 drug compounds labeled as “TdP risk”,
40 labeled as “possible TdP risk”, and 74 with other less reliable evidence of QT prolongation. A
much more complete data collection for adverse drug reactions has been developed and named the
Side Effect Resource (SIDER) database (http://sideeffects.embl.de/) [Kuhn et al., 2010].
SIDER is a public, computer-readable drug side effect resource with links between drugs and
ADRs, obtained from the Drug Labels provided by the FDA with text mining tools. We mapped
the drugs in SIDER to the DrugBank database [Knox et al., 2011,Wishart et al., 2008] via PubChem
Compound ID and removed those drugs with trivial or too simple structures, resulting in 797 drugs
associated with 1,362 ADR labels, which are represented by the COSTART controlled vocabulary.
Apparently, there are much more ADRs than the number of related drugs.
After obtaining the proper data sets, the learning process consists of three components: (i)
feature extraction and selection, (ii) predictive model selection, and (iii) model assessment. Feature
extraction methods are first used to compute various descriptors for each sample and convert it
to a vector, in which each component is a molecular descriptor, e.g. molecular weight, number
of hydrogen bonds, and etc. Second, with a feature vector and the corresponding class label as a
datum point, a set of such points are divided into three disjoint sets: training, validation, and testing
set. Model selection is needed to choose a model of optimal performance, which in practice means
selecting best learning parameters based on training and validation sets. Finally, we assess the




Computers can only recognize numbers. Chemical compounds must be converted into numbers in
some means. We call these numbers “chemical descriptors” (features) and those conversion means
“feature extraction methods”. The quality of models related to chemicals highly depends on the
performance of feature extraction methods. Chemical compounds have well-defined geometric
structures that can be easily converted into a connected, weighted, and undirected graph repre-
sentation. Each chemical has a number of atoms represented as vertices and a number of bonds
between atoms represented as edges in the molecular graph. Usually vertices are labeled with the
atom element type (atomic symbol or number, e.g. carbon atoms are labeled with C or 6), and
edges are labeled with the bond type (bond order or separate integers, use 1, 2, 3, 4 for single, dou-
ble, triple, and aromatic bonds, respectively). Edges in a graph are undirected because chemical
bonds have no associated directionality. Figure 4.1 shows an example of a chemical structure and
the corresponding graph representation.
Figure 4.1: A chemical structure and the corresponding graph representation.
There have been many methods that represent a chemical by a set of descriptors based on
frequency, molecular properties, topological and geometric substructures [Wale et al., 2007,Desh-
pande et al., 2005, Horvath et al., 2004], e.g. DRAGON descriptors [Dra, 2008], Daylight fin-
gerprints [Day, 2007], extended connectivity fingerprints (ECFP) [Rogers et al., 2005], Maccs
keys [Day, 2007], cyclic patterns and trees [Horvath et al., 2004], signature molecular descrip-
tors [Faulon et al., 2004], and frequent subgraph-based descriptors [Huan et al., 2003, Kuramochi
& Karypis, 2004]. All these feature extraction methods have been well developed and have demon-
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strated their effectiveness and success in many experiments and applications. They can also be
used to rapidly predict the physical, chemical, and biological properties of small molecules to
screen large database and identify suitable drug candidates [Agrafiotis et al., 2002, C. & Hopkins,
2004, Dobson, 2004].
4.2.1 Important Chemical Descriptors
Here we introduce some sets of commonly used chemical descriptors in detail, including the 20
sets of chemical descriptors provided by DRAGON 5.4 software [Dra, 2008], signature molecular
descriptors [Faulon et al., 2004], and frequent subgraph-based descriptors [Huan et al., 2003].
4.2.1.1 DRAGON Descriptors
DRAGON is a commercial software package developed by Milano Chemometrics and QSAR Re-
search Group [Dra, 2008] for computing chemical descriptors that can be used to evaluate molec-
ular structure-activity or property relationships (QSAR/P), as well as for high-throughput virtual
screening of chemical databases. Users need molecular structure files (in format SDF, SMILES,
etc.) as input, and are given formatted output files. Although DRAGON can work on 2D structures,
only much less descriptors can be calculated in this case. To make full use of DRAGON software,
3D optimized structures with all hydrogen atoms included should be used.
DRAGON 5.4, which we used in this work, computes 1664 molecular descriptors that are clas-
sified into 20 descriptor sets (or logical blocks): constitutional descriptors (DR01), topological
descriptors (DR02), walk and path counts (DR03), connectivity indices (DR04), information in-
dices (DR05), 2D autocorrelations (DR06), edge adjacency indices (DR07), Burden eigenvalues
(DR08), topological charge indices (DR09), eigenvalue-based indices (DR10), Randic molecular
profiles (DR11), geometrical descriptors (DR12), RDF descriptors (DR13), 3D-MoRSE descrip-
tors (DR14), WHIM descriptors (DR15), GETAWAY descriptors (DR16), functional group counts
(DR17), atom-centered fragments (DR18), charge descriptors (DR19), and molecular properties
(DR20). For more detailed introduction to DRAGON software and descriptors, refer to the help
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manual at its homepage (http://www.talete.mi.it/index.htm).
For instance, in a molecule with known molecular composition and atom connectivities, func-
tional group counts (DR17) are simply defined as the number of specific functional groups, and
atom-centered fragments (DR18) are defined as the number of specific atom types. For each atom-
centered fragment, its frequency occurring in the chemical structure is counted, and so far 120
atom-centered fragments defined by Ghose and Crippen [Viswanadhan et al., 1989] are included.
Finally, molecular properties (DR20) include a set of heterogeneous molecular descriptors describ-
ing physico-chemical and biological properties as well as some molecular characteristics, such as
hydrophilic factor, octane-water partition coefficient, molar refractivity, and etc. Since the charge
descriptors (DR19) are not available to many chemicals in our data sets, they will be excluded in
our study.
4.2.1.2 Signature Molecular Descriptors
Faulon et al. [Faulon et al., 2004] proposed an algorithm of signature molecular descriptors by
enumerating all molecular signatures with a given height from chemical structures. Specifically,
the signature of a molecule is a vector whose components are counts of the number of occurrences
of a particular atomic signature in the molecule. An atomic signature is a canonical representation
of the subgraph surrounding a particular atom. This subgraph includes all atoms and bonds up to a
predefined distance, called signature height, from a given atom. The optimal signature height for
chemicals is usually in range of 1-5.
To generate the signature lists of a chemical, a signature translation program named “transla-
tor” was downloaded from the homepage of Faulon et al. [Faulon et al., 2004]. Given a chemical
structure with a predefined signature height, a list of available signatures and their occurring fre-
quencies can be generated very efficiently. The running time for generating the signatures of most
chemical structures is some seconds. Given a data set with m chemicals, a list of available signa-
tures for each chemical are generated, and then all distinct signatures present in all chemicals (the
union of all signature lists, e.g. totally n signatures) can be obtained. Finally each chemical will be
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associated with an n-dimensional vector, in which each component is the number of occurrence of
each signature in the chemical.
4.2.1.3 Frequent Subgraph-based Descriptors
Frequent subgraph mining is widely studied since frequent subgraphs are believed to be related
to some structural or functional motifs in chemical and biological structures. Huan et al. [Huan
et al., 2003] developed a depth-first search algorithm for fast frequent subgraph mining (FFSM),
which identifies all connected subgraphs that occur more frequently than a predefined frequency
threshold ! called support threshold in a graph database. Each chemical compound is represented
by a binary vector with length equal to the number of all mined subgraphs, and then each sub-
graph is mapped into a specific vector index. If a chemical compound contains a subgraph, the
corresponding bit is set to one, and it is set to zero otherwise. [Huan et al., 2003, Smalter et al.,
2008]
By mining all frequent subgraphs from a chemical database, FFSM creates an n-dimensional
feature vector for each chemical, and hence provides frequent subgraph-based descriptors. A po-
tential disadvantage of this method is that it is unclear how to select a suitable value of the support
! for a given problem. A very high value will fail to discover important substructures whereas
a very low value will result in combinatorial explosion of frequent subgraphs. In Figure 4.2, a
graph database with 3 graphs is in the top row, and the returned frequent subgraphs are listed in
the bottom row with support = 2/3.
4.2.2 Comparison of Chemical Descriptors
It becomes a critical task to select high-quality feature extraction methods for computing chem-
ical descriptors. Since the performance of different chemical descriptors vary significantly, it is
necessary to do a case study on comparing the performance of different chemical descriptor sets.
There are two basic hypotheses for protein-chemical interaction prediction: 1) chemicals shar-
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Figure 4.2: A graph database with 3 graphs in upper row, and frequent subgraphs returned by FFSM
algorithm with support = 2/3 in lower row.
ing chemical similarity should also share target proteins; 2) targets sharing similar ligands should
share similar biological patterns, or binding sites. The classical paradigm here is as follows: if two
chemicals (proteins) are considered very similar to each other and we know one of them interacts
with a protein (chemical), we would expect that it is very likely for the other to interacting with
the same target (chemical) too. The key question of predicting if a chemical interacts with a given
protein is how to measure the distance (or similarity) between two chemicals. Since the quality of
chemical descriptors play a critical role in such predictions, it is of great importance to investigate
which chemical descriptors perform better than the others.
There have been many previous studies on comparing the prediction performance of chemi-
cal descriptors. Hert et al. [Hert et al., 2004] compared a range of different 2D fingerprints for
similarity-based virtual screening, and found that these fingerprints were notably more effective
than fingerprints based on a fragment dictionary. They concluded that the combination of these
fingerprints with data fusion based on similarity scores provides an effective virtual screening tool
in lead discovery. Gedeck et al. [Gedeck et al., 2006] analyzed how the quality of QSAR predic-
tions depended on the data sets and descriptor types, and they revealed that none of the descriptors
was best for all data sets. Although 2D fragment based descriptors usually performed better than
simpler descriptors based on augmented atom types, it was necessary to test them in each individual
case.
In addition, Karypis et al. [Wale et al., 2007] introduced some new descriptor sets such as graph
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fragment based descriptors (GF), and conducted a comprehensive comparison of the performance
of the newly developed descriptors with Daylight fingerprints [Day, 2007], extended connectivity
fingerprints (ECFP) [Rogers et al., 2005], Maccs keys [Day, 2007], cyclic patterns and trees [Hor-
vath et al., 2004] in the context of SVM-based chemical compound classification and ranked re-
trieval. The goal of his work was to analyze what properties of descriptor spaces were important on
providing effective representations for molecular graphs, and their experiments demonstrated that
descriptor class ECFP and GF consistently and statistically outperformed previously developed all
other descriptor sets.
However, some other widely used chemical descriptors were not covered in these previous stud-
ies. For instance, DRAGON 5.4 [Dra, 2008] provided a collection of 20 widely used classes of
chemical descriptors. Huan et al. [Huan et al., 2003] developed a fast frequent subgraph min-
ing (FFSM) algorithm to generate frequent subgraph-based descriptors for chemicals. Faulon
et al. [Faulon et al., 2004] developed an algorithm of signature molecular descriptors for both
protein sequences and chemicals. A case study on comparing the performance of these 22 sets of
chemical descriptors are a necessary and beneficial complement to existing studies. We conduct a
detailed performance comparison for the 20 sets of DRAGON descriptors [Dra, 2008], the frequent
subgraph-based descriptors [Huan et al., 2003], and the signature molecular descriptors [Faulon
et al., 2004] on 14 high-quality chemical data sets collected from literatures and online databases.
Here we conduct a comprehensive comparison of the above mentioned chemical descriptor sets,
and our results provide important insights on how to select chemical descriptors to achieve optimal
performance for protein-chemical interaction prediction.
4.2.3 Some Conclusions
The detailed experimental procedures are not described here. Interested readers may refer to the
original paper [Zhang & Huan, 2010]. Experimental results show that FFSM descriptors and sig-
nature descriptors (height = 3) perform better than 17 DRAGON descriptors and equivalently to
the other three: DR06(2D autocorrelations), DR07(edge adjacency indices), and DR17(functional
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group counts). In addition, some single DRAGON descriptor sets consistently perform better than
other descriptor sets over almost all the data sets. For instance, descriptor class DR06, DR07, and
DR17 generally outperform all other DRAGON descriptor sets. DR09(topological charge indices)
and DR18(atom-centered fragments) also show decent accuracy compared to other DRAGON de-
scriptors. Finally, using any single DRAGON descriptor class almost always yields better perfor-
mance than using all DRAGON descriptors together, and the reason might be due to over-fitting.
With wise selection of some DRAGON descriptor sets, we can earn robust and optimal perfor-
mance for protein-chemical interaction prediction. Our results shed light on selecting descriptor
extraction methods wisely to obtain best prediction performance. Simply using all of them or ran-
domly selecting some of them will diminish the prediction performance. A combination of DR06,
DR07, DR17, and a few other DRAGON descriptor sets would be a robust and optimal selection.
The molecular signatures and FFSM descriptors are satisfactory candidates for virtual screening
and protein-chemical interaction prediction.
A major reason that the FFSM descriptors outperform most DRAGON descriptors is that FFSM
has implicit functions of descriptor selection, since it only counted frequent subgraphs and infre-
quent descriptors were removed. In many cases frequent subgraphs have been proven to corre-
spond to some biological or chemical structural motifs. FFSM descriptors can be a better method
if approximate matching of subgraphs is allowed. In addition, signature descriptors also perform
very excellently after careful tuning of the parameters, partially since they completely character-
ize a chemical by including geometrical and topological descriptors, atomic properties, chemical
bonding and hydrodization information. Finally, through our experimental results we should keep
in mind that no descriptors can be claimed the best for all data sets and all situations, and our
comparisons and conclusions are made on a statistically average basis.
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4.3 The BioAssay Network
PubChem provides valuable chemical genomics information in studying genes, pathways, cells and
diseases, especially for identifying promising potential drug targets. The valuable data in PubChem
are, however, noisy, high dimensional, with large volume, and contain outliers and errors. For
instance, the activity score, which measure the biological activity level of screened compounds,
are normalized in many different approaches without a consensus. Here we used network-based
approaches to characterize the BioAssay data in PubChem, construct a BioAssay network and
analyze its topological features using various statistical tools.
4.3.1 Related Work
Biological network analysis approaches have been intensively applied to organize complex bio-
logical data so that retrieval, analysis, and visualization of these data can be highly efficient. In
addition, biological network analysis can also reveal important biological patterns and functions
that are deeply hidden in mass data repository. For instance, Stelzl et al. [Stelzl & et al., 2005]
used the Y2H system to generate and analyze a human PPI network, and calculate many interesting
and critical patterns and characteristics. This was viewed as an important step toward the complete
human protein-protein interactome. Many follow-up studies had been performed and made the
human PPI network more and more complete and sophisticated. Chaurasia et al. [Chaurasia et al.,
2007,Chaurasia et al., 2009] built a comprehensive web platform - the Unified Human Interactome
database (UniHI, http://www.unihi.org), for querying and accessing human protein-protein
interaction data.
Using association data of approved drugs and drug targets obtained from the DrugBank database
[Wishart et al., 2006, Wishart et al., 2008], Yildirim et al. [Yildirim et al., 2007] built a bipartite
network composed of these drugs and their drug targets, which was an important step toward the
complete characterization of the global relationship between protein targets of all drugs and all
disease-gene products in the human protein interactome. Quantitative topological analyses of this
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drug-target network revealed that the targets of current drugs are highly overlapped and new drugs
tend to bind previously targeted proteins [Yildirim et al., 2007]. Based on disease genes data from
the Online Mendelian Inheritance in Man (OMIM) database [Hamosh et al., 2005], Goh et al. [Goh
et al., 2007] built a bipartite human disease network consisting of 1,284 distinct diseases, 1,777
disease genes, and 2,929 disease-gene associations, and then generated two biologically relevant
network projections: human disease network and disease gene network. This network-based ap-
proach revealed that genes associated similar disorders are more likely to have interactions between
their products and higher expression profiling similarity between their transcripts, indicating the
existence of disease-specific functional modules.
4.3.2 Data Statistics
We obtained human PPI data from various sources, including UniHI and CCSB-HI1. UniHI
is a unified human PPI network containing over 250,000 human PPIs collected from 14 major
PPI sources, including high-quality systematic interactome mapping and literature curation, while
CCSB-HI1 is another widely used human PPI database. Data of approved drug targets were down-
loaded from the DrugBank database [Wishart et al., 2006, Wishart et al., 2008]. As of January
22, 2009, there are 1,493 FDA-approved drugs, and more than 800 human target proteins. In
addition, for human essential genes (a human gene was defined as essential if a knockout of
its mouse ortholog confers lethality), we first extracted mouse essential genes from the Mouse
Genome Informatics Database [Eppig et al., 2005], and obtained human essential genes via the
human-mouse ortholog associations. Finally, since PubChem only provides protein GI numbers
for BioAssay targets, but drug targets and essential genes are identified by official gene sym-
bols (http://www.genenames.org/) in their corresponding databases, we manually converted the GI
number of each BioAssay target into official gene symbols. We then mapped BioAssay targets,
drug targets, and essential genes via gene symbols into other biological databases, and identified
228, 1,339 and 2,546 entries among the total 21,051 human proteins in UniHI, respectively.
We downloaded all bioassay screening data from the PubChem BioAssay Database. As of
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January 2009, 1306 bioassays (1,126 with at least one active compound) and more than 30 mil-
lion compounds had been deposited into PubChem by a variety of screening centers, and the size
of PubChem kept increasing continuously. For each of the 1306 bioassays, tens to hundreds of
thousand of compounds were tested either against specific target proteins in vitro or within a cell
for investigating disease-related mechanisms. Out of more than 30 million compounds in Pub-
Chem, there were totally 151,930 compounds that are active in at least one bioassay, and 555,859
bioassay-active compound pairs across all the bioassays. On average each active compound was
active in 3.7 bioassays, and each bioassay had 493.7 active compounds, and therefore a very sparse
bipartite network of bioassays and compounds can be observed.
In addition, 680 bioassays were found associated with at least one target protein and were
considered target-based, and the rest 626 bioassays were hence assumed cell-based bioassays. In
Fig. 4.3a, we summarized the therapeutic focus of all cell-based bioassays, and found that cancer
studies (32%, anticancer and tumor growth inhibition), cell death (17%), and stem cell (10%) are
the three most common types of screenings. We have found 289 distinct protein GI (gene identifier)
numbers for all target-based bioassays, and 215 of them had official associated gene symbols. We
then obtained the target protein subcellular locations for all target-based bioassays from the Gene
Ontology database and describe their distributions in Fig. 4.3b, which demonstrates that the per-
centage of currently selected MLI membrane protein targets (19%) was significantly smaller than
the 50% ratio of current drug targets that are membrane proteins (P < 0.001, Chi-squared 1-degree
test) [Drews, 2000]. In addition, we explored the molecular functions of the MLPCN targets by
mapping their GI numbers into EC numbers, resulting in 113 proteins with EC numbers that were
involved with 253 bioassays. We used the first two numbers of their EC numbers to classify them,
as shown in Fig. 4.3c, which revealed that hydrolases (46%) and transferases (38%) were the major
function classes of MLPCN target enzymes. Finally, for target-based bioassays, the distribution
of organisms from which the target proteins were taken showed that 81% of MLPCN target pro-
teins were from human beings, and the remaining targets were from animals (6%), bacteria (6%),





































































Figure 4.3: Distributions of the BioAssay data. (a) Distribution of the purposes of the 626 cell-based
bioassays. (b) Distribution of the target protein cellular components of the 680 target-based bioassays.
(c) Distribution of the organisms from which bioassay target proteins were taken. (d) Distribution of the
function classes the 113 bioassay target emzymes.
4.3.3 Generating and Characterizing the BioAssay Network
The complexity of the BioAssay data described above showed that deep investigation will be dif-
ficult without organizing and visualizing the data in a rational matter. It is natural to generate
a bipartite network for bioassays and compounds in PubChem. To visualize the BioAssay data
with reasonable complexity, we can generate a BioAssay network projection as a complementary,
bioassay-centered view of the bioassay space, where bioassays are represented as nodes and two
bioassays are connected if they have similar binding profiles. We used Jaccard coefficient (the
fraction of active compounds shared by two bioassays in the total number of distinct active com-
pounds of them) to measure the similarity of bioassay binding profiles. By connecting any two
bioassays that shared at least 10% active compounds, we generated a network of bioassays with
899 nodes and 6,080 edges as shown in Fig. 4.4a. Cell-based bioassays were represented by circles
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and colored according their screening purposes, while target-based bioassays were represented by
rectangles and colored by their cellular components from the Gene Ontology database.
In Fig. 4.4a, on average a node were connected via about 6 links and had about 13.5 neigh-
bors (the mean shortest path length = 6.09). A large number of clusters with 2-3 bioassays were
observed in Fig. 4.4a. They were usually primary, confirmatory, or summary screens for the same
bioassay, and certainly most of their active compounds were identical. Besides many medium-
sized clusters with 4-20 nodes, there were two giant clusters composed of most bioassays, within
each of which there was an extremely dense component. The two clusters corresponded to the
NCI tumor cell line growth inhibition assays and the NCGC cell death related (cytotoxicity, via-
bility, and etc.) assays. A clear trend was observed that in most cases bioassay data in the same
cluster were submitted by the same organization for similar purposes or against similar target pro-
teins. In addition, We found that there did exist a few clusters that contain both target-based and
cell-based bioassays, while most clusters in the network have nodes of the same bioassay type
(either target-based or cell-based). According to the definition of an edge in this network, such
heterogeneous clusters revealed that the binding profiles of some target-based and some cell-based
bioassays are to some extent similar (10% similar in this case), which can be helpful on under-
standing the protein-compound interactions within the cell-based bioassays and possible identify
critical proteins in the cell-based bioassays.
We calculated the bioassay degree distribution P(k), measuring the probability of a given bioas-
say connects with other k bioassays (Fig. 4.4b), and found that P(k) decreased gradually as the de-
gree k increased. A power-law fitting with correlation coefficient as 0.955 and R2 = 0.527 revealed
that the exponent = -1.009. Hence, this is a typical scale-free network according to the definition
by Barabasi et al. [Barabasi & Albert, 1999], in which a small fraction of nodes have most of
the linked connected, and the majority of nodes have only a few links, as observed in Fig. 4.4a.
In addition, the distribution of the average clustering coefficient (Fig. 4.4c) was found approxi-
mately independent on the node degree, and slightly fluctuated around the mean 0.78 (standard





























































Figure 4.4: The BioAssay networks and topological distributions. (a) The BioAssay network in which
nodes are bioassays and two bioassays are connected if they share at least 10% active compounds. The size
of each node is proportional to the number of its active compounds, and the coloring of nodes is similar
to Figure 4.4a. (b) Distribution of the network node degrees. The power-law fitting clearly shows that is a
typical scale-free network. (c) Distribution of the average clustering coefficients. The almost constant fitting
shows the BioAssay network is not hierarchical, not as other biological networks.
network [Ravasz et al., 2002], although typical biological networks were usually both scale-free
and hierarchical. One reason could be that the edges in the bioassay network have no clear biolog-
ical meaning.
4.3.4 Some Conclusions
In this work, we integrated the bioassay data from PubChem and other biological databases such
as DrugBank and UniHI, and systematically analyzed them using biological network analysis ap-
proaches. We first calculated a variety of distributions of the bioassay data to identify some im-
portant trends in bioassay screenings and target selections. We then built a BioAssay network,
and network topology analysis demonstrated that this network is a scale-free network but is not
hierarchical, which is different from typical biological networks that are usually both scale-free
and hierarchical. Some cell-based bioassays share a large portion of active compounds with target-
based bioassays, which is helpful to determine the interacting proteins in the cells. By integrating
other information related to adverse drug reactions, network analysis approaches provide valuable
tools for further understanding the mechanisms of many ADRs systematically.
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Chapter 5
Novel Network Features for Predicting
Potential Drug Targets
A significant number of drug failures were attributed to the utilization of inappropriate drug targets
at the early preclinical stages [Butcher, 2003]. Although great efforts have been exerted on drug
research and development, only a limited number of drug targets have been identified. The majority
of drug targets came from a few gene families, e.g. about 60% current drug targets are membrane
proteins [Yildirim et al., 2007], while in human genome only 15"39% genes were predicted to
contain transmembrane segments [Ahram et al., 2006]. To this end, the drug target space has not
been fully explored, especially in the regions of other gene families. It is highly desirable for
the pharmaceutical industry to use in silico approaches to help identify correct drug targets in the
interaction network space.
5.1 Introduction
Genes in human genome have been classified into two classes: the druggable genome (genes that
express proteins binding to drug-like molecules with potency greater than a threshold [Hajduk
et al., 2005, Hopkins & Groom, 2002], e.g. 10 µM) and the remaining undruggable genome. Ac-
cording to the estimation of Hopkins et al. [Hopkins & Groom, 2002], there are approximately
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10% human genes that can potentially become drug targets. However, the boundary between the
druggable and undruggable genome is ambiguous and dynamic, and highly depends on the screen-
ing libraries. Identifying novel drug targets, especially from the currently considered undruggable
genome, could be a promising solution to the current dilemma in drug discovery.
It is well known that proteins rarely function in isolation inside or outside cells, but rather
behave as part of highly interconnected cellular networks [Chaurasia et al., 2007,Rual, 2005,Stelzl
& et al., 2005]. It will be advantageous to investigate proteins in the context of human protein-
protein interaction (PPI) networks, with the hypothesis that topological environment of drug targets
are distinct from that of non-drug-target proteins. For instance, Yildirim et al. [Yildirim et al.,
2007] constructed a drug-target network and found that most known drug targets formed a giant
cluster in the human PPI network. They concluded that drug targets were usually not essential
genes, but they are close to essential genes and disease genes in the network. Therefore, known
drug targets, disease genes, and essential genes are special groups of proteins in the human PPI
network. It is the motivation for us to propose network topological features of proteins regarding
to their relationships to these special proteins.
Machine learning algorithms have been widely used in pharmaceutical and bioinformatics stud-
ies. By integrating novel network and/or sequence features with advanced machine learning tech-
niques, we proposed a framework to build highly accurate models to predict if a protein is likely
to be a potential drug targets or not. By analyzing the relevance of proposed features, we can pri-
oritize a set of proteins according to their predicted druggability, and thus design high-throughput
screening to verify them more efficiently.
5.2 Related Work
Various computational methods have been proposed and applied for identifying potential drug
targets. Zheng et al. [Zheng et al., 2006] reported properties of new druggable proteins based
on analysis of approved drug targets, including membership of a target family, involvement in
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no more than two pathways, presence in no more than two tissues, and etc. In addition, Hajduk
et al. [Hajduk et al., 2005] used the 3D structural information to predict whether a particular
protein can bind with small, drug-like compounds. Although these methods achieved reasonable
performance, they suffer from either poor generalization capability or limited availability of data
such as protein 3D structures.
Supervised learning has also been widely used for drug target identification. For instance, Li
et al. [Li & Lai, 2007] predicted potential drug targets based on simple sequence properties such as
hydrophobicity, polarity, and etc., and achieved about 80% accuracy using SVM cross validation
on the 186 selected drug targets. In addition, Bakheet et al. [Bakheet & Doig, 2009] proposed
a comprehensive list of properties of human drug target proteins, including EC numbers, Gene
Ontology terms, Glycosylation, and etc., analyzed their correlation to drug targets, and also used
them as features to predict potential drug targets. Recently, Zhu et al. [Zhu et al., 2009] used
five topological features extracted from human PPI networks to identify potential drug targets, and
proposed a measure to rank proteins in the PPI network according to their potential of being drug
targets.
If a protein is modulated by external stimulus, it is highly likely that its interacting partners,
even the whole module, are also subject to the perturbation. Given a sufficiently complete network
of high-quality PPI annotations, drug targets can be distinguished from non-drug-target proteins
due to their distinct response to network perturbations, which is our basic assumption to use solely
network topological features to predict potential drug targets. By investigating a set of 15 network
features related to known drug targets, disease genes, and essential genes, we formalized the pre-
diction of potential drug targets as a typical supervised learning problem. To this end, we applied
sophisticated machine learning algorithms to analyze these network features and build accurate
models to predict potential drug targets.
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5.3 Human Protein Interaction Network
To extract network topological features for proteins, we need a human protein-protein interaction
(PPI) network with as accurate and complete as possible interaction annotations. UniHI (http:
//www.unihi.org) is a unified human PPI network containing over 250,000 human PPIs collected
from 14 major PPI sources with careful data integration and literature curation [Chaurasia et al.,
2007, Chaurasia et al., 2009]. It also provides quality scoring systems for each data source. After
careful curation, we obtained a human PPI network with 13,602 proteins as nodes and 157,349
PPIs as edges by removing redundant nodes and/or edges, merging duplicated nodes and/or edges,
and excluding non-human proteins and other noises.
Approved Drug Targets: We obtained the gene symbols of the target proteins of all approved
drugs from the DrugBank database [Wishart et al., 2008,Wishart et al., 2006], and use official gene
symbols to cross-reference proteins in the UniHI network and in DrugBank. We mapped the genes
symbols of drug targets in DrugBank to the curated UniHI network, and excluded any drug targets
that have some network topological features unavailable, resulting in a set of 1,092 drug targets for
positive training samples and network feature calculation.
Human Disease Genes: We downloaded all “Genes Associated with Diseases” from the GeneCards
database (http://www.genecards.org/), and used gene symbol mapping to identify 1,521 pro-
teins as disease genes in UniHI. In addition, we removed any disease genes that have been approved
drugs, and obtained a final set of 1,157 disease genes. They will be used to calculate important
topological features for proteins in the UniHI network.
Human Essential Genes: A human gene was defined as “essential” if a knockout of its mouse
ortholog confers lethality. To find human essential genes, we first extracted mouse essential genes
from the Mouse Genome Informatics Database [Eppig et al., 2005], and obtained 2,564 human
essential genes through the human-mouse ortholog associations. Using gene symbol mapping we
obtained 2,059 essential genes in the UniHI network, and finally used 1,759 of them after removing
those that either have been used as drug targets or disease genes, or have some topological features
unavailable.
32
Table 5.1: The 15 topological features extracted from the human PPI network.
Feature(Count) Formula Description
Degree (1) ki Number of direct links to node i
Clustering coefficient (1) 2ni/ki(ki+1) ni is the number of links among the ki neighbors of node i
Topological coefficient (1) " j J(i, j)/ki See text
Minimal SPL (3) min j(di j) Minimal SPL to drug targets, disease and essential genes
Mean SPL (3) " j di j/|P| Average SPL to drug targets, disease and essential genes
Fraction of neighbors (3) kpi /ki Fraction of node i’s neighbors as drug targets, disease or essential genes
Characteristic distance (3) See text Measure of clustering of drug targets, disease and essential genes
Putative Non-drug-target Proteins: It is indispensable to have negative samples to build an ac-
curate model, that is, we need some proteins that can be surely determined as not drug targets. This
is technically difficult since no researcher is interested in validating that a protein is definitely not
a drug target. To solve this dilemma, we simply excluded any proteins that have been used as drug
targets, disease genes, and essential genes from consideration [Bakheet & Doig, 2009, Li & Lai,
2007, Zhu et al., 2009]. In addition, any proteins that have some topological features unavailable
were also removed, resulting in a set of 9,674 proteins. In all experiments, we randomly selected a
number of proteins from this set as our negative samples. It is sure that there will exist some false
negatives, however, with random sampling the error rate is acceptable (<5%) considering that only
less than 10% random proteins could be drug targets [Hopkins & Groom, 2002].
5.3.1 Network Topological Features
A network is an undirected acyclic graph consisting of a number of nodes and edges. A node can
represent any object, and an edge connects two nodes and usually carries some physical meaning
such as interaction, similarity, and etc. In this work, we proposed 15 topological features extracted
from human PPI networks, including three general topological features: degree, clustering coeffi-
cient, and topological coefficient, as summarized in Table 5.1.
The degree (DEG) of a node is the number of edges connecting it to other nodes. The clustering
coefficient [Barabasi & Oltvai, 2004] of a node is defined as Ci = 2n/(ki*(ki-1)), where n denotes
the number of direct neighbors of a given node i, and ki is the number of links among the n
neighbors of node i. If the clustering coefficient (CLU) of a node equals 1.0, the node is at the
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center of a fully connected cluster called a clique. If the clustering coefficient is close to 0, the
node is in a loosely connected region. We can calculate average clustering coefficient over nodes
with the same degree, and then obtain the distribution of average clustering coefficient over node
degrees. The average of Ci over all nodes of a network assesses network modularity.
The topological coefficient (TPG) [Stelzl & et al., 2005] Ti of a node i with ki neighbors is
computed as Ti = "m J(i,m)/ki, where J(i,m) is defined for all nodes m that share at least one
neighbor with node i. The value J(i,m) is the number of neighbors shared between the nodes i
and m, plus one if there is a direct link between i and m. The topological coefficient is a relative
measure for the extent to which a node shares neighbors with other nodes. Nodes that have one or
no neighbors are assigned a topological coefficient of 0. Topological coefficients can be used to
estimate the tendency of the nodes in the network to have shared neighbors.
5.3.1.1 Shortest Path Length-related Features
Next we defined six network features that are related to shortest path lengths (SPLs) between pro-
teins and three pharmaceutically important sets of proteins/genes: approved drug targets, human
disease genes, and essential genes. The shortest path length (SPL) between two nodes in a net-
work is defined as the minimal number of consecutive edges between them. Given a protein in
the UniHI network, the first three features are computed as its minimal SPLs to the nearest drug
target, disease gene, and essential gene, not including the protein itself. These features evaluate
the minimal distance between a protein and pharmaceutically important proteins. In addition, the
remaining three features are the mean SPLs between a protein and all drug targets, disease genes,
and essential genes in the UniHI network. These features evaluate the overall average distance
between a protein and those important special proteins.
5.3.1.2 Characteristic Distance Features
The final six features are related to the clustering between proteins and the three pharmaceutically
interesting sets of proteins. If we use a visual graph to view how the proteins distribute in the
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UniHI network, we can find the aggregation between proteins and drug targets (disease genes, and
essential gens) are different from one to another. So the first three features will be defined as the
fraction of approved drug targets, disease genes, and essential gens in the direct neighbors of a
given protein. For instance, if a protein has 15 direct neighbors (its degree = 15), 3 of them are
known drug targets, 2 of them are disease genes, and 0 of them are essential genes, these three
features will be calculated as 0.2 (3/15), 0.133(2/15), and 0.0 (0/15), respectively. These features
provide a simple measure how the pharmaceutically important proteins are clustering around a
protein.
To gain more understanding on the probability of proteins being potential drug targets, we
developed a model to quantify the clustering of drug targets, disease genes, and essential genes
surrounding other proteins. By computing the fraction Fi of drug targets, disease genes, and es-
sential genes at each distance di, we obtained the distribution of these three sets of proteins around
each other protein in the network. We then defined the characteristic distance Dpc as follows:
1/(Dpc )2 = "ni=1 Fi/d2i , where n is the diameter of the network and p represents a protein from the
three sets. The mechanism underlying this formula was from electrostatics and the Coulomb law.
We can view each drug target (disease gene, and essential gene) as a “unit charge” that generated
an electric field with field strength Fi/d2i , and all these electric fields accumulated at the position
of a given protein. Therefore, the last three features are computed as the characteristic distance
between a protein and all approved drug targets, disease genes, and essential genes, respectively.
5.3.2 Classifiers
Classifiers played an important role by taking descriptor vectors and class labels as input and
generate prediction models as output. There are many widely used classifiers, e.g. support vector
machines (SVM), K-nearest neighbors (KNN), neural network, random forest, and etc. Each has
their advantages and disadvantages. The following three classifiers are used in our study.
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5.3.2.1 Support Vector Machines
Kernel classifiers, exemplified by the support vector machines (SVM), have gained popularity in
many health related applications. Kernel classifiers utilize a specially designed function, called
kernel function, to handle complex, non-linear relationships. Specifically, this is done by first
mapping the original data to a new feature space and then deriving a liner relationship in the feature
space. Coupled with large margin separation principle as utilized in SVM, kernel classifiers have
the following advantages: (i) low chance of over-fitting in a high dimensional feature space, (ii) no
need to explicitly compute the coordinates of the data and hence are computational efficient and
(iii) empirically give comparable (and usually better) results to competing methods such as Neural
Networks. Here we used SVMs to build highly accurate model for the baseline of comparison using
tenfold cross validation and bootstrapping. The LIBSVM [Chang & Lin, 2001] implementation
and RBF kernels were used in all experiments.
As a supervised learning method widely used for classification and regression, support vec-
tor machines (SVM) [Burges, 1998] view input data as two sets of vectors in an n-dimensional
space, each with different class labels. SVM constructs a separating hyperplane in that space by
maximizing the margin between the two data sets. To calculate the margin, two additional parallel
hyperplanes are constructed, one on each side of the separating hyperplane, and are “pushed up"
against the two sets of data points respectively during the optimization process. Intuitively, a good
separation is achieved by the two parallel hyperplanes with the largest distance to each other.
We downloaded the state-of-the-art implementation named LIBSVM [Chang & Lin, 2001] of
the SVM classifier. Signature, DRAGON, and FFSM descriptors take chemical compounds in SDF
format as input, convert them into n-dimensional descriptor vectors. Then LIBSVM treats each n-
dimensional vector as a point in n-dimensional space, and build a decision boundary between
actives and inactive samples in that space.
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5.3.2.2 Logistic Regression
Logistic regression is a generalized linear model for pattern recognition. Such models include a
linear exponential part followed by a “link function”. First the linear function of input features is
calculated and run through the logistic link function. The optimal coefficients of the linear function
are learned from training data. Comparing with linear regression, logistic regression can be used
to construct a model which estimates probabilities, e.g. for medical diagnosis and credit scoring.
With proper regularization, the coefficients of a logistic regression model can be used to evaluate
the relative significance of each feature. Here we used a !1-regularized logistic regression (LLR)
algorithm proposed by Boyd et al. [Koh et al., 2007] to run our experiments.
5.3.2.3 k-Nearest Neighbors
The k-nearest neighbors (kNN) algorithm is a simple classification method based on the votes of
the k nearest neighbors of a given data point in the feature space. Given a training data set with
class labels, the parawise distance (or similarity) between a testing data point and each training
sample will be calculated and sorted, and the top k closet (or most similar) training samples are
picked, and the majority of the k class labels will be assigned to the given testing data point. This
method can be used to identify the most similar known drug target to a protein that was predicted
as a potential drug target when k = 1.
5.4 Results
Based on the descriptions of the 15 network features proposed for each protein, they were com-
puted for 1,092 known drug targets extracted from DrugBank, and 9,674 putative non-drug-target
proteins in the UniHI database. The 1,092 known drug targets played two roles in the experiments:
some known drug targets were used to calculate the four related network features, and the others
were served as training positive samples in cross validation.
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5.4.1 Results Using No Drug-target-related Features
Due to the trick usage of known drug targets in feature extraction and cross validation, we first
excluded the four drug-target-related features from consideration, and hence built the baseline for
performance comparison using the remaining 11 features. SVMs with RBF kernels, L1-regularized
logistic regression, and kNN algorithms were used to classify proteins into two classes: drug
targets or not drug targets. With a highly unbalanced data set consisting of 1,092 positive and
9,674 negative samples, we randomly selected 500 positive and 1000 negative samples to make a
balanced subset. We used 80% positive and 80% negative samples for training, and the rest 20%
for testing. Tenfold cross validation was applied the training set to select the best model parameters
(C and # for SVMs, $ for L1-regularized logistic regression, and k for kNN).
After the optimal model parameters were identified, a single model was built on the training
set and tested on the testing set to obtain the generalization accuracy as TP+TN/N, where TP =
true positive, TN = true negative, and N is the total number of testing samples. We repeated the
whole experimental process for 100 times to obtain stable classification results. The accuracies
and optimal parameters for each classification method are summarized in Table 5.2, which showed
that up to 75% accuracy was achieved by L1-regularized logistic regression using only 11 features.
Table 5.2: Summary of baseline results from experiments using 11 features.
Algorithm Model Parameters Testing Accuracy
SVMs C = 4.539+/-1.15 # = 2.406+/-0.804 0.691+/-0.030
!1-regularized Logistic Regression $ = 0.0006+/-0.0011 0.757+/-0.028
k-Nearest Neighbors k = 3 0.694+/-0.017
In addition, the best models obtained from L1-regularized logistic regression provide the coef-
ficient of each feature in the linear function. From 100 cross-validation experiments, we obtained
100 sets of coefficients from the best models. According to Hastie et al. [Hastie et al., 2009], the
Z-score is defined as the mean coefficient divided by its standard error for each of the 11 features.
a Z-score whose absolute value is greater than 2.0 means the corresponding feature is significant
to the model (confidence level 95%) [Hastie et al., 2009]. From Table 5.3 we found that the feature
degree, topological coefficient, and fraction of neighboring essential genes were not significant.
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Clustering coefficient, minimal and average SPLs to disease genes, fraction of neighboring dis-
ease genes, and characteristic distance to disease genes are features negatively correlated to the
druggability of proteins, especially for minimal and average SPLs to essential genes. Meanwhile,
average SPLs and characteristic distance to essential genes are positively correlated features.





Minimal SPLs to the nearest disease gene -3.018
Minimal SPLs to the nearest essential gene -8.007
Average SPLs to the nearest disease gene -3.090
Average SPLs to the nearest essential gene 3.450
Fraction of neighboring disease genes -4.871
Fraction of neighboring essential genes -1.028
Characteristic distance to disease genes -3.854
Characteristic distance to essential genes 2.552
5.4.2 Results Using All Network Features
Feature Extraction: When we take the four drug-target-related features into consideration, we split
the 1,092 known drug targets into two sets: one for feature extraction, and the other using for
positive training samples. We randomly selected 50% known drug targets for calculating the 15
network features described in section 3.2 for the remaining 50% drug targets (546 positive samples)
and all the putative non-drug-target proteins (9,674 negative samples).
Data Set Creation: Given the highly unbalanced data set with much more negative samples
than positive samples, we created a balanced data set by randomly selecting 500 positive samples
and 1,000 (the number of negative samples are always twice as many as positive samples). For
each such data set, we randomly selected 80% positive samples and 80% negative samples as a
training set, and the rest 20% data as a testing set.
Model Construction and Selection: Tenfold cross validation was applied to the training set to
select the best models. We used grid search to find the best combination of model parameters,
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e.g.,C and # for SVM RBF kernels, $ for L1-regularized logistic regression, and k for kNN.
Model Assessment: After we selected the best models, we used all the training samples to
construct a single final model using the identified optimal parameters, and applied this model
to the testing samples to calculate the testing (generalization) accuracy. We repeated the whole
experimental process for 100 times using random sampling to achieve stable prediction accuracy,
and reported the mean and standard deviation of testing accuracy in Table 5.4. The second row in
Table 5.4 demonstrated that the best accuracy obtained using SVMs, L1-regularized LR, and kNN
(k=5) is 0.774, 0.782, and 0.733, respectively.
We also repeated the experimental procedure as described above using different percentages of
known drug targets for feature extraction, such as 30%, 70%, 80%, and 90%. Note that the number
of positives selected in step 2 were changed accordingly since the total numbers of positive samples
available were different. All resulting accuracies and standard deviations obtained using SVMs,
LLR, and kNN are summarized in Table 5.4.
Table 5.4: Summary of mean accuracy (standard deviation) using different fractions of known drug targets
for feature extraction.
% Drug Targets SVMs LLR kNN (k=5)
30 0.770 (0.015) 0.784 (0.014) 0.736 (0.016)
50 0.774 (0.018) 0.782 (0.019) 0.733 (0.021)
70 0.762 (0.024) 0.787 (0.025) 0.727 (0.025)
80 0.752 (0.030) 0.792 (0.030) 0.720 (0.031)
90 0.732 (0.041) 0.766 (0.041) 0.696 (0.041)
To visualize the trend in the results more clearly and compare them with baseline results, we
plotted the results using dot line in Fig. 5.1 with different colors, and the baseline results are
represented with red horizontal lines. Overall, by introducing the four drug-target-related features,
the cross validation accuracy obtained using SVMs, LLR, and kNN increased by 8.4%, 3.5%,
and 4.2%, respectively. With up to 80% accuracy, the best models from L1-regularized logistic
regression are considered meaningful for predicting potential drug targets.
Fig. 5.1 demonstrates that as the fraction of known drug targets used for feature extraction
increases, the accuracy first slightly fluctuates (increases for SVMs and LLR, and decreases for
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Figure 5.1: Summary of cross-validation accuracy using SVM, logistic regression, and kNN.
kNN), and then decreases significantly. The main reason for this pattern is that less training data
were used to learn models when more fraction of drug targets was used for feature extraction. In
addition, the standard deviation bars enlarged dramatically when the fraction of drug targets for
feature extraction increased, because less training samples were used and 10 random samplings
were not enough to lower the variance. There is a tradeoff between the number of training samples
and the number of drug targets used for feature extraction, so the optimal partition is about 40%-
60%.
5.4.3 Comparison with Previous Work
Zhu et al. [Zhu et al., 2009] proposed a SVM classification method to predict potential drug targets
using five network topological features: degree, clustering coefficient, 1N index, shortest distance
to drug targets, and average distance to drug targets, which are included in our 15 feature set. To
compare the performance of our feature set with Zhu et al. [Zhu et al., 2009], we applied a similar
cross-validation experimental procedure: a) Partitioned the set of drug targets into two parts: one
for feature extraction, and the other used for training; b) Randomly selected 30%, 50%, 70%, 80%
and 90% of drug targets for feature extraction, and repeated the random sampling for 10 times; c)
Randomly selected a balanced data set consisting of twice as many negative as positive samples,
and repeated the random sampling for 10 times. We used grid search to select the best parameters
C and # for RBF kernels.
The results for our method and Zhu et al.’s method [Zhu et al., 2009] were listed in Table 5.5
41
Table 5.5: Accuracy (standard deviation) of our method and the method by Zhu et al..
% Drug Targets for SVMs LLR kNN ( k= 5)
Feature Extraction Our method Zhu et al. Our method Zhu et al. Our method Zhu et al.
30 0.794(0.015) 0.695(0.017) 0.795(0.014) 0.722(0.016) 0.758(0.017) 0.677(0.021)
50 0.789(0.018) 0.696(0.024) 0.790(0.018) 0.729(0.019) 0.752(0.016) 0.664(0.023)
70 0.794(0.022) 0.691(0.028) 0.797(0.019) 0.736(0.026) 0.774(0.020) 0.665(0.033)
80 0.796(0.031) 0.680(0.034) 0.800(0.026) 0.747(0.028) 0.772(0.028) 0.667(0.040)
90 0.770(0.041) 0.666(0.039) 0.786(0.041) 0.723(0.039) 0.754(0.041) 0.654(0.050)
for comparison. For each partitioning of drug targets, our best five features (characteristic dis-
tance to known drug targets and to disease genes, minimal and mean SPL to known drug targets,
and topological coefficient) outperformed the method by Zhu et al. for 9.3-11.6% using SVMs,
5.3-7.3% using L1-regularized logistic regression, and 8.8-10.9% using kNN at k = 5. A simple
explanation of the superiority of our feature set was that our method systematically not only inte-
grated information from both drug targets and disease genes, but also integrated information from
many drug targets and/or disease genes into one feature. Our experimental results demonstrated
that disease gene information did help identify potential drug targets.
In addition, we also compared our feature set with the protein sequence features used by Li
et al. [Li & Lai, 2007]. We downloaded all protein sequences from UniProt (http://www.uniprot.org),
mapped all human proteins onto the UniHI network, and obtained 1,075 drug target sequences, and
7,099 putative non-drug-target sequences. We then applied Needleman-Wunsch global alignment
algorithm [Needleman & Wunsch, 1970] to calculate the pairwise sequence identities for each of
the sequence sets, and iteratively removed protein sequences to cull all sequences in each set with a
given identity threshold (e.g. 30% in this work). Eventually we achieved 660 drug target sequences
and 5,006 non-drug-target sequences, and in each set no pairwise sequence identity are greater than
30%. We then calculated exactly the same 146 protein sequence features as in Li et al. [Li & Lai,
2007] using the online server PROFEAT by Chen et al. [Li et al., 2006].
In the experiments, both methods only used the 660 positive and 5,006 negative samples to
conduct cross validation at different sizes of training set. We assured that the numbers of training
samples for both methods are very close to each other. At each size of training set, we randomly
selected 50 data sets with approximately twice as many negative as positive samples, and the final
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Table 5.6: Accuracy (standard deviation) of our method and the method by Li et al..
% Drug Targets for SVMs LLR kNN ( k= 5)
Feature Extraction Our method Li et al. Our method Li et al. Our method Li et al.
30 0.754(0.022) 0.710(0.042) 0.775(0.022) 0.692(0.033) 0.723(0.020) 0.651(0.037)
50 0.753(0.025) 0.700(0.032) 0.771(0.026) 0.699(0.019) 0.713(0.023) 0.660(0.024)
70 0.731(0.031) 0.696(0.013) 0.765(0.030) 0.691(0.012) 0.703(0.030) 0.649(0.016)
80 0.737(0.041) 0.688(0.009) 0.794(0.036) 0.679(0.012) 0.710(0.037) 0.645(0.009)
90 0.732(0.046) 0.669(0.015) 0.739(0.055) 0.666(0.008) 0.689(0.050) 0.622(0.017)
accuracy and standard deviation were obtained by averaging results over the 50 experiment, as
shown in Table 5.6. Clearly our feature set outperformed the 146 sequence features for 3.5-6.3%
using SVMs, 7.4-11.5% using L1-regularized logistic regression, and 5.3-7.2% using kNN at k=5.
The best accuracy was 79.4% using our method, but 71% using the sequence features.
5.4.4 Relevance of Network Features
Our L1-regularized logistic regression models provided not only classification accuracy, but also
the coefficients of all involving features in the models. At each partitioning we repeated the exper-
iments for 100 times, and in each experiment we calculated the Z-scores for each network feature
as the mean coefficients divided by their standard errors as described in Hastie et al. [Hastie et al.,
2009]. High Z-scores that are beyond the region [-2.0 2.0] indicate significant features. The Z-
scores for three network features: degree, clustering coefficient, and topological coefficient, were
shown in Fig. 5.2. We found that the Z-scores topological coefficient are within the range [-8 -2],
and thus this network feature shows significantly negative correlation to prediction results. The
Z-scores of feature degree and clustering coefficient are within [-2.0, 2.0], and hence have only
marginal significance.
The remaining 12 features naturally fall into four groups, each with three features that are re-
lated to drug targets, disease genes, and essential genes, respectively. The mean Z-score and stan-
dard deviation bar of each feature was plotted in Fig. 5.3. We discovered some interesting patterns.
First, the characteristic distance to known drug targets (Fig. 5.3a) was found the most significant
predictor since its Z-scores are very negative in the range [-14,-4], showing that proteins with
43



















Figure 5.2: Z-scores of network features: degree, clustering coefficient, and topological coefficient.
shorter characteristic distance to known drug targets have higher chance to be drug targets, which
is intuitive because shorter characteristic distance means topologically more similar. In addition,
characteristic distance to disease genes were also observed significantly negatively correlated to
prediction results, though characteristic distance to essential genes was unsurprisingly marginally
significant predictor.
Moreover, the minimal and mean SPLs (Fig. 5.3b and c) to known drug targets are both highly
significant predictors, but with opposite inferences: a protein with greater minimal SPL and shorter
mean SPL to known drug targets have higher probability to be potential drug targets. Observations
on disease genes are quite similar, but SPLs to disease genes have only marginal significance.
For essential genes, the significance is also very marginal, although they tell that a protein with
shorter minimal SPL and greater mean SPL to essential genes has higher chance to be potential
drug targets.
Finally, fractions of neighboring drug targets, diseases and essential genes are three weak pre-
dictors since their Z-scores are all within [-1.0,1.0] (Fig. 5.3d). It is somehow intuitive since
considering only direct neighbors in the PPI network is superficial. It is noticeable that when 30%
known drug targets were used for feature extraction, the Z-scores of most network features were
more significant than other values. The reason is that when small number of known drug tar-
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Figure 5.3: Summary of the Z-scores of four sets of topological features: (a) characteristic distance, (b)
Mean SPL, (c) Minimal SPL, and (d)Fraction of neighboring special proteins. Each panel contains three
features related to known drug targets, disease genes, and essential genes, respectively.
gets were used for feature extraction, the advantages of the four drug-target-related features were
weakened.
5.4.5 Combining Network & Sequence Features
Now we have two sets of features for identifying potential drug targets: one extracted from protein
interaction networks, and the other extracted from protein sequences, so it is natural and straight-
forward to integrate them together for better prediction performance. Our experimental procedures
were very similar to experiments using only network features, except that fewer positive and neg-
ative samples were available. Given 660 positive and 5,006 negative samples, we still used 30%,
50%, 70%, 80%, and 90% known drug targets for calculating the four drug-target-related features,
and calculated the 15 network features and 146 sequence features for the remaining positive and all
negative samples. At each of the five partitioning thresholds, we randomly selected 90% positives
for training and 10% for testing, with twice as many negatives as positives in each set. The other
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experimental steps were the same as described previously. The results of repeating the experiments
for 100 times are summarized as in Table 5.7. As expected, the performance of combined features
is better than sequence features, but worse than network features.
Table 5.7: Experimental results using both network features and sequence features.
% Drug Targets for SVMs LLR
Feature Extraction Combined Features Feature Selection Combined Features Feature Selection
30 0.737+/-0.037 0.735+/-0.033 0.749+/-0.033 0.741+/-0.035
50 0.726+/-0.045 0.748+/-0.042 0.759+/-0.041 0.766+/-0.043
70 0.711+/-0.050 0.736+/-0.051 0.756+/-0.051 0.764+/-0.045
80 0.699+/-0.060 0.719+/-0.055 0.749+/-0.065 0.768+/-0.058
90 0.685+/-0.068 0.707+/-0.083 0.727+/-0.086 0.762+/-0.084
In addition, using Z-scores of the features calculated from L1-regularized logistic regression
models, we selected four network features (degree, topological coefficient, characteristic distance
to disease genes and to known drug targets) and five sequence features with Z-scores beyond
the interval [-1.0, 1.0], which are considered at least marginally significant to the druggability of
proteins. With the nine selected features, SVM classification performance improved slightly, which
LLR performance didn’t improve at all, mainly because LLR has performed feature selection with
L1 regularization. The LLR prediction accuracy using all combined features can be up to 77%.
Although it is slightly worse than the performance using only network features, it is much more
stable. When more known drug targets are used for feature extraction, the results of using only
network features fluctuated more dramatically than using combined features. Moreover, we also
applied SVM recursive feature elimination (RFE) [Guyon et al., 2002] as feature selection on the
combined features, but didn’t achieve any improvement.
From our experiments, we concluded that the performance of network features highly depends
on the completeness of the human protein interaction network and the number of known drug
targets. Sometimes the interaction profiles of proteins are hard to obtain and thus are incomplete.
For such proteins, our network features may not perform well, and sequence features can provide
important complementary information for identifying potential drug targets. Although combined
features didn’t outperform network features, they provided more robust and stable results than
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the latter. As demonstrated in Table 5.7, when the percentage of known drug targets used for
feature extraction increased, the results using combined features varied more gently than using only
network features. Therefore, we here created a framework for identifying potential drug targets by
integrating network features and sequence features efficiently. More sophisticated feature selection
methods may also help improve the performance of the combined features.
5.5 Conclusions
We proposed a set of 15 topological features extracted from human PPI networks, applied sophisti-
cated machine learning algorithms such as SVMs, logistic regression, and kNN to construct highly
accurate models using these features to predict whether a human protein can be a drug targets or
not, and achieved excellent performance with up to 80% prediction accuracy. In addition, we ana-
lyzed the correlation of each topological feature to the probability of being drug targets for human
proteins by calculating the Z-scores of the model coefficients obtained by L1-regularized logistic
regression, and found that some topological features were highly important to the druggability of a
protein, such as characteristic distance to drug targets, shortest and average distance to drug targets
and disease genes, and topological coefficients. Moreover, we compared the performance of our
feature set with two previous work, and observed that our method outperformed them for 5-11%
higher accuracy. Analysis demonstrated that the superiority of our features was originated from
on highly integrated information from many drug targets and from both known drug targets and
disease genes simultaneously. Our feature extraction only rely on the interacting profiles of pro-
teins, and can by easily applied to many other applications. By integrating network features with






As discussed in earlier chapters, interactions between drug compounds and proteins or other cel-
lular components are major causes of adverse drug reactions. Hence it is important to obtain the
profile of interacting proteins for a given drug. However, the annotations between drug compounds
and human proteins are very sparse, as shown in the data in PubChem. It is highly desirable to
develop machine learning tools to predict the missing links between drugs and interacting pro-
teins. In this chapter, we proposed two chemogenomics-based multi-task learning algorithms for
protein-chemical interaction prediction.
6.1 Introduction
Interactions between proteins and small-molecule chemicals modulate many protein functions and
biological processes, and identifying these interactions is a crucial step in modern drug discovery.
Chemical biological assays are generally used to obtain protein-chemical interaction data, but their
usage is largely restricted by the experimental expenses and time cost. In silico methods [Bleicher
et al., 2003] provide important complementary tools for identifying active compounds for target
proteins from a large database of chemical structures with low cost [Robert & Goodnow, 2006].
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While the literature is rich that general machine learning algorithms (e.g. support vector machines,
!1-regularized logistic regression) achieve decent performance on protein-chemical interaction pre-
diction [Ning et al., 2009, Erhan & L’Heureux, 2006, Jacob & Vert, 2008], most of them are for a
single protein with sufficient binding samples.
When only limited binding compounds are available for proteins, traditional single task learn-
ing (STL) methods that independently learn one single task at a time inevitably suffer from over-
fitting and are unable to build accurate models. Multi-task learning (MTL) [Caruana, 1997] is an
excellent alternative approach that learns multiple related tasks jointly and transfers knowledge
among them, which has been empirically as well as theoretically shown to generally improve per-
formance of predictive models [Ando & Zhang, 2005,Argyriou et al., 2006]. In multi-task learning,
the total training error of all tasks is minimized, the model parameters of all tasks are optimized
jointly, and the generalization performance of models is improved.
There are other situations where MTL methods can help overcome the dilemma confronted by
STL methods. Complex diseases such as Alzheimer’s disease (AD) and cancers often associate
with multiple target proteins. For instance, at least 43 identified proteins have been associated
with AD [Stephenson et al., 2005]. Compounds that selectively inhibit only one of these disease-
associated proteins are unable to effectively fight these diseases. Identifying promiscuous com-
pounds that can inhibit multiple proteins associated with the same complex diseases is thus critical
for future drug discovery.
In this chapter, we propose two complementary MTL algorithms for predicting active com-
pounds for multiple related proteins, some of which may have very few binding samples. We hy-
pothesize that the performance of protein-chemical interaction prediction can be highly improved
by learning models for multiple related proteins jointly, integrating information from both proteins
and chemicals, and selecting the most discriminative features for the final models. Moreover, our
proposed MTL methods can be applied to identification of promiscuous compounds that interact
with multiple related proteins. This typical multi-label classification [Tsoumakas & Katakis, 2007]
problem is first split into multiple binary classification tasks with one label as a task, which are then
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learned jointly in the MTL framework [Ji & Ye, 2009, Wu et al., 2010].
In the first MTL method, we propose the Maximum-a-Posteriori (MAP) optimization method
to integrate information from both proteins and chemicals in the same framework. Our main
contribution is to exploit a covariance-coupled Gaussian prior for encoding protein features to
regularize the logistic loss functions of compound features, though Gaussian prior has been used
in some other learning problems [Chen & Rosenfeld, 2003, Bickel et al., 2008]. Here each task
is to predict if a set of compounds interact with a given target protein. The characteristic of each
task is simply represented by the features of the target protein, and the relatedness among different
tasks is predefined by target protein similarity.
Generally features extracted from protein sequences and chemical structures have high dimen-
sionality, and not all features own the same level of discriminativity. Selecting a limited number of
highly discriminative features is thus critical for both improving performance and reducing com-
putational cost. Here we adopt a boosted multi-task learning algorithm for face verification [Wang
et al., 2009], and repurpose it for protein-chemical interaction prediction. This process is much
like the drug repurposing in recent drug discovery, and significant modifications have been made
to fit the problem of protein-chemical interaction prediction.
The second MTL method boosts chemical features with a number of independent boosting
[Freund & Schapire, 1995,Mason et al., 2000] classifiers and learns the correlations between each
task and each of these classifiers. Here base learners are two-leaf decision stumps of compound
substructure features, and a boosting classifier is a weighted linear combination of these base learn-
ers. Multiple boosting classifiers and the relatedness among multiple tasks are learned jointly, and
boosting and MTL are integrated into the same framework to take advantages from both tech-
niques.
We compare our proposed MTL methods with traditional STL methods and existing MTL
methods to demonstrate their performance improvement. We especially focus on the situation
where some tasks have very few or even no training samples, and evaluate how our MTL methods
perform and the effect of knowledge transfer among related tasks. We also investigate the perfor-
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mance of our methods on predicting the interactions between promiscuous compounds and their
target proteins, which is pharmaceutically important for overcoming complex diseases in future
drug discovery.
6.2 Related Work
MTL approaches have been widely studied in bioinformatics and chemoinformatics problems.
Zhang et al. [Zhang et al., 2010] proposed a sparse multi-task regression (MTR) model for identi-
fying common mechanism of responses to therapeutic targets by capturing the global structure
of association using an intrinsic template shared among experimental conditions. Puniyani et
al. [Puniyani et al., 2010] combined information from genetic markers across multiple populations
to identify causal markers using !1,2-regularized MTR for joint association analysis of multiple
populations. [Bogojeska et al., 2010] presented an approach for the problem of predicting virolog-
ical response to combination therapies by learning a separate logistic regression model for each
therapy. [Xu et al., 2010] applied two MTL approaches for predicting protein subcellular localiza-
tion for 20 organisms. All these existing methods deal with data from the same feature space, i.e.,
each sample contains features from only one type of objects.
Utilizing both protein features and compound features is a key (and to some extent ignored)
issue in applying MTL for protein-chemical interaction prediction. Existing methods either totally
ignored protein features, or simply integrated both sets of features using kernel tricks. Similarity
between two pairs of proteins and compounds were expressed as either a weighted linear combi-
nation [Ning et al., 2009, Erhan & L’Heureux, 2006] or the tensor product [Jacob & Vert, 2008]
of protein similarity and compound similarity. These data integration methods oversimplified the
problem and achieved limited performance, and also might not well handle compounds with mul-
tiple interacting targets. These difficulties motivated us to develop novel MTL methods to handle
these pharmaceutically important problems.
The rest of this chapter is organized as follows: in Section 2 we introduce how we collect data
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sets, extract features, and provide details of our proposed MTL methods. Our experimental results
are presented in Section 3 with comprehensive comparisons to existing methods. In Section 4 we
conclude our work with insights on potential applications of our proposed MTL methods.
6.3 Methods
In this section, we describe the two proposed MTL methods in detail. We discuss how we integrate
compound and protein features into the same framework, characterize task relatedness, select the
most discriminative features, and derive the problem formulation step by step.
6.3.1 Notation
Let X # RN$D1 denote the compound feature matrix, where N is the number of chemical com-
pounds and D1 is the dimensionality of compound features, and P # RM$D2 denote the protein
feature matrix, where M is the number of proteins (tasks) and D2 is the dimensionality of protein
features. For protein-chemical interaction prediction, a data sample is a protein-compound pair
and we have Ncp # [N,NM] data samples since each chemical interacts at least one protein and at
most M proteins. Y denotes the Ncp $ 1 vector of sample labels. In binary classification as we
study here, each element of Y is taken from {1,-1}, representing that the given pair of proteins and
chemicals is active or inactive, respectively.
6.3.2 !2-regularized logistic regression
While Gaussian prior has been used as !2-regularization to provide prior knowledge in various
machine learning applications [Chen & Rosenfeld, 2003, Bickel et al., 2008], in this work we
encode protein features into the inverse of a covariance matrix (partial correlation matrix) in the
prior, and the likelihood term is represented by logistic functions of compound features. Our main
contribution is proposing this novel framework for composite data that each sample consists of two
parties: one is encoded in the logistic loss term and the other is encoded in the Gaussian prior term.
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Below we give details of a covariance-coupled !2-regularized logistic regression MTL method,
labeled as GaussMTL1, which maximizes the posteriori with a Gaussian prior of model parameters
with zero mean and constant variance. In the MTL framework, each task t is assigned a D1$1
vector vt of logistic regression parameters, and the concatenated parameter vector v for M tasks is
of size MD1$1. Similarly as existing !2-regularized logistic regression, our goal is to maximize




where yi is the binary label of the data sample pair xi, %%1 is the inverse of a covariance matrix
encoding protein features and is a function of matrix P, and $ is the regularization parameter to be
tuned. % is an MD1$MD1 matrix with 1’s at the diagonal. It can be viewed as a M$M super-matrix
whose elements are D1$D1 diagonal matrix blocks. The matrix block at position (i, j) describes
the similarity kernel k(ti, t j) between task ti and t j, and its diagonal elements are all set as k(ti, t j)& ,
where & # [0,1] is a scaling factor to control the magnitude of protein information to be considered
in our models. All the remaining elements in % are 0’s. Eventually % is a sparse matrix to define
the task similarity using protein similarity kernels.
After plugging in the logistic functions of compound features, maximizing objective func-




log(1+ exp(%yix&i v))+$v&%%1v, (6.2)
where yi is the label and xi is an MD1$1 vector obtained by extending the compound feature vector
(size D1$1) of sample i, i = 1,2, ...,N. If the data sample i belongs to task m,m = 1,2, ...,M,
the mth block of D1 elements are set as the D1 compound features of data sample i and all the
remaining elements as 0’s. Such treatment simplifies the problem and the model parameters of
all M tasks can be optimized simultaneously. Each training sample is included in the objective
cost function with a term consisting of logistic and exponential functions, so the cost function
of thousands of training samples have thousands of such terms. The LBFGS (Limited-memory
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Broyden-Fletcher-Goldfarb-Shanno) method is used to maximize the cost function [Matthies &
Strang, 1979, Nocedal, 1980].
6.3.3 Boosted multi-task learning
When it is difficult to predefine task relatedness, an alternate method is to jointly learned task
relatedness during the training process. Wang et al. proposed a boosted multi-task learning algo-
rithm [Wang et al., 2009] for face verification, and achieved significant performance improvement.
Here we present a boosted MTL method for protein-chemical interaction prediction by repurposing
this method to fit our need. This process is like drug repurposing in recent drug discovery.
The basic idea of boosting is that a strong learner can be achieved by appropriately combining
a set of weaker base learners. Here base learners are compound feature-based decision stump.
AnyBoost [Mason et al., 2000] is an abstract boosting algorithm for finding linear combinations of
functions that minimize arbitrary cost functionals, while many existing boosting methods, includ-
ing AdaBoost [Freund & Schapire, 1995] which directly uses prediction errors as cost functions,
are found to be just special cases of AnyBoost. AnyBoost can handle more complex problems that
may contain hidden variables, with a gradient descent optimization methods. Specifically, we learn
K independent boosting classifiers jointly for M target proteins, where K < M to enforce clustering
of similar tasks. Every task produces its own final classifier as a weighted linear combination of
the K boosting classifiers. Task relatedness is thus modeled by the composition of the K boosting
classifiers and their weights for each task.
6.3.3.1 Base learner for boosting
The very first step of a boosting approach is to define its base learners. A base learner should be
a weak learner with prediction accuracy slightly better than random guessing. In this method a
simple two-leaf decision stump derived from compound substructure features is used. Given a set







I fi exists in xi
%I otherwise
(6.3)
where I # {1,%1}, and the value of I is selected to minimize the prediction error using this base
learner, so that it has at least 50% accuracy. A specific I value is determined for each task by
applying the base learner on the training data of that task.
6.3.3.2 Boosted multi-task learning algorithm
Given M tasks (target proteins) and each task is to predict if a set of compounds interact with a
given protein, we learn K independent boosting classifiers, where K < M. Each boosting classifier






where hk,t(xi) and 'k,t are the base learners defined in Eq.(6.3) and the optimal boosting coefficient
for boosting classifier k (k = 1, ...,K) obtained in iteration t. The key point for identifying the K
boosting classifiers is to select hk,t(xi) and 'k,t minimizing the training error.
With logistic loss functions, a boosting classifier hk, and a compound feature xi, the probability





where yi = 1 denotes that the compound does interact with the target protein using feature xi as
base learner, and yi = -1 otherwise. When we have multiple tasks to learn at the same time, the
joint probability distribution is the product of the probability of each task as defined above.
Now we have K boosting classifiers {hk} for M tasks, the key point is to evaluate how well
classifier k explains the data of task m (m = 1, ...,M) with a prior (k on each classifier k. Previ-
ously [Wang et al., 2009] has proposed an expectation-maximization(EM) algorithm on multi-task
learning for face recognition. We here use a similar EM algorithm with T iterations to learn {hk}
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and {(k} as follows:
























where cm # {1,2, ...,K} is the index of the selected boosting classifier for task m, (k serves as
the prior probability of boosting classifier k. The “(t)” symbol on a variable denotes its value
in the tth iteration. Xm and Ym are column vectors representing all samples of task m and their
labels, while xm,i and ym,i denote an sample i of task m and its label. Thus qm,k stands for the
correlation coefficient between task m and boosting classifier k. The Eq.(6.6) is the E-step of the









Eq.(6.8) provides a complex cost function for the AnyBoost algorithm to learn {hk} and {(k}, and
it can be further written as follows by plugging in Eq.(6.5):
C(t+1)k =%"
m,i
q(t)m,k log[1+ exp(%ym,ihk(xm,i))]. (6.9)
Let h(t+1)k = h
(t)
k +'k,t+1hk,t+1 be the updating function of hk. According to AnyBoost we first
maximize the function C(t+1)k by taking the derivative:
+C(t+1)k
+hk(xm,i)








Without detailed derivation of the AnyBoost algorithm, we find a new base learner hk,t+1 by maxi-
mizing "m,i wkm,ihk,t+1(xm,i), and then find its weight 'k,t+1 by maximizing the cost function C
(t+1)
k .
After the optimal {hk} and {(k} have been learned by the EM algorithm, the final model of each
task is projected into the functional space of these boosting classifiers {hk}, and the probability of
56












The final classifier for task m is defined as y = 1 if p ( 0.5 and -1 otherwise.
There are some tricks in the implementation of this boosted MTL method. Using a sequen-
tial greedy search the best base learner that maximize the cost function can be identified at each
iteration. The trick is that the process could be very time-consuming if the number of candidate
features is large. Removing candidate features that are identical for all training samples can sig-
nificantly reduce the searching space and speed up the process. The second trick is to compute the
boosting coefficient 'k,t for the previously selected base learner {h
(t)
k } by maximizing the convex
cost function C(t+1)k . The cost function can have up to thousands of logistic and/or exponential
terms, and are optimized by the L-BFGS method [Matthies & Strang, 1979, Nocedal, 1980].
The above method takes only the compound features into consideration. It is tempting to ask
if the performance can be improved when we integrate protein features into this framework. A
simple way is to use tensor product of protein and compound features as candidate features. Given
a D1$1 protein vector and a D2$1 compound vector, the tensor product can be concatenated into
a D1D2$1 vector. We refer to the original boosted MTL method as BoostMTL1 and this variant as
BoostMTL2 in the rest of this chapter.
6.4 Results
In this section we begin our discussion with an introduction to the collection, cleanup, and repre-
sentation of protein-chemical interaction data, and then evaluate the performance improvement of
our proposed MTL methods over three baseline methods on the three data sets.
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6.4.1 Data set and feature extraction
We manually created two sets of protein-chemical interaction data from the BindingDB database
[Liu et al., 2007] and the PubChem database (http://pubchem.ncbi.nlm.nih.gov). The first one
(the AD set) has 10 target proteins associated with Alzheimer’s Disease (AD) [Stephenson et al.,
2005], and the second one (the Cancer set) consists of eight target proteins associated with various
cancers such as breast, prostate, and lung cancer [Benson et al., 2006]. For data from PubChem, the
binding activity for each compound has been defined. The BindingDB database provides specific
IC50 and/or Ki values for each binding compound of a target, and a compound is defined as active
(inactive) to its target if its IC50 or Ki value ) 100 nM (( 10,000 nM). We have set these threshold
values weaker than in literature to enhance the size of the “binding” set (and implicitly recognizing
that some compounds bind even if they do not couple strongly enough to be considered a hit).
Table 6.1: Target proteins in the AD set and the Cancer set.
AD Active Inactive Cancer Active Inactive
AChE 71 210 AR 44 61
APP 107 32 CYP19A1 275 226
BHMT 4 0 ATM 1 42
CASP 201 101 ERBB1 2 23
IL6 0 2 HER2 61 6
MHCII 4 13 RAR-' 31 33
NEP 360 59 FLT1 122 187
S100B 0 2 KDR 62 15
SNCA 25 19
MAPT 44 65
Note that in both sets the negative samples are real and verified by experiments. Although
in reality there are much more negative than positive samples, our data sets have slightly more
positive than negative samples (826 vs. 503 in the AD set and 598 vs. 597 for the Cancer set),
since experimentalists are not of great interest to verify negative samples. These two data sets are
nonetheless highly unbalanced, since some proteins have few binding compounds, and some of
them have only positive or negative samples. For instance, in the AD set only four active, two in-
active, and two inactive compounds are available for protein BHMT, IL6, and S100B, respectively.
Such data characteristics are the first motivation for us to develop sophisticated MTL algorithms
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for protein-chemical interaction prediction. Detailed distributions of binding compounds for the
first two sets are listed in Table 6.1.
The third class of proteins we are interested in is GPCR proteins, and we simply adapted an
existing data set of GPCRs from [Jacob & Vert, 2008], which consists of 100 GPCR proteins, 219
compounds, and 399 positive interaction pairs. The distribution of the protein-chemical binding
data is shown in Figure 6.1. Unlike the first two data sets, there are no validated negative samples
for proteins in this GPCR set, and an equal number of randomly selected protein-chemical pairs
that are known not to be positive are treated as putative negative samples.








































Figure 6.1: Distribution of (a) the number of binding compounds of GPCR proteins, and of (b) the number
of binding GPCR proteins of compounds.
Molecular signature descriptors [Faulon et al., 2004] are used to extract features from chem-
ical structures. We use this method because it achieves excellent performance for extracting fea-
tures from chemical structures, and generally outperforms the widely used DRAGON descriptors
(http://www.talete.mi.it) from our previous work [Zhang & Huan, 2010]. In detail, each element
of a molecular signature vector is the number of occurrences of a particular atomic signature in
the molecule. An atomic signature is a canonical representation of the chemical substructure sur-
rounding a particular atom, including all atoms and bonds up to a predefined number of consecu-
tive bonds from the given atom, called the signature height. For a set of chemicals or proteins, this
method first extracts all distinct atomic signatures and their frequencies in each structure, and then
makes a union of n features from all structures. Finally, each structure i is converted into a vector
vi of n elements, and each element j corresponds to the feature j. If structure i contains feature j
for f j times, we have vi[ j] = f j, where f j is a non-negative integer and f j = 0 means that feature j
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doesn’t exist in structure i.
Note that signature descriptors are originally developed for chemicals. When they are applied
to proteins, the method simply makes a pseudo structure for a protein by replacing each amino
acid with its chemical structure, since in many cases it is difficult to obtain the 3D structures
for proteins. The strategy looks too simple, but in practice signature descriptors work very well
for protein sequences. In this chapter we set the signature height at 2 for compounds and at 4
for proteins, and remove all signature descriptors that are existent in less than 1% compounds
(proteins). We end up with "200 features for each compound and "50 features for each protein.
Here we found that there are less signature descriptors for all proteins than for all small-molecule
chemicals in the data sets. This looks counter-intuitive, but is reasonable since we have much more
distinct chemicals (1200-1300) than proteins (8-10). Refer to the original publication [Faulon et al.,
2004] for more detailed introduction to signature descriptors.
6.4.2 Baseline methods
SVMs and !1-regularized logistic regression (!1-RLR) are two excellent STL methods and selected
as our comparison baselines. Note that no protein descriptors are used in these two methods. If a
task has only positive or negative samples, STL methods cannot build models for it and the pre-
diction accuracy for this task is set to 50% for comparison. The third reference method is a widely
used MTL approach called tensorSVM, which integrates protein and compound information using
tensor product of their feature vectors and computes the similarity between two pairs of proteins
and compounds as the product kernels of the protein similarity and the compound similarity. We
utilized the RBF kernels and the precomputed kernels in the LIBSVM package [Chang & Lin,
2001] for the SVM and tensorSVM method, respectively. The !1-regularized logistic regression
algorithm proposed by Boyd et al. [Koh et al., 2007] is used for the method !1-RLR.
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6.4.3 Optimization of model parameters
With 20% randomly selected samples of each task as the independent testing set, we applied 10-
fold cross validation on the rest of the data, used exponential grid search to select model parameters
(cost parameter C for SVM and tensorSVM, regularization strength $ for !1-RLR), and evaluated
the models on the unused testing set to obtain testing accuracy. This process is repeated for 10
times, and the mean testing accuracy and F1 score are reported. For all methods, testing accu-
racy, precision, recall, and F1 score are defined as (TP+TN)/S, TP/(TP+TN), TP/(TP+FN), and
2*TP/(2*TP+TN+FN), respectively, where TP is true positive, TN is true negative, FN is false
negative, and S is the total number of testing samples.
The GaussMTL1 method involves two parameters to be tuned: the protein feature scaling factor
& and the regularization strength $ . Tuning of & is expensive, and preliminary results show that
the validating accuracy is not very sensitive to small changes of & . We apply 2D grid search for
optimizing & and $ jointly. Here 11 values of & # [0,1] were uniformly selected, and at each
value of & exponential grid search of $ was performed in each partitioning as described above. We
repeat the above process for 10 times to identify the optimal $ by maximizing the mean overall
accuracy of all tasks. Finally, the learned logistic regression parameters and the optimal & and
$ were applied to the testing set to obtain the generalization accuracy. We repeated the whole
experiments for 10 times and reported the mean testing accuracy and F1 score.
The boosted MTL methods also have two model parameters to be discreetly selected: the
number of base learners in each boosting classifier (T ), and the number of boosting classifiers
(K). To avoid an expensive exhaustive grid search of T and K jointly, we used an iterative search
procedure as follows: we first fixed K at M/2 (M is the number of tasks in a data set) and searched
for optimal T from six values: 5, 10, 20, 30, 40, and 50. Here the variant tensor-product boosted
MTL method (BoostMTL2) was also investigated. Once the optimal T was identified, we fixed the
T value and again searched for optimal K from values 1,2, ...,M. Theoretically we could continue
the process further, but we stop after the first iteration since empirical study showed that there was
no much further improvement.
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Table 6.2: Prediction accuracy comparison on the AD data set and the Cancer data set. !!1-RLR stands for !1-
regularized logistic regression. The standard deviations are included in parenthesis when available or non-zero.
Method Overall AChE APP BHMT CASP IL6 MHCII NEP S100B SNCA
GaussMTL1 91.0(1.0) 94.0(1.7) 95.7(3.7) 95.0 96.2(3.1) 95.0 72.5(18.4) 93.6(1.6) 90.0(31.6) 71.1(10.7)
88.2(3.1) 90.8(2.8) 95.0 90.7(2.7) 95.0 72.5(18.4) 87.5(1.6) 90.0(31.6) 67.1(12.2)
GaussMTL0 89.3(1.0) 91.4(1.8) 94.0(3.0) 90.0 94.4(3.1) 100.0 72.5(20.4) 92.8(2.2) 90.0 67.9(10.2)
87.2 (2.2) 90.1(1.9) 90.0 88.7(3.5) 100.0 72.5(20.4) 83.5(1.0) 90.0 62.2(9.5)
tensorSVM 57.8 91.8(0.0) 85.1(0.1) 10.0 88.1(0.1) 25.0 68.3(0.4) 85.3(0.0) 10.0(0.3) 47.5(0.2)
79.5(32.2) 61.7(40.1) 0.0 74.0(24.1) 0.0 10.0(31.6) 61.1(30.3) 0.0 40.0(51.6)
BoostMTL1 87.8(1.4) 88.2(2.9) 95.0(3.8) 90.0 94.3(3.3) 90.0 77.5(27.5) 89.8(3.5) 95.0 53.3(18.0)
81.5(6.0) 88.1(6.8) 90.0 81.2(9.4) 90.0 77.5(27.5) 87.1(2.2) 95.0 56.2(11.0)
BoostMTL2 87.7(1.3) 88.4(2.9) 95.0(3.8) 90.0 94.4(2.7) 90.0 82.5(26.5) 89.3(3.3) 90.0 51.1(18.3)
80.7(6.2) 86.1(7.2) 90.0 81.1(8.9) 90.0 82.5(26.5) 87.6(2.0) 90.0 53.8(10.8)
SVM 77.3 89.2(7.0) 90.8(6.2) 50.0 91.7(5.2) 50.0 50.0 82.7(6.7) 50.0 48.3(12.3)
81.7(8.3) 88.9(5.2) 50.0 88.3(8.9) 50.0 50.0 71.1(7.3) 50.0 55.0(7.2)
!1-RLR! 78.6 90.0(3.7) 85.6(9.2) 50.0 92.4(2.5) 50.0 50.0 83.1(6.1) 50.0 54.0(17.1)
78.3(10.9) 84.4(9.4) 50.0 82.2(11.6) 50.0 50.0 75.6(11.8) 50.0 60.6(9.2)
Method Overall MAPT AR CYP19A1 ATM ERBB1 HER2 RAR-' FLT1 KDR
GaussMTL1 88.6(0.7) 63.6(6.1) 91.0(4.2) 86.6(1.6) 96.7(5.4) 100.0 95.7(5.0) 85.4(6.7) 90.5(2.5) 79.4(10.6)
59.1(5.6) 84.4(5.0) 71.4(6.0) 96.1(2.5) 100.0 91.3(4.2) 67.5(14.4) 70.9(7.0) 80.0(5.6)
GaussMTL0 86.5(1.0) 65.4(6.5) 90.0(3.5) 84.6(2.2) 93.7(5.4) 100.0 94.0(5.0) 83.3(5.7) 88.3(2.6) 76.2(10.6)
56.4(7.2) 81.0(6.2) 70.5(5.6) 92.2(2.5) 100.0 90.7(3.9) 64.4(13.9) 70.8(7.0) 76.5(4.8)
tensorSVM 74.8 67.4(0.1) 80.2(0.1) 88.2(0.0) 73.3(0.1) 62.6 60.3(0.1) 74.1(0.1) 82.9(0.1) 76.6(0.2)
29.2 54.2 69.2(17.4) 20.0 10.0 50.0 40.0 50.2(9.8) 13.3
BoostMTL1 84.8(4.6) 65.9(7.8) 82.4(14.7) 85.7(4.3) 98.9(3.5) 98.0 96.4(6.1) 73.8(24.4) 81.0(6.8) 83.8(7.3)
57.1(7.8) 58.0(13.8) 57.1(11.9) 98.3(2.2) 98.0 90.6(2.3) 57.0(10.7) 66.2(4.6) 81.2(3.6)
BoostMTL2 85.2(4.5) 66.4(7.2) 81.4(14.3) 86.9(3.4) 98.9(3.5) 98.0 96.4(6.1) 70.8(27.1) 81.9(7.2) 83.1(8.4)
56.2(7.6) 63.4(10.5) 55.0(9.7) 98.3(2.2) 98.0 90.6(2.3) 59.3(12.0) 67.7(4.0) 79.3(6.6)
SVM 81.2 61.2(9.2) 88.1(8.0) 88.4(2.1) 50.0 50.0 50.0 79.2(9.8) 90.4(3.8) 60.0(22.5)
57.8(8.8) 79.0(13.7) 68.0(13.2) 50.0 50.0 50.0 66.0(16.5) 71.0(9.9) 66.0(10.8)
!1-RLR! 79.2 66.7(8.8) 85.4(8.2) 87.8(3.0) 50.0 50.0 50.0 75.6(11.2) 87.1(3.7) 60.0(11.5)
54.4(7.3) 73.0(15.7) 55.0(12.7) 50.0 50.0 50.0 71.0(15.2) 71.0(7.0) 59.0(8.8)
6.4.4 MTL with substantial training data
We first tested the hypothesis that our proposed MTL methods can build more accurate models
for predicting protein-chemical interactions by learning multiple related tasks (target proteins)
jointly. With the optimal model parameters & , K and T , we used the experimental procedures
described above to evaluate the performance of our methods comparing with the baseline methods,
and showed the testing accuracy on the AD set and the Cancer set in Table 6.2. Note that in the
tables each method has two rows of results, and the top row is for results from experiments using
80% data samples of each task, and the bottom row is for results from experiments using at most
20 data samples of each task. We highlighted the best accuracy obtained using various methods
for the whole data set and for each task.
We noticed that MTL methods always perform better than STL methods and tensorSVM on
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Figure 6.2: Distributions of task-by-task prediction results measured by F1 score from experiments (a)
using 80% data samples of each task, and (b) using at most 20 data samples of each task as the training set.
Results are mean over 10 repeated experiments using random sampling, and deviations are not shown.
method is at least 12.4% and 9.2% better than that of the reference methods for the AD set, and
7.2% and 2.6% better for the Cancer set, respectively. We compared the results of the GaussMTL1
method to !2-regularized logistic multi-task regression method: a special case of the GaussMTL1
method by setting the scaling factor & = 0, which means no protein information is taken into
consideration. This method is labeled as GaussMTL0. We observed a 1.7% improvement on
the overall accuracy by incorporating protein features into the models, which reveals that protein
features do help construct more accurate learning models.
Though the overall accuracy of GaussMTL1 is 3.2"3.8% higher than the boosted MTL meth-
ods on both data sets, there is no clear winner on accuracy of specific tasks. Explicitly (GaussMTL)
or implicitly (BoostMTL) defining task relatedness does not produce significant difference in the
testing results. For the two boosted MTL methods, the tensor-product boosted MTL method
(BoostMTL2) performs almost no better than the compound feature boosted MTL method (Boost-
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Table 6.3: Prediction accuracy using various numbers of training data. ! Percentage of training samples
from other tasks.
# Training Samples 80%! 20%!
MHCII ERBB1 MHCII ERBB1
0 40.0% 38.4% 32.9% 54.8%
4 63.1% 92.4% 67.7% 91.9%
8 67.8% 94.1% 67.8% 95.3%
12 78.0% 98.5% 74.0% 95.4%
MTL1), although it affords substantially more computational workload.
When we break down the results task by task, we noticed that the major improvement of our
methods come from those tasks with few training samples. Since our methods are designed to have
a strong regularization among tasks and hence perform knowledge transfer among related tasks, it
is clear that such regularization is essential for constructing high quality models for tasks with low
sample sizes. In addition, we calculated the results of F1 score (a measure that combines precision
and recall using their harmonic mean) for each task, and similar trends as using prediction accuracy
holds as shown in Figure 6.2(a). Similarly, we also calculated the results of F1 score using at most
20 training samples for each task as shown in Figure 6.2(b), and found similar patterns supporting
the improved performance of our MTL methods.
To better investigate the relationship of task sample size, regularization, and testing accuracy,
we conducted a small case study using two tasks with about 20 data samples: MHCII in the AD
set and ERBB1 in the Cancer set. They were picked just due to the small number of labeled
samples available. Experimental results on these two tasks are coherent with other tasks as shown
in Table 6.2 and 6.2. We incrementally set the number of samples in the training set as 0, 4, 8, and
12 with either 80% or 20% data samples of other tasks used for training, to investigate the effect
of the sample size on model accuracy. The results of the GaussMTL1 method are listed in Table
6.3. We notice that there is a significant improvement if we have more than 4 samples for the task.
If we use more than 12 training samples, our methods have been able to achieve decent prediction
accuracy.
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6.4.5 MTL with limited training data
In previous experiments, we used 80% of the data of each task for training and the rest 20% for
testing. In order to test the robustness of our proposed MTL methods, we significantly reduced the
number of training samples and repeated the experiment as described previously. In particular, for
a task with more than 20 samples, we kept at most 20 samples from it and all data from other tasks
in the training set, and moved the extra samples of this task into the testing set. If a task has less
than 20 training samples, no more samples will be moved out of the training set. We conducted
this experiment for each task in the two data set, and repeated it for 10 times to calculate the mean
accuracy. All results are shown in the lower rows for each method in Table 6.2.
The results are consistent to what we reported before. For 16 out of the 18 tasks in the two data
sets, our methods perform better than the reference methods, while !1-RLR and SVM outperform
our methods on the RAR-' task and the FLT1 task for 3.5% and 0.1%, respectively. For the nine
tasks with substantial data samples among the 16 tasks, our methods outperform reference methods
for 6.0% on average. For the seven tasks with limited samples, our methods have more significant
predictive performance: 92.8% for GaussMTL1, 94.9% for BoostMTL1 and 95.6% for BoostMTL2.
The performance difference is originated from the fact that our proposed MTL methods transfer
knowledge among related tasks while integrating data from diverse domains.
6.4.6 MTL for multi-target PCI prediction
Multi-target drug design is a promising direction for overcoming complex diseases in future drug
discovery. Due to technical difficulty and data availability, the AD set and the Cancer set consists
of almost no promiscuous compounds that interact with multiple target proteins. We then adopt
the GPCR data set from [Jacob & Vert, 2008], and its data distribution is shown in Figure 6.1.
The 100 GPCR proteins belong to the same protein family, and many of them have been known
drug targets. However, most GPCR proteins in the data set has very few binding compounds, and
STL methods will not work for them. Here we use our proposed MTL methods to handle this
multi-label classification problem.
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Though theoretically the GaussMTL method can be used for this multi-label classification prob-
lem, the covariance matrix of 100 tasks are too large to be efficiently handled by computer systems,
so only the BoostMTL1 method will be investigated in this section. Compared to previous experi-
ments, MTL for multi-target protein-chemical interaction prediction involves two critical changes:
one is how to partition data into training and testing sets, and the other is how to calculate the ac-
curacy and to evaluate the multi-label prediction performance of the BoostMTL1 methods. There
are two ways to partition data: 1) random sampling as described above, and 2) random partitioning
that is restricted so that a given promiscuous compound must belong to either training set or testing
set, but not both. The first partitioning method allows a compound to be in both training set (active
to target ') and testing set (active to target , *= '). This is equivalent to the case that we know
some targets of a compound and want to find more targets for it, while the second method is more
challenging since it attempts to find binding proteins for a compound without knowing any binding
information of it.
For evaluating the capability of the BoostMTL1 method on handling multi-label classification
problem, the prediction accuracy is calculated only based on promiscuous compounds with binding
information to at least two target proteins. Since the negative samples of this GPCR data set is
putative, we also calculate the prediction recall (number of true positives over all positives) for
each method. A summary of the accuracy and recall results over all tasks is shown in Table 6.4,
which demonstrates that the BoostMTL1 method significantly outperforms tensorSVM using both
partitioning methods described above on both prediction accuracy and recall. Unsurprisingly, the
partitioning method 1) performs better than method 2) since some binding information of testing
compounds is carried in training data using method 1).
Table 6.4: Prediction results for multi-target protein-chemical interactions on the GPCR data set.
Method Boosted MTL1 TensorSVM
Partition 1 Partition 2 Partition 1 Partition 2
Accuracy 92.9% 79.7% 71.9% 62.2%
Recall 97.2% 85.7% 76.5% 70.3%
We further calculated the multi-label prediction accuracy and recall based on the predicting
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Figure 6.3: Histogram of the accuracy and recall of each promiscuous compound when (a) it can only
exist in either the training or the testing set, but not both; and (b) part of the binding information of testing
compounds may exist in the training set.
results of each promiscuous compound. For instance, if a compound in the testing set is interacting
with three proteins and inactive toward two proteins, and the prediction reports two true positives
and two true negatives, we can easily calculate the accuracy and recall on this compound as 80%
and 66.7%, respectively. We calculate the accuracy and recall for each promiscuous compound,
repeat the experiment for 10 times using both partitioning methods, and obtain the distribution of
the accuracy and recall for promiscuous compounds in the GPCR set, as shown in Figure 6.3. In
both distribution plots, most compounds have accuracy and recall in the range of 0.9"1.0, and our
BoostMTL1 method significantly outperforms tensorSVM on predicting promiscuous compounds.
The superiority of our boosted MTL method for multi-target protein-chemical interaction predic-
tion is clearly demonstrated with high accuracy and recall.
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6.4.7 Multi-task learning with imbalanced training data
In previous experiments, for each task we randomly selected 80% data or at most 20 samples as
the training set. We didn’t restrict the ratio of positive and negative samples in the training set, and
literally this ratio is approximately close to the ratio of all positive and all negative samples for
each task. In many real applications such as virtual screening, the data sets usually consist of much
more negative than positive samples and are thus very imbalanced. In this section we investigated
how the ratio of positive/negative samples influenced the prediction accuracy. First we picked
task AChE and selected 60-80% data as the training set depending on the data availability, and
randomly selected 80% data as the training set for all other tasks in the AD set. We enforced that
the training set of the AChE task consists of 10%, 20%, 30%, 40%, and 50% positive samples. At
each ratio we conducted an experiment using the four variants of our MTL methods, as described
in Section 3.3. The prediction accuracies for the task AChE using training sets with various ratios
of positive/negative samples were plotted in Figure 6.4, which demonstrated that although the
prediction accuracy can be improved with more balanced training data, the performance of our
MTL methods was still promising with highly imbalanced training sets.


















Figure 6.4: Prediction accuracy fluctuation when different percentages of positive samples in the training
set of task AChE.
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6.4.8 Sensitivity of model parameters
In this section we investigated the sensitivity of prediction accuracy to the changes of critical
model parameters in our MTL methods: & in the GaussMTL method, and K and T in the Boost-
MTL methods. The experimental procedure as described previously is applied to show how the
prediction results change when more protein information are taken into consideration. It does re-
veal that integrating protein features into the MTL framework improves the prediction accuracy
for 1.7%. For the AD set, the accuracy fluctuates and the best performance of 91.0% is achieved
at & = 0.6. When & increases the accuracy on the Cancer set decreases, and & = 0.1 gives the best
prediction accuracy 88.6%.
The results of experiments on the parameter T for both boosted MTL methods are shown in
Figure 6.5(a), which reveals that both methods achieve the best accuracy at T = 10 for the AD set
and T = 40 for the Cancer set. Although introducing protein features using tensor-product kernels
significantly increases the dimensionality of training data for one to two orders of magnitude, it
shows almost no performance improvement compared to the BoostMTL1 method. In addition, the
results of experiments on the parameter K are plotted as in Figure 6.5(b), which shows that when
K < M the accuracy increases while there are more boosting classifiers, and the best accuracy is
obtained at K = 9 (87.8%) and K = 7 (84.8%) for the two data sets, respectively. More boosting
classifiers increase the dimensionality of the final boosting models in the functional space, although
more computation cost is needed.
6.5 Discussion
Traditional single-task learning methods learn each task independently and neglect potential rich
information resources hidden in other related tasks, and their performance is largely restricted by
not only the insufficient availability of labeled samples for many proteins, but also the emergence
of more challenging problems such multi-target drug design. In this chapter, we first transform
this typical multi-label classification problem into the MTL framework, and then develop novel
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Figure 6.5: Model parameter sensitivity of the boosted MTL methods. (a) Number of boosting classifiers
fixed at M/2 (M = number of tasks); (b) Number of base learners in each boosting classifier fixed.
approaches to integrating heterogenous data, learn multiple related tasks jointly by capturing task
relatedness and transferring knowledge among them. In the first method, we encode a covariance
matrix of protein similarity kernels into the Gaussian prior of logistic regression parameters so
that information from both proteins and compounds is taken into consideration. In the second
method we design a two-leaf decision stump based on compound substructure features as boosting
base learners, and apply the AnyBoost algorithm to boost these weak learners and to select highly
discriminative features. Experimental results not only demonstrate that our methods significantly
outperform baseline methods with either substantial data or limited data from each task, but also
reveal that the BoostMTL1 method perform much better than the tensorSVM method on identifying
promiscuous compounds for multi-target drug design. Our proposed MTL methods can not only
be applied to protein-chemical interaction prediction, but also a wide range of other association
prediction problems. They are especially developed for data samples consisting of two types of
objects, such as protein-chemical/DNA/gene interactions, and gene-function annotations.
Both MTL methods have their limitations. BoostMTL doesn’t support learning a task without
training data from it, while the GaussMTL method can perform such tasks, though the accuracy is
not highly satisfactory. GaussMTL has challenging time complexity since computing the inverse of
of the covariance matrix increases cubically with the number of tasks increasing, while BoostMTL
is an efficient algorithm and its time complexity is linear relative to the number of candidate fea-
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tures. The major limitation of our MTL methods is that the data sets we used are relatively small,
and we have not tested the MTL algorithms in a virtual screening environment for evaluating their
performance with highly imbalanced databases consisting of 104%105 compounds. In conclusion,
our proposed MTL methods provide valuable solutions to the previously mentioned challenges on
predicting protein-chemical interactions. It is highly promising that integrating MTL and boost-




Drug-induced QT Prolongation Prediction
Using Multi-view Learning
There are much more ADRs than approved drugs, according to the SIDER database [Kuhn et al.,
2010]. We first select some specific critical ADR and construct accurate models using a sparse
multi-view learning algorithm to handle the noisy data. In next chapter, we then extend our method
to the multi-task learning framework so that multiple ADRs can be predicted jointly. The ADR
we picked is Torsades de pointes (TdP), which is a rare form of polymorphic ventricular tachy-
cardia that exhibits distinct characteristics on the electrocardiogram (ECG), and is considered as
a major life-threatening condition for patients as it can degenerate into ventricular fibrillation and
sudden death [Ouillé et al., 2011]. In the past decade, the single most common cause of the with-
drawal or restriction of the use of marketed drugs has been recognized as the prolongation of the
QT interval associated with TdP [Lasser et al., 2002]. Until 2004, at least nine drugs that were
marketed in the U.S. or elsewhere have been removed from the market or had their availability
restricted due to the risk of prolonging QT interval, such as Astemizole [de Abajo & Rodríguez,
1999] and Grepafloxacin [Ball, 2000]. Therefore it is crucial to discover and filter out those drug
candidates with potential risk of QT prolongation and/or TdP as early as possible in the drug de-
velopment pipeline to save expenses and lives in clinical trials. Note that in this chapter the terms
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QT prolongation and TdP risk are used exchangeably for ease of description.
7.1 Introduction
TdP is often associated with a prolonged QT interval, which may be congenital or acquired. Drug-
induced QT prolongation has triggered significant attention from pharmaceutical industry. Since
2005 the U.S. Food and Drug Administration (FDA) and European regulators have required that
nearly all new molecular entities must be evaluated in a thorough QT study to determine its ef-
fects on the QT interval [UCM, 2005]. Although QT interval can be influenced by many factors,
understanding of the underlying genetic mechanisms of QT prolongation have been significantly
improved during the past decade. At present a few ion-channel related genes have been identi-
fied, and their gene products are found to profoundly influence the balance of ion-channel currents
that determine the duration of the myocyte’s action potential and thus the QT interval [Moss,
2006], including three potassium ion channels Ikr(Kv11.1, hERG, KCNH2), Ik1(Kir2.1, KCNJ2),
and Iks(Kv7.1, KCNQ1), one sodium ion channel INa(Nav1.5, SCN5A), and one calcium ion chan-
nel ICaL(Cav1.2, CACNA1C) [Ouillé et al., 2011]. Presumably, compounds that inhibit one or
more these involved ion channels are more likely to obstruct the normal cardiac ion conduction
and thus prolong the QT interval. This key observation is crucial for identifying compounds with
potential TdP risk.
There are various means for pharmaceutical companies to obtain QT prolongation information
induced by their interested compounds, such as animal models and human clinical trials, whereas
the FDA Adverse Event Reporting System is another important source for such information. How-
ever, data obtained from these sources are either expensive and time-consuming or noisy, while
computationally predicting this rare but serious adverse drug effect (ADE) in humans remains
highly challenging. With thorough literature search we identified 142 compounds [Ouillé et al.,
2011,Woosley, 2003] that are possibly associated with QT prolongation and TdP with different risk
levels, including 28 compounds labeled as risk, 40 as possible risk, and 74 as conditional or con-
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genital risk (http://www.azcert.org). It is not surprising that most of these drug compounds
have such uncertain labels, since it is non-trivial to determine the causation between drugs and
TdP risk, especially when multiple drugs are simultaneously taken by patients. With such limited
and noisy data, traditional machine learning methods cannot build accurate models for predicting
the QT prolongation and TdP risks of potential drug candidates. On the other hand, additional
knowledge on the mechanism of QT prolongation are available but unused.
A variety of applications have limited and noisy labeled samples such as QT prolongation pre-
diction, where traditional single-view learning (SVL) methods such as support vector machines
work poorly. Multi-view learning (MVL) has been applied to many challenging machine learn-
ing and data mining problems, especially when complex data from diverse domains are involved
and only limited labeled samples are available. The underlying assumption of multi-view learn-
ing [Sindhwani & Niyogi, 2005, Sindhwani & Rosenberg, 2008, Culp et al., 2009] is that different
views are conditional independent and relatively complementary to one another, so that combin-
ing knowledge from multiple views can afford performance gain. Existing MVL algorithms can
be classified into three categories: co-training [Yu et al., 2007], co-regularization [Sindhwani &
Niyogi, 2005], and manifold regularization [Sindhwani & Rosenberg, 2008] according to how
they optimize the objective function and integrate information from multiple views. Among MVL
algorithms in the co-regularization framework, all previous work used !2-norm co-regularization
for it is easy to optimize the smooth objective function. In this chapter, we propose an !1-norm
co-regularized MVL algorithm to boost prediction performance on the important bioinformatics
problem: prediction of QT prolongation effect using the limited and noisy data available. No-
ticeably, although this MVL algorithm is developed for predicting the effect of QT prolongation,
the method itself is domain independent and could be applied to a wide range of other real-world
applications with limited and noisy multi-view data.
All previous MVL algorithms that use !2-norm co-regularization have a smooth objective func-
tion optimized by an alternate optimization approach [Yu et al., 2007, Krishnapuram et al., 2004],
i.e., in each iteration one view is optimized with the other views fixed until convergence of mapping
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functions in all views. However, we will demonstrate that our proposed !1-norm co-regularized
MVL method is more advantageous after properly reformulating the objective function and com-
puting its gradient in the analytic form. Moreover, We developed a simultaneous optimization
approach that optimizes the mapping functions from all views simultaneously. With comprehen-
sive experimental studies, simultaneous optimization is found to be much faster than previously
widely used alternate optimization.
Although !1-norm regularization (lasso) methods have been widely exploited in various appli-
cation domains, our work is the first attempt to apply !1-norm in multi-view learning. It seems that
the mixed regularization employed here is somehow similar to the fused lasso penalty [Liu et al.,
2010, Tibshirani et al., 2005] in which the coefficients and the difference between coefficients are
both lasso penalized. However, our !1-norm co-regularized MVL method regularizes the difference
of functional values instead of the function difference as in the fused lasso, i.e., our regularization
is in the mapping space while the fused lasso penalty is in the functional space. Refer to the related
references and the Methods section for more details.
For predicting drug-induced QT prolongation using multi-view learning, the first view is easily
directed to drug chemical structures, while there is a few options for the second view. One choice
is the general binding profiles of the drug compounds to human protein. More specifically, we can
use the binding information of compounds to those human proteins associated with QT prolonga-
tion, i.e. the five ion-channel proteins mentioned previously. However, it is challenging to obtain
binding data between the compounds interested and the five QT prolongation-related ion-channel
proteins mentioned above. When the binding activity between a compound and one of the ion
channels is unknown or unavailable, we build protein-chemical interaction prediction models to
predict it until the activity matrix is filled up completely. By learning these two-view data, !1-norm
co-regularization enforces sparsity in the learned mapping functions and naturally carries the func-
tionality of feature selection, and hence the prediction results are expected to be more accurate and
interpretable. Comprehensive experimental studies are designed for demonstrating the advantages
of our proposed MVL method on the prediction of drug-induced QT prolongation.
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7.2 Related Work
Many computational methods for facilitating the prediction of drug-induced QT prolongation and
TdP risk have been developed and applied in various applications such as drug discovery and de-
velopment. Yap et al. [Yap et al., 2004] used linear solvation energy relationships descriptors to
measure the TdP-causing potential of compounds and built prediction models with support vector
machines (SVMs). Their method simply ignored the different confidence levels of data and con-
sidered all risk, possible risk, and conditional or congenital risk compounds as positive samples,
and the interpretability and meaning of their results were limited. Recognizing the fact that the
hERG protein is frequently associated with QT prolongation, Yao et al. [Yao, 2008] and Redfarn
et al. [Redfern, 2003] developed models using hERG inhibition activity and other relevant data
to predict drug-induced QT prolongation, and investigated its relationships with various electro-
physiological properties. The limitation is that hERG is not the only or necessary binding protein
to induce this serious ADE. In addition, Champerous et al. [Champeroux et al., 2005] classified
training samples into three categories according to their confidence levels, and developed a com-
plex algorithm called TPDscreenT M combined with a database from reference compounds with
available clinical data to predict the risk of TdP and QT prolongation at the early stage of drug
development.
Given the fact that the development of QT prolongation and TdP is associated with multiple
genes [Moss, 2006], simulation studies of multiple ion channels blockade have been conducted
by Mirams et al. [Mirams et al., 2011]. They collected multiple ion channels (hERG, INa, and
ICaL) data on 31 drugs associated with various risk of TdP, and performed simulations with a
series of mathematical models of cardiac cells to integrate information on multi-channel block,
resulting in improved prediction of TdP risk. Ouillé et al. [Ouillé et al., 2011] picked five TdP-
associated ion channels, including three potassium channels (IKR, IK1, and IKS), one sodium (INa)
and one calcium (ICaL) channel, and elucidated the mechanisms of drug-induced TdP using ion
channel blocking profiles. They studied the effects of known torsadogenic and non-torsadogenic
compounds on these ion channels, investigated their functions in the generation of drug-induced
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TdP and QT prolongation, and identified that INa and IK1 play roles that are as important as IKR in
safety pharmacology. This study motivated us to use the blocking profiles of the five ion channels
as the second view to improve our MVL models.
!2-norm co-regularization has been highly prevalent in MVL algorithms due to its ease of im-
plementation, while our proposed !1-norm co-regularized MVL method can be more advantageous.
To our best knowledge, this work is the first attempt to formulate the prediction of drug-induced
QT prolongation as a MVL problem, integrate the complex relevant knowledge from two diverse
domains, and build accurate models using limited and noisy available data. Finally, the rest of this
chapter is organized as follows: in Section II we introduce our new MVL methods in more detail.
Data collection, feature extraction, and all experimental and comparison results are described in
Section III. We then conclude our work in Section IV with insightful observations.
7.3 Methods
In our data set, each sample has two view vectors. For labeled samples, the two view vectors
are associated with the same label, while unlabeled samples have no label but can be helpful on
improving model performance. In this section we discuss our proposed !1-norm co-regularized
MVL algorithm in detail, including how we integrate information from all views and derive the
problem formulation. We also derive the analytic form of the gradients of the objective functions
for simultaneous optimization, as compared to the traditional alternate optimization technique.
7.3.1 !1-norm Co-regularized Multi-view Learning
Suppose we have V views and for each view v = 1,2, ...,V , use Xv # RN$Mv to denote the feature
matrix with N samples and Mv features on view v. Let xi represents the concatenated row feature
vector for sample i = 1,2, ...,N. The N samples can be partitioned into two subsets L and U: a
small number of labeled samples {(xi,yi)}i#L in L, and a set of unlabeled sample {xi}i#U in U,
where |L|+ |U| and the label yi # {%1,1}. The basic idea underlying co-regularized multi-view
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learning is to learn one mapping function hv on each view v so that these functions agree each other
on an unlabeled sample as much as possible while the error on the labeled samples is minimized.








where xi,v represents the feature vector in the v view for sample i. The view mapping functions h1,
h2, ..., hv are obtained by minimizing the following objective function over these view functions:













where the first term is the loss function that penalizes the misclassification on labeled samples, the
second term is to regularize the mapping function on each view with !p-norm (1 ) p )+-) so that
irregular solutions will be filtered out, and the final term is to penalize the disagreement among the
prediction results from different view functions and to drive them to agree one another as much as
possible. Here parameters {$ j} are the strength of !1-norm regularization terms in all views, and
µ is the coupling parameter that regularizes the prediction disagreement using unlabeled data. By
minimizing the sum of these three terms, co-regularization based MVL aims to identify a set of
regular mapping functions that minimize misclassification rates on labeled samples and agree one
and another on the predictions of unlabeled samples as much as possible.
For simplicity, without loss of generality we consider only two views and take least square










,h1(x1i )%h2(x2i ),22, (7.3)
By applying a linear mapping function Wv on view v = 1,2, hv(Xv) = XvWv, where Wv is a Mv $1
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column coefficient vector for view v, we have a metricized objective function as follows:








If !2-norm co-regularization is used in Equation (7.4), this objective function is convex and
smooth, and is usually optimized using the alternate optimization approach [Yu et al., 2007, Kr-
ishnapuram et al., 2004], i.e., alternately optimizing one view with the other view fixed until con-
vergence. When we use !1-norm co-regularization as in Eqn.(7.4), the objective function becomes
convex but not smooth. However, by reformulating this function properly we can optimize both
views simultaneously. Let [.] denote the horizontal concatenation of two matrices Z1 # Rn$p and
Z2 #Rn$q, and then [Z1 Z2]#Rn$(p+q). We concatenate column vectors W1,W2 and matrices X1,X2
as W = [W T1 W
T
2 ]
T , XL = [X1 X2]x#L, and XU = [X1 %X2]x#U . The objective function F in Eqn.(7.4)
can be rewritten as
F(W ) = ,Y % 1
2




= (Y % 1
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µ(XUW )T XUW, (7.5)
where ($ ) is a (M1 +M2)$ 1 constant vector with the first M1 elements as $1 and the remaining
M2 elements as $2. It is straightforward that we can derive the analytic form of the gradient of the








+$ ! sign(W ), (7.6)
We then use the LBFGS (Limited-memory Broyden-Fletcher-Goldfarb-Shanno) method [Matthies
& Strang, 1979, Nocedal, 1980] to minimize the objective function in Equation (7.5). With the
known analytic form of the gradient as in Equation (7.6), the optimization process can be very
efficient. Once the optimal value of the concatenated vector Wopt is obtained, the prediction on
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new samples with two views (xnew1 ,x
new
2 ) is defined as
ynew = sign([xnew1 x
new
2 ]Wopt/2), (7.7)
Finally the prediction accuracy, precision, and recall can be computed by comparing ynew with the
ground truth.
7.3.2 !2-norm Co-regularized Multi-view Learning
The !2-norm co-regularized MVL method has been discussed in many previous work [Sindhwani
& Niyogi, 2005,Sindhwani & Rosenberg, 2008]. The objective function of this MVL method is as
follows,








Some previous works use an alternate optimization method to identify optimal W1 and W2. The
alternate process can be very time-consuming, however we can apply some reformulation tricks
and implement it in a more efficient matter. Similar to !1-norm co-regularization, the gradient of















where variables W , Y , XL, XU , and U have the same meaning as in the previous subsection. W11
and W22 are vectors with the same length of W , and are obtained by appending 0’s at the end of the
original vector W1 and at the beginning of W2, respectively. With this gradient we can optimize the
objective function in Equation (7.8) similarly as for our !1-norm co-regularized MVL method.
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Table 7.1: Summary of data and results for the second view generation.
Ion channels AID Active Inactive # Used Accuracy
INa / 8 17 All 0.788
ICaL / 53 24 All 0.750
Ikr 376 250 1703 200 0.789
Iks 2642 3878 301,738 200 0.778
Ik1 2032 926 1,338 200 0.739
7.4 Results
In this section, we began our discussion with an introduction to how we collected, cleaned, and
represented the TdP-related drugs and those compounds with known binding activity to available
human proteins, including the five TdP-associated ion-channel proteins. For performance com-
parison, three reference methods are selected as comparison baselines. SVMs [Burges, 1998] is
a widely used single-view supervised learning algorithm with excellent performance. The LIB-
SVM [Chang & Lin, 2001] implementation and RBF kernels were used in all experiments. As a
generalized linear method, !1-regularized logistic regression (LLR) [Koh et al., 2007] is another
excellent single-view supervised learning method can construct a model that estimates probabili-
ties, e.g. for medical diagnosis and credit scoring. In this chapter, we used the algorithm proposed
by Boyd et al. [Koh et al., 2007] to run our experiments of the LLR method. The third reference
method is the !2-norm co-regularized MVL method, which has been discussed in many previous
works [Sindhwani & Niyogi, 2005, Sindhwani & Rosenberg, 2008] and introduced in the METH-
ODS section.
7.4.1 Data set and feature extraction
We collected the compound set of drug-induced QT prolongation from the home page of University
of Arizona CERT (http://www.azcert.org/) [Woosley, 2003] and the work by Ouillé et. al
[Ouillé et al., 2011]. We merged these two data sets by removing redundant and/or inconsistent data
points, resulting in a set of 28 drug compounds labeled as “TdP risk”, 40 labeled as “possible TdP
risk”, and 74 with other less reliable evidence of QT prolongation. In our experiments we treated
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the 28 drugs with “TdP risk” labels as positive samples, the 40 drugs with "possible TdP risk"
labels as positive or unlabeled samples, and the remaining 74 compounds as unlabeled samples
whose labeled to be determined by our MVL models. For negative samples, we extracted all
approved drugs from the DrugBank database [Wishart et al., 2006, Wishart et al., 2008], excluded
all drug compounds that are associated with QT prolongation and/or TdP risk with even very weak
evidence, and obtained a set of 1,221 drug compounds as putative negative samples.
We used molecular signature descriptors [Faulon et al., 2004] to extract features from chemical
structures. In a molecular signature vector, each component is the number of occurrences of a
particular atomic signature in the molecule. An atomic signature is a canonical representation of
the substructure surrounding a particular atom, including all atoms and bonds up to a predefined
number (called the signature height) of consecutive bonds from the given atom. We set the signa-
ture height at 2 for all compounds, filtered out all atomic signatures with frequency less than 4%,
and finally obtained about 100 features for each compound. We used drug signature descriptors as
the first view of our data set.
In our experimental study, we first randomly selected an equal number of negative and positive
samples and combined them with unlabeled data to make a balanced subset, from which we ran-
domly selected 20% positive and 20% negative samples for testing. We used the remaining 80%
labeled and all unlabeled samples for training with 10-fold cross validation to select the best model
parameters. For each experimental setting, we repeated the experiment for 50 times using random
sampling, and reported the mean and standard deviation of testing accuracy, precision, and recall,
which are defined as (TP+TN)/S, TP/(TP+TN), and TP/(TP+FN), respectively, where TP is true
positive, TN is true negative, FN is false negative, and S is the total number of testing samples.
7.4.2 Generating the second view
In the MVL framework, each data sample has multiple feature vectors, one from each view. Our
first view is taken from compound structures also using molecular signature descriptors [Faulon
et al., 2004]. We set signature distance at 2 and frequency threshold at 4%, and ended up with a
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vector of "90 non-negative features for each compound. We first used the binding profiles of all
drug compounds to the five ion-channel proteins as the second view. For the binding activity that
are unknown or unavailable, we have built protein-chemical interaction prediction models to find
appropriate decisions, resulting in a vector of five binary elements, in which a bit is set to 1 if a
drug compound inhibits an ion channel, and 0 otherwise. To this end, we manually searched for
binding compounds of the five picked ion channels from the PubChem database. For the potassium
ion channels IKR, IK1, and IKS, we identified multiple target-based bioassays that use them as target
proteins, and then selected bioassays with AID 376, 2032 and 2642 for each of them, respectively.
Each assay provides hundreds of active compounds and a large number of inactive compounds.
For the calcium ion channel ICaL and the sodium ion channel INa, we identified multiple related
target-based assays with few tested compounds. We decided to use those tested compounds with
activity less than 1µM as active and the rest as inactive, and obtained 8 (53) weakly active and 17
(24) inactive compounds for the ion channel INa (ICaL).
We randomly selected 100 active and 100 inactive compounds for the potassium ion channels
as a balanced data subset and used all active and inactive compounds identified for the sodium
and calcium channel. The model construction and selection process is as follows: first 20% ac-
tive and 20% inactive compounds were randomly selected as the testing set and the rest 80% as
the training set, and 10-fold cross validation were applied to the training set with support vector
machines (SVMs) and RBF kernels to build one model for each ion channel using its own binding
compounds. In 10-fold cross validation, the training data was randomly split into 10 equal disjoint
subsets. Nine subsets were used for training a model, and the rest subset was used as a validation
set for validating the model. The cross-validation process repeated for 10 times with each subset
used exactly once as the validation set. Each experiment was repeated for ten times, and a com-
pound was considered to be active to an ion channel if it was predicted as active for six or more
times. Eventually our models have an average accuracy of about 73-78%, as shown in Table 7.1.
Though informative, the binding profiles to the five ion-channel proteins has two limitations as
the second view: the dimensionality of the resulting feature vectors is small and the feature values
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were obtained from predictions due to insufficient availability of experimental data. An reasonable
alternative is to use the binding profiles of each drug compound to many human proteins as the
second view. We obtained the protein binding profiles of the drug compounds from the STITCH
[Kuhn et al., 2008, Kuhn et al., 2010] database, which integrates information about chemical-
protein interactions from metabolic pathways, crystal structures, binding experiments, drug-target
relationships, and text-mining results. Additional interactions in STITCH are extracted from other
databases such as DrugBank [Wishart et al., 2006,Wishart et al., 2008]. Each proposed interaction
is associated with a relevance score and can be traced back to the original data sources. We mapped
the 1,363 drug compounds to the STITCH database and identified at least one interacting human
proteins for 791 of them, and the total number of human proteins that are interacting with ten
or more of the 791 drug compounds is 1,783. Hence the second view of a drug compound is
represented by a binary vector of 1,783 elements, in which a bit is set on if the compound is
interacting with the protein at the index, and is set off otherwise.
7.4.3 Model Construction and Selection
There are three model parameters to be optimized for the !1-norm and !2-norm co-regularized
MVL methods in the training process: $1 and $2 are the strength of !1-norm regularization terms
in the two views, and µ is the coupling parameter that regularizes the prediction disagreement using
unlabeled data. These real-valued parameters allow flexible tradeoffs between different regulariza-
tion terms, and thus finding their optimal values is crucial for model selection. Our algorithm takes
four input parameters: the number of features m1 in the first view, labeled samples XL from two
views and their labels Y , unlabeled samples XU from both views, and outputs the mapping function
W . Input parameter m1, Y , XL, and XU are constant during the optimization process, while the three
model parameters $1, $2 and µ are to be determined using grid search.
We used 10-fold cross validation along with an exponential grid search strategy to identify
the optimal model parameters as described previously. First 20% labeled samples were randomly
selected as testing data and the rest 80% was split into 10 equal subset, nine as the training set and
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the other as the validating set. The object function in Equation (7.5) was minimized regarding to
the mapping function vector W on the training set for each given set of $1, $2, and µ values. The
obtained optimal W was then applied to the validating set to calculate the validation accuracy with
the given model parameters. We repeated this cross-validation process for 10 times and achieved
the mean validation accuracy. Note that if the mean accuracy is less than 50%, we considered this
training process was failed and a new process would be initiated. The set of model parameters ($1,
$2, µ) that maximize the mean validation accuracy were selected as the best model parameters,
which are applied to the unused testing set to compute the final testing accuracy, precision and
recall.
7.4.4 Experimental Results
In this section, we compared our proposed !1-norm co-regularized MVL algorithm (!1-MVL) with
SVMs, !1-regularized logistic regression (LLR), and the !2-norm co-regularized MVL method
using both our proposed optimization (!2-MVL) and alternate optimization (!2-MVL-ALT) tech-
niques, and evaluated their performance using testing accuracy, precision, and recall. Note that
our results were obtained from 20 repeated experiments, so the performance differences between
different methods should be considered significant. We tested these five methods at various exper-
imental settings to investigate the contribution and influence of the related factors on prediction
performance.
First we use the ion-channel binding profiles as the second view, and the data set consists of
28 positive, 40 possible positive, 74 unlabeled and 1,221 putative negative samples. If we used
only 28 positive samples and treated the 40 possible positive samples as unlabeled, we then have
114 unlabeled samples. The results of the five methods were summarized in the first five rows
in Table 7.2. We found that our !1-MVL method significantly outperformed not only the SVL
methods (SVMs and LLR) for 5-6%, but also the !2-MVL method for about 3.3% on prediction
accuracy. For precision, the !1-MVL method was slightly better than SVMs and LLR, and much
better than !2-MVL methods. All MVL methods have much better recall than SVMs and LLR. All
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Table 7.2: Prediction accuracy using ion-channel binding profiles. Standard deviations included in paren-
thesis.
|XL| = 28 |XL| = 68
Method |Xu| Accuracy(%) Precision(%) Recall(%) |Xu| Accuracy(%) Precision(%) Recall(%)
SVM / 72.7(6.0) 77.9(9.6) 72.5(10.5) / 68.7(4.9) 69.2(5.8) 69.6(3.9)
LLR / 71.2(7.8) 77.9(10.5) 65.8(13.3) / 67.6(7.4) 70.1(9.0) 65.7(8.4)
!1-MVL 114 77.1(7.0) 80.2(8.5) 82.5(9.6) 74 71.6(3.8) 70.7(5.1) 72.3(5.4)
!2-MVL 114 74.8(7.6) 73.9(7.7) 81.7(9.1) 74 69.3(6.2) 70.6(6.1) 68.6(7.4)
!2-MVL-ALT 114 74.4(7.5) 73.6(8.0) 80.5(7.6) 74 69.6(6.6) 69.7(5.9) 69.1(7.4)
!1-MVL 0 75.9(7.8) 78.9(7.3) 81.5(9.2) 0 69.8(6.1) 71.1(5.5) 69.6(6.6)
!2-MVL 0 73.1(6.1) 76.4(6.2) 78.1(11.8) 0 67.5(7.3) 68.0(6.5) 67.5(7.6)
!2-MVL-ALT 0 74.8(5.2) 77.6(7.4) 79.5(7.6) 0 68.7(6.5) 69.4(6.0) 68.9(5.7)
these performance metrics consistently reveal that our proposed !1-MVL method performs better
than the reference methods. Moreover, to investigate the contribution of the unlabeled samples to
prediction performance, we replaced the matrix XU with a zero matrix of the same dimensionality,
and performed similar experiments described above. We listed the results in the last three rows in
Table 7.2. We observed apparent decrease of the !1-MVL method on accuracy and recall, while
the precision results are still comparable or slightly better than previous experiments. We can
approximately estimate the contribution of unlabeled samples in the the !1-MVL method is about
1.1%, which is non-trivial considering that the total accuracy improvement of our MVL method is
only 5-6% compared to SVL methods. Although the ion-channel binding profiles has very small
dimensionality as the second view, its contribution to the performance improvement is significant
by comparing the results of the MVL methods with the SVL methods.
If we gave them more confidence on the 40 drug compounds labeled as “possible TdP risk”and
used them as positive samples, we would have more labeled and less unlabeled samples. With 68
positive samples, we did similar experiments to investigate the influence of the number of labeled
samples on prediction performance. All results with the same experimental settings as above are
summarized in right columns in Table 7.2. By using those “possible positive samples” as positive
samples, we observed significant performance decrease on all methods. Although the !1-norm
co-regularized MVL method is still better than the baseline methods, the performance advantage
shrank to 1-2%. By adding unreliable positive samples to our data set, we introduced many false
positives and thus compromised the prediction accuracy. Moreover, the precision of the !1-MVL
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Table 7.3: Prediction accuracy using general protein binding profiles. Standard deviations included in
parenthesis.
|XL| = 21 |XL| = 45
Method |Xu| Accuracy(%) Precision(%) Recall(%) |Xu| Accuracy(%) Precision(%) Recall(%)
SVM / 67.5(9.5) 69.8(11.1) 59.0(15.5) / 64.2(5.3) 67.3(9.1) 57.2(9.2)
LLR / 69.0(9.1) 71.6(11.0) 60.0(15.1) / 61.9(5.6) 68.6(10.3) 49.4(11.8)
!1-MVL 71 69.1(6.4) 73.0(8.7) 61.3(11.0) 47 68.1(6.4) 73.0(9.7) 61.3(10.8)
!2-MVL 71 67.5(7.4) 70.1(9.0) 56.7(8.5) 47 67.5(11.4) 70.1(9.0) 56.7(10.5)
!2-MVL-ALT 71 64.7(7.3) 68.5(7.5) 56.7(7.4) 47 64.7(11.3) 68.5(8.4) 56.7(8.4)
!1-MVL 0 68.3(6.4) 72.6(5.7) 60.7(8.5) 0 69.3(5.4) 72.6(6.7) 60.7(8.5)
!2-MVL 0 65.0(5.7) 70.1(7.6) 54.4(6.0) 0 65.0(5.7) 70.1(8.6) 54.4(7.0)
!2-MVL-ALT 0 66.7(5.9) 71.0(8.8) 55.0(8.1) 0 66.7(7.0) 71.0(8.8) 55.0(8.1)
method decreased about 10%, which more clearly demonstrates that the data set contains much
more false positives than before, according to the definition of precision. We also found that the
precision of !2-MVL method dropped only about 3%. The observation showed that our proposed
!1-MVL method is more sensitive to false positive samples. Finally, it is easy to notice that the
performance of the MVL methods fluctuated very slightly when we have different numbers of
unlabeled samples, apparently because the contribution of unlabeled samples have been offset by
introducing more false positive samples.
As an independent view, the ion-channel binding profiles have very small dimensionality and
most of the feature values were obtained from SVM predictions. We were then seeking to use
the general protein binding profiles of the drug compounds as the second view, and the STITCH
database provided valuable binding information for many human proteins. Through label mapping,
the number of compounds labeled "TdP risk", "possible TdP risk", and other less reliable TdP
evidence is 21, 24, and 47, respectively, and the number of negative compounds is 699. In exactly
the same set of experiments as previously, we first used 21 positive, 71 unlabeled, and 21 randomly
selected negative samples, and later used 45 positive, 47 unlabeled, and 45 randomly selected
negative samples, and each experiment is repeated for 20 times. At the first step, 20% labeled
samples were randomly selected as the testing set, and 10-fold cross validation was applied to the
rest 80% labeled and all unlabeled samples for selecting optimal model parameters. We also tested
the contribution of unlabeled samples by replacing them with a zero matrix of the same size in our
methods, as shown in Table 7.2.
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Surprisingly, the performance using this alternate second (Table 7.3) view is significantly worse
than the ion-channel binding profiles in all experimental settings. One reason might be that the
general protein binding profiles is not relevant to QT prolongation. Therefore, the ion-channel
binding profiles provided significant relevant information about QT prolongation with just five
features.
7.4.5 Time Complexity
Finally, there are totally three implementations of the !1-MVL and !2-MVL methods using si-
multaneous or alternate optimization, which alternately optimizes one view with the other view
fixed iteratively until convergence of each mapping function. We used the same convex mini-
mizer (LBFGS algorithm) and convergency threshold for objective functions and gradients from
different MVL methods. In this section, we compared the time complexity of the !1-MVL and
!2-MVL methods by varying the number of repeated experiments under identical programming
and running environments. We ran all experiments using 28 positive and 114 unlabeled samples,
and repeated for 1, 3, 5, 7, and 10 times on a multi-core cluster, and reported the CPU time used
by each method, as plotted in Figure 7.1. From the curves of the !2-MVL, we found that the si-
multaneous optimization technique is 3"4-fold faster than alternate optimization. If we instead
used alternate optimization to implement the !2-MVL, the !1-MVL is then about two-fold faster.
When simultaneous optimization is applied to both MVL methods, the !1-MVL is two-fold slower
than the !2-MVL method, maybe because the !1-MVL method has a non-smooth convex objective
function.
7.4.6 Contribution of the Second View
In this section we discussed the contribution of the ion-channel protein binding profiles of the
drug compounds as the second view to final models, since this view significantly improved the
performance of our !1-norm co-regularized MVL method, comparing with the single-view learning
methods such as SVM and LLR. In the final models, we extracted the model coefficients of these
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Figure 7.1: Computational time with more repeating experiments. “L2-MVL-ALT” stands for the !2-norm
MVL method implemented using alternate optimization.
five binary features from the second view, and calculated the mean and standard deviation of these
coefficients under the four different experimental setting previously described. According to the
fourth chapter in [Hastie et al., 2009], the mean to standard deviation ratio, called Z-score, of
a feature’s model coefficient measures the significance of this feature’s contribution to the final
models. From Table 7.4 we can find that the ion channel IK1 plays a relatively more important role
since its Z-score # [0.92,1.33] is much greater than other ion channels. This finding also partly
matches the observation in [Ouillé et al., 2011], in which ion channel INa and IK1 are found to play a
key role in the generation of drug-induced QT prolongation and TdP. In our models the importance
of the ion channel INa was not identified, mainly because we have very few training samples (8
weak positives and 17 negatives) available for this ion channel in the data set. In addition, the
Z-scores of ICaL and IKS are very close to zero, and can be reasonably considered as the evidence
of the sparsity of our final models, i.e., two our of the five ion-channel feature was considered no
significant relevance, and we can set the corresponding coefficients as zero.
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Table 7.4: Z-scores of LLR model coefficients for the five ion-channel proteins.
|XL| |Xu| INa ICaL IKR IKS IK1
28 114 0.308 0.061 0.300 0.082 1.327
28 0 -0.134 -0.077 0.042 -0.024 1.916
68 74 0.337 0.039 0.615 -0.090 0.923
68 0 0.434 -0.020 0.454 -0.097 0.968
7.5 Discussion
In this chapter we aim to construct accurate prediction models with very limited and noisy data that
are available, and propose a novel !1-norm co-regularized multi-view learning algorithm on pre-
dicting drug-induced QT prolongation. By implementing our MVL method and the !2-norm coun-
terpart with a reformulation trick and optimized mapping functions on all views simultaneously,
we achieve 3-4 fold speed increase over the previously used alternate optimization technique [Yu
et al., 2007,Krishnapuram et al., 2004], and result in more intuitive and sparse models. It is critical
not to mess up our mixed regularization with the fused lasso penalty [Liu et al., 2010, Tibshirani
et al., 2005] since they take place in different spaces, and have distinct working mechanisms. We
conduct experiments under various settings to investigate the contribution and influence of the
number of unlabeled samples and labeled samples. Experimental results show that our !1-MVL
method outperforms not only two excellent SVL methods (SVMs and LLR), but also the widely
used !2-norm co-regularized MVL method with the measurement of testing accuracy, precision,
and recall.
To handle the challenge of limited and noisy labeled samples, we extract the second view for
all TdP related drug compounds from critical related works, and pick five ion-channel proteins
that have been found highly relevant to the QT prolongation effect. The contribution of the sec-
ond view has been clearly demonstrated by our comprehensive experiments and significant higher
prediction accuracy in both the !1-norm and !2-norm co-regularization framework. From the coef-
ficients in the final models, we analyzed the significance of the contribution of each ion channel to
QT prolongation, and our finding partly matched previous work [Ouillé et al., 2011]. We design an
alternative as the second view using the general human protein binding profiles, whose dimension-
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ality can be up to 1,783 though we use compress it to about 180 features. The experimental results
are surprisingly worse than the previous five-dimension view, which reveal that the ion-channel
view is more relevant.
Our !1-MVL method also has limitations. We observe that the variance of our experimental
results is somehow remarkable from both Table 7.3 and 7.2, and hence the model stability of our
MVL method is yet satisfactory. Due to the limited availability of ion-channel protein binding
profiles, the five-dimension view is obtained from prediction. The models used to predict our
second view data give prediction accuracy of 73-78%, which means that our second view data
have 22-27% noise. Experiment results showed that when more false positives are introduced, the
performance of our MVL method decreases dramatically. As more ion-channel binding data of
drug compounds become available, our MVL method should expect even better performance.
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Chapter 8
Inductive Multi-task Learning with
Multiple View Data
In this chapter, we extend our MVMT learning algorithm to handle multi-view data with missing
views and to model more complex task relationships. For data with missing views, the extended
MVMT learning method learns a decision function only on each view present in a task. In addi-
tion, we use the task relationship learning technique to model multi-task data with more complex
task relationships, where those tasks may be positively or negatively correlated, or even have no
correlation. The simple !2–regularization technique will oversimplify the problem and distort the
decision boundary. The extended MVMT learning methods can be applied to more applications.
Our contribution in this chapter is on novel methodology development.
8.1 Introduction
In many real-world applications, it is becoming common to have data extracted from multiple
diverse sources, known as “multi-view” data. Each data source is referred as a view [Culp et al.,
2009]. Mining and learning with multi-view data (i.e. multi-view learning, or MVL) has been stud-
ied extensively [Blum & Mitchell, 1998, McCallum et al., 2000, Sindhwani & Niyogi, 2005, Sind-
hwani & Rosenberg, 2008,Amini et al., 2009,Culp et al., 2009]. For instance, in multi-lingual text
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categorization [Amini et al., 2009], each language represents a view. For scientific document cate-
gorization, each document has two views: the bag-of-words features and their citations [McCallum
et al., 2000]. In classifying webpages [Blum & Mitchell, 1998], we may have three views for a
given webpage: the content of the webpage, the text of any webpages linking to this webpage, and
the link structure of all linked pages. The limitation of these MVL methods is that they essentially
learn a single task individually at a time.
In this chapter, we study a new direction of multi-view learning where there are multiple related
tasks with multi-view data (i.e. multi-view multi-task learning, or MVMT Learning). MVMT
Learning has many real-world applications. For instance, sentiment classification for music re-
views and news comments is two related tasks, and they both share word features from the com-
ments or reviews. In protein functional classification, each protein has features from multiple views
(e.g. protein sequences, 3D structures) and may be associated with multiple functional classes. In
image annotation [Boutell et al., 2004], each image has features extracted from multiple sources
and can be annotated with multiple objects such as a boat, a bird and etc. The interplay of mul-
tiple views and multiple tasks in the same learning problem motivates us to investigate multi-task
learning in the multi-view framework.
Despite the wide application areas, multi-task learning (MTL) with multi-view data only caught
the attention of the research community recently. Cavallanti et al. [Cavallanti et al., 2010] devel-
oped linear algorithms for online multi-task learning. Though there may be multiple views, each
task has only one view in their settings. He et al. [He & Lawrence, 2011] proposed a graph-based it-
erative algorithm (IteM2) for multi-view multi-task learning with applications to text classification.
The IteM2 algorithm projects any two tasks to a new Reproducing Kernel Hilbert Space (RKHS)
based on the common views shared by the given two tasks. Though impressive preliminary results
have been obtained in text categorization applications, the treatment of MVMT learning in IteM2
is limited. First IteM2 is a transductive learning method, hence it is unable to generate predictive
models on independent, unknown testing samples. A consequence of the transductive learning is
that the training data set must have the same fraction of positive samples as in the testing data set.
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In addition, the method is designed primarily for text categorization where the feature values are
all non-negative 1, since otherwise Proposition 4.1 and Theorem 4.2 in [He & Lawrence, 2011]
will not hold. There are many real-world data sets with a significant portion of features with nega-
tive values that the IteM2 method is unable to handle. In this chapter IteM2 is the most important
competing method that our proposed MVMT method will compare with.
We propose an inductive learning framework to address the general MVMT learning problem.
Our starting point is a MVL framework based on co-regularization where we train multiple clas-
sifiers, one for each view, with the goal to obtain those classifiers that are in-agreement with one
another on the unlabeled samples and achieve minimal classification errors on the labeled samples
simultaneously [Sindhwani & Niyogi, 2005, Sindhwani & Rosenberg, 2008]. We add a couple of
regularization factors (e.g. !2 regularization [Evgeniou & Pontil, 2004]) to ensure the functions that
we learn from each task are similar to each other, resulting in a convex objective function, which
makes the subsequent optimization easy. In addition, our algorithm is flexible when one view is
completely missing for a task. In many application we may have structured view missing, and our
algorithm extends to these cases naturally with the regularization function that we use. Moreover,
it is quite often that not all tasks in multi-task learning are uniformly related to each other [Chen
et al., 2010b, Kim & Xing, 2010]. To handle this, we introduce a positive semi-definite matrix to
capture the relationship of tasks that may not be uniformly related to each other.
In summary, the main contributions of this work are two-fold. First we propose a general induc-
tive learning framework for the challenging multi-view multi-task problems using co-regularization
and task relationship learning. Secondly we design efficient algorithms to optimize the objective
function with either close-form solutions or iterative optimization solutions. We conducted com-
prehensive experimental evaluations of our MVMT methods on three real-world MVMT data sets,
and compared our MVMT methods with the state-of-the-art methods, including the competing
IteM2 method.
The rest of this chapter is organized as follows. In Section 2, we briefly review related work
1Refer to page 3 in He et al. [He & Lawrence, 2011]
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on multi-view learning and multi-task learning. We explain our co-regularized MVMT algorithms
and their implementations in details in Section 3. We have experimentally evaluated our methods
on three real-world data sets and compared our results with those from the state-of-the-art methods.
We present the results in Section 4 and conclude our work in Section 5.
8.2 Related Work
Multi-view semi-supervised learning has attracted significant research interest in recent years
[Dasgupta et al., 2001, Abney, 2002, Muslea et al., 2002, Balcan & Blum, 2005, Wang & Zhou,
2007, Christoudias et al., 2008, Wang & FitzGerald, 2010]. The underlying assumption of multi-
view algorithm is that each view is conditionally independent from other views [Blum & Mitchell,
1998] and is sufficient for constructing a predictive model [Amini et al., 2009, Dasgupta et al.,
2001]. We briefly overview MVL methods that are widely used. Based on how information
from multiple views is integrated, existing MVL algorithms can be roughly classified into a va-
riety of categories. Co-training [Blum & Mitchell, 1998] iteratively labels unlabeled samples
using the models built from existing labeled samples, and expands the pool of labeled samples
until convergence of performance [Dasgupta et al., 2001, Nigam & Ghani, 2000]. Manifold co-
regularization [Sindhwani & Rosenberg, 2008] was proposed based on a reproducing kernel Hilbert
space with a data-dependent co-regularization norm to explore the structure of unlabeled multi-
view data. Recently co-regularization [Sindhwani & Niyogi, 2005] attracted the attention of the
community due to its simplicity of optimizing a single regularized objective function.
When each task has only a limited number of samples, multi-task learning has been empirically
as well as theoretically shown to provide better predictive models with closely related tasks [Ando
& Zhang, 2005, Argyriou et al., 2006]. Some early MTL approaches assumed that either the
function parameters of different tasks are similar [Evgeniou & Pontil, 2004] or multiple tasks
share a subset of features [Argyriou et al., 2006]. These MTL methods imposed a regularization




















































Figure 8.1: Graphical representation of the multi-view multi-task learning framework.
proposed that the relatedness of multiple tasks has a structure such as a graph or a tree [Kim &
Xing, 2010, Chen et al., 2010b], or different tasks share a common subspace representation [Chen
et al., 2010a]. Another group of MTL methods [Zhang et al., 2010] pose no assumption on the
structure of task relatedness, and learn task relationship automatically from the input data, and
provide more modeling flexibility.
8.3 Inductive Multi-view Multi-task Learning
In this section, we propose a general inductive learning framework for multi-task learning with
multiple view data. We apply co-regularized MVL within each task, and the multiple related tasks
are learned jointly using task regularization or task relationship learning. We handle the special
case that some entire views are missing from some tasks, analyze the complexity of our MVMT
methods, and develop efficient optimization algorithms to achieve optimal solutions.
8.3.1 Notations
In this chapter, we use bold capital letters (e.g. X) to represent a matrix and bold lowercase letters
(e.g. x) to denote a vector. Lowercase letters (e.g. x) are used for scalars, and Greek letters (e.g $ )
for regularization parameters. We use [m : n] (n > m) to denote a set of integers in the range of m
to n inclusively. Unless stated otherwise, all vectors are column vectors.
Suppose we are given a set of N labeled and M unlabeled data samples for T tasks. In general
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we have limited supply of labeled samples but abundant supply of unlabeled samples, i.e. M - N.
We use Nt and Mt denote the number of labeled and unlabeled samples in task t # [1 : T ], thus
we have N = "t Nt and M = "t Mt . Each sample has features from V views and the total number
of features from all the V views is denoted as D. Let Dv be the number of features in the view
v # [1 : V ], and we have D = "v Dv.
For each view v present in task t, the feature matrix of the labeled samples is Xvt #RNt$Dv . The
feature matrix of the unlabeled samples is Uvt # RMt$Dv . Let yt # {1,%1}Nt$1 be the label vector
of the labeled samples in the task t. We write Xt = (X1t ,X2t , . . . ,XVt ), and Ut = (U1t ,U2t , . . . ,UVt ),
corresponding to the concatenated feature matrix of the labeled and unlabeled samples for task t,
respectively. It is common that in some applications not all tasks have features available from all
the V views, so we introduce an indicator matrix Id # {1,0}T$V to mark which view is missing
from which task, i.e. Id(t,v) = 0 if the view v is missing from task t, and = 1 otherwise. Using this
notation, we only handle “structured” missing views in the sense that if a view is present in a task,
it is present in all the samples in the task; if a view is missing from a task, it is missing in all the
samples in the task. Throughout the chapter we use subscripts to denote tasks and superscripts to
denote views.
8.3.2 Problem and Algorithm Overview
We illustrate the problem of learning multiple related tasks with multi-view data in Figure 8.1. We
hypothesize that we can construct better classification models by considering information from
multiple views and learning multiple related tasks jointly. In our method we learn one linear
mapping function fvt : RDv . {1,%1} for each view v present in the task t, and search for those
mapping functions based on two intuitions: (1) for a given task t, we expect that the mapping
functions fvt ’s from all its views agree with one another as much as possible on the unlabeled
samples, and (2) for a given view, we expect that all the mapping functions in different tasks
behave similarly. We formalize the two intuitions using regularization functions in a supervised
learning framework, and describe the details of the learning framework below.
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8.3.3 Co-regularized Multi-view Learning
The basic assumption underlying multi-view learning for a single task is that the multiple views
are conditionally independent and each view generates a predictive model that can be used to make
predictions on data samples, while the final models are obtained from these view models. Without
prior knowledge on which view contributes more to the final models than other views, we assume
that all views contribute equally, following [Sindhwani & Niyogi, 2005, Sindhwani & Rosenberg,
2008]. The final models are obtained by averaging the prediction results from all view functions
as follows:






where x has totally V views, xv is the set of features for view v, and f v is the view function
generated on view v.
In multi-view learning, we want the models built on each single view to agree with one another
as much as possible on unlabeled samples. Co-regularization is a technique to enforce such model




L(y, f (X))+ $
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, f,2 + µ
2 "v' *=v
, f v'(Uv')% f v(Uv),2, (8.2)
where ,., denotes the !2 norm. L(., .) is the loss function that penalizes the misclassification
on labeled samples. f v(Uv) is the prediction results by applying the function f v to each sample
in the unlabeled data for the view v. $ is the parameter that regulates the strength of the !2-norm
regularization on view functions, and µ is the coupling parameter that regularizes the disagreement
of different views. By minimizing the three terms jointly, an optimal set of view functions that
minimize the misclassification of labeled samples and maximize the agreement on the prediction
results on unlabeled samples can be identified.
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8.3.4 Task Regularization in MVMT Learning (regMVMT)
Given multiple related tasks with multi-view data, it is advantageous to learn these tasks in the
same framework to achieve the benefits of both multi-task learning and multi-view learning. One
approach to extend the co-regularized MVL framework is to learn each of the multiple task indi-
















where f vt is a view specific mapping function for the view v in the task t.
Apparently the formula does not take advantage of the presence of multiple related tasks. In
order to get benefit from the additional information, we apply an additional regularization function
that penalizes the difference of the view specific functions on the same view across different tasks.
For each view v # [1 : V ] in task t # [1 : T ], we learn a linear mapping function indexed by a
parameter wvt #RDv$1. We denote wt #RD$1 as the column vector by concatenating all wvt for the


















Using the least square loss function, we have the objective function for the T tasks with V



































where wvt , wt , $ , and µ were explained before. # is a new regularization parameter to penalize
the difference of view mapping function across different tasks for the same view. We call this
formalization “the regularized multi-view multi-task learning” (regMVMT).
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To solve the related optimization problem of regMVMT, we denote the objective function as F ,























Set Eq.(8.6) to zero, rearrange the terms and we have:























where IDv is a Dv $Dv identity matrix. Note that we can have such an equation for each view v
in the task t. To learn wvt , we must also learn wv
'
t from other views v' (v' *= v) in the task t and
wvt ' from other tasks t
' *= t on the view v. Eventually we have to learn all wvt ’s jointly from a large
set of equations as in Eq.(8.7) by taking derivatives regarding to each view in each task, as in the
following linear equation system:
LW = R, (8.8)
where L # RT D$T D is a sparse block matrix with TV $TV blocks. Each block corresponds to a
view in a task and its size is the feature dimensionality of the view.
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Matrix L has the following form:
%
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R = Vec([E11, ...,E1V ,E21, ...,E2V , ...,ET 1, ...,ETV ]), (8.9)
where Vec() denotes the function stacking the column vectors in a matrix to a single column vector.
Here column vector W and R are generated by stacking all column vectors wvt and Evt , respectively.
Note that L is a sparse block matrix with TV $TV blocks, and block matrix Atv, Btvv' , and Ct 'v are
defined in Eq.(8.7). The analytic solution of W can be easily obtained from Eq.(8.8) by taking the
inverse of matrix L . When there is a new data sample from task t with x!t as the concatenated row
feature vector of all the V view, the predictive outputs y!t is given by:
y!t = sign(x!t wt). (8.10)
Note that by setting # = 0 the regMVMT algorithm degenerates to the co-regularized multi-view
learning algorithm. Similarly set µ = 0 the regMVMT algorithm degenerates to the regularized
multi-task learning algorithm. These two methods are special cases of our MVMT method when
there is only one task or one view for each task, and we will implement them as comparison
baseline methods. In Figure 8.2 we show a comparison between the regMVMT method and the
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competing transductive IteM2 method on a data set for webpage classification. Here we could see
that regMVMT improves significantly upon the IteM2 method. Detailed experimental studies are
in Section 4.























Figure 8.2: Preliminary results on the WebKB data set.
8.3.5 Learning Task Relationships in the MVMT Framework (regMVMT+)
In many MTL applications, tasks may not be uniformly related to each other. A remedy to those
situation, as we investigate here, is to introduce a task relationship inference component [Zhang
et al., 2010]. The basic idea is to use a positive semi-definite . # RT$T to model the similarity
among T related tasks, and hence . must be with finite complexity. For single-view MTL problem,















s. t. . / 0, tr(.) = 1, (8.11)
where W is a matrix whose tth column is wt for task t. ,.,F is the matrix Frobenius norm. tr() is
the trace of a matrix.
When we have V views for the T task, we learn a task similarity matrix .v for each view v of
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s. t. .v / 0, tr(.v) = 1,v # [1 : V ], (8.12)
where wt is a column vector concatenated from wvt ’s for all v # [1 : V ], and Wv is a matrix whose
tth column is wvt for all t # [1 : T ]. The inverse of .v is a T $T matrix whose element at (i, j) is
the similarity between task i and j.
Though the objective function is convex regarding to both {wt} and {.v}, simultaneous opti-
mization of them is technically and computationally challenging. Alternate optimization of wt’s
and .v’s individually can achieve the optimal solutions efficiently. If we fix the {wt}’s and op-
timize the {.v}, take the partial derivative of the objective function in Eq.(8.12) with regard to
{.v}, and set it to zero. The analytic solution to {.v} is:
.v =
(WvT Wv) 12
tr((WvT Wv) 12 )
. (8.13)
Once .v is learned, we can use the same algorithm that we have derived in Eq. 8.7. We find that
only the block matrix Atv and Ct 'v are different from the formulas in Eq.(8.7), while the formulas
of matrix Btvv' and Etv remain unchanged. The new Atv and Ctv are as follows:




Ct 'v = #cvtt 'IDv , (8.14)
where cvi j denote the element (i, j) of the inverse of matrix .v, and it is a scalar constant in each
iteration. We denote this approach regMVMT+ since it is a variant extension of the regMVMT
method.
8.3.6 Dealing with Missing-view Data
In the previous subsections, we consider the ideal case that all tasks in a data set have complete data.
When we have incomplete data, the MVMT learning problem becomes more challenging. Missing
103
value imputation has been widely discussed, and here we are not concerned about randomly missed
feature values. We aim to handel the case of “structured” missing views. In the context of this
discussion, we focus on completely missing views for a task in the sense that if a view is present
in a task, it is present in all the samples in the task; if a view is missing from a task, it is missing
in all the samples in the task. We recognize that there is a more challenging case where we have
partially observed views (i.e. some views are missing from some samples in a task). Partially
observed views is beyond the scope of this chapter. A straightforward strategy to handel structured
missing views is to remove any tasks with missing views, which, however, will significantly reduce
the number of related tasks available and also discard useful information present in the remaining
views of those tasks.
To handel structured missing views, we introduce an indicator matrix Id # 1,0T$V to mark the
missing views for the T tasks with a total of V views for each task, i.e. Id(t,v) = Itv = 0 if the view
v # [1 : V ] is missing in the task t # [1 : T ], and Itv = 1 otherwise. Let Vt ) V and Tv ) T denote
the real number of views in task t and the number of tasks for view v, and we need to use Vt and
Tv to replace V and T in all the above equations, respectively. In addition, the indicator scalars
Itv, It 'v, and Itv' must be associated with the corresponding matrices from X and U. In matrix .v,
a task is considered uncorrelated to any other tasks in terms of view v if it does not has the view
v, and the dimension of .v will be reduced by one row and one column. Though .v may have
different dimensionality for different v, we learn each .v individually and we only need the trace
of the resulting product matrix.
If view v is missing from task t, wvt in W , Evt in R, and the ((t % 1)V + v)-th block row and
block column in matrix L are all-zero matrices. After removing these all-zero blocks from L ,
W , and R, we have their compact versions L ', W ', and R ', respectively. Eq.(8.8) is converted to:
L 'W ' = R'. (8.15)
Solving this equation is similar to Eq.(8.8).
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8.3.7 Analysis of the regMVMT Algorithm
The objective function in Eq.(8.5) is convex regarding to wt’s, hence it has a global minimum.
From the derivation of the matrix L , we can tell that it is symmetric. Since matrix L is obtained
from the derivative of a convex function, it must be at least positive semi-definite. If there is no
all-zero row or column in matrix Id , i.e. each task has at least one view and each view present in
at least one task, matrix L ' is also positive semi-definite.
The implementation of the regMVMT algorithm is straightforward with the analytic solution.
We first calculate the block matrices Avt ,Btvv',C
v
t , and the column vector Evt for each view v present
in each task t, construct the large sparse square matrix L and the long column vector R according
to the equations in Eq.(8.9). We then easily obtain the solutions wt’s as in Eq.(8.8) by computing
the inverse of matrix L for a given set of regularization parameters. The parameters $ , µ , and #
will be optimized using standard cross validation. Note that the first column of each input feature
matrix is an extra added unit vector to offset the intercepts (b) of linear functions. Since the inter-
cepts are not included in any regularization terms, an identity matrix with the first diagonal element
as 0 is multiplied with the constant terms ($ + #(T %1) and %#) in Eq.(8.7) when constructing the
matrix Atv and Ctv.
Let DT denote the number of rows or columns in L , and we have DT = "T,Vt,v=1 ItvDv, where
Dv is the number of features in view v. When there is no missing view in any task, we have
DT = T $D. Though the process of constructing square matrix L is complex, the speed-limiting
step of the regMVMT algorithm is the inversion of the large sparse matrix L in Eq.(8.9). The
construction of matrix L has a time complexity of O(T (T %1)D2+2(N+M)D2), and computing
its inverse matrix is of complexity O(D3T ), so the total number of features instead of the number of
data samples dominates the time complexity. Matrix L is highly sparse, symmetric, and positive
semi-definite, and the overall time complexity of the regMVMT algorithm is dependent on its
sparsity structure.
Lemma 8.3.1. The time complexity of the regMVMT algorithm is O((1+2n̄/T )D2T + 13D
3
T ), where
n̄ is the average number of samples in each task, DT = "T,Vt,v=1 ItvDv.
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Proof. It is straightforward that constructing matrix L and vector R has time complexity of
O((1+ 2n̄/T )D2T ), and the inversion of the positive semi-definite matrix L has time complexity
of O(13D
3
T ) using Chomsky decomposition. Hence we have the described overall time complex-
ity.
The constant factor hidden behind the asymptotic complexity depends on the sparsity structure
of matrix L . Since DT is generally much greater than T,V,N, and M, the running time is deter-
mined by the total number of features DT from all views present in all tasks. In addition, when
we store matrices in sparse matrix format, the space complexity of our algorithm is dependent on
the number of non-zero elements in matrix L and the space used by other much small matrices is
eligible. We can easily obtain the space complexity from the structure of matrix L .
Proposition 8.3.1. The space complexity of the regMVMT algorithm is O("t D2t +DtT (T %1))
approximately.
In real-world data sets, the number of views V is usually small (2 " 5), and the total number of
features D from all views is generally much greater than the number of tasks T . Generally D can
be in the range of a few hundred to thousands, and feature selection approaches are needed when
it is even larger. Due to the limit of the matrix size in most computer systems, our algorithm can
only handle up to tens of tasks, and learning problems with hundreds of tasks or more are hence
beyond the scope of this chapter.
8.3.8 Implementations of the regMVMT and regMVMT+ Algorithms
To summarize what we have discussed above, we present the efficient regMVMT algorithm in
detail, as shown in “The regMVMT Algorithm” pseudo code block. The inputs are the label vector
yt and feature matrix Xvt of labeled samples, the unlabeled feature matrix Uvt for view v in task
t, and model parameters {$ ,µ ,#}. The output of the regMVMT algorithm is the optimal linear
decision functions for all T tasks. The parameters $ , µ , and # will be optimized using standard
five-fold cross validation. Note that the first column of each input feature matrix is an extra added
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Algorithm 1 The regMVMT Algorithm
1: Input: {yt}Tt=1,{Xt}Tt=1,{Ut}Tt=1,$ ,µ,# .
2: Output: {Wt}Tt=1.
3: Initialize matrix L and vector R to be zero.
4: for (t,v) # [1 : T ]$ [1 : V ] do
5: Construct matrix Atv and vector Etv as in Eq.(8.7).
6: Construct matrix Btvv' and Ct 'v as in Eq.(8.7) for each v
' *= v, t ' *= t.
7: end for
8: Construct square matrix L and column vector R in Eq.(8.9).
9: Compute W := L %1R.
10: Split W into T vectors, and return {Wt}Tt=1.
unit vector to offset the intercepts of linear mapping functions. Since the intercepts are not included
in all regularization terms, an identity matrix with the first diagonal element as 0 is multiplied with
the constant terms ($ + #(T %1) and -#) in Eq.(8.7) when constructing the matrix Atv in line 5 and
the matrix Ctv in line 6, respectively.
The implementation of the regMVMT+ algorithm is similar to the regMVMT algorithm. One
difference is the construction of block matrix Atv’s and Ctv’s. An additional difference is that
regMVMT+ is an iterative algorithm, and within each iteration the optimization of wt’s uses a
procedure that is very similar to the regMVMT algorithm. We repeat the procedure until the pre-
defined convergence thresholds of wt’s and .v’s have been met or we have reached a maximal
number of iterations. It is expected that this method needs significantly more computational time
for the numerical solutions.
We design an efficient iterative algorithm to optimize both wt’s and .v’s alternately and im-
plement it as in “The regMVMT+ Algorithm” pseudo code block 8.3.8. First .v is initialized to
1
T IT (IT is the T $T identity matrix) for each view v, which corresponds to the assumption that all
tasks are initially uncorrelated. We optimize the convex objective function in Eq.(8.12) over wt’s,
update .v’s using Eq.(8.13), and then plug in the new .v’s to Eq.(8.12) to optimize wt’s again. The
procedure is repeated until the convergence of both wt’s and .v’s under a predefined threshold.
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Algorithm 2 The regMVMT+ Algorithm
1: Input: {yt}Tt=1,{Xt}Tt=1,{Ut}Tt=1,$ ,µ,# ,Nit ,/
2: Output: {Wt}Tt=1,{.v}Vv=1
3: Initialize W0 := 0 and .v0 := 1T IT for v # [1 : V ]
4: for it = 1 to Nit do
5: for (t,v) # [1 : T ]$ [1 : V ] do
6: Construct matrix Atv in Eq.(8.14) and vector Etv in Eq.(8.7)
7: Construct matrix Btvv' in Eq.(8.7) and Ct 'v in Eq.(8.14) for each v
' *= v, t ' *= t
8: end for
9: Construct square matrix L and column vector R in Eq.(8.9)
10: Compute W := L %1R
11: Update .v using Eq.(8.13) for each v # [1 : V ]
12: if ,W%W0,1 < / & ,.v %.v0,1 < / then
13: break
14: else
15: W0 := W
16: .v0 := .v for each v # [1 : V ]
17: end if
18: end for
19: Split W into T vectors, and return {Wt}Tt=1 and {.v}Vv=1
8.4 Experimental Results
In this section, we present the experimental results of the two proposed MVMT methods and
four baseline methods on three real-world multi-view data sets with multiple tasks. The baseline
methods that we used are detailed below.
Regularized MTL (regMT): If we consider no co-regularization on different views in a given
task, we convert the MVMT learning problem into the single-view MTL problem [Evgeniou &
Pontil, 2004] by concatenating the feature vectors from all views to a single feature vector and
merging multiple views into one view. Comparison with this baseline method can help demonstrate
the benefits from using multiple views instead of a single view.
Co-regularized MVL (coMV): By ignoring the multi-task relatedness, we apply the co-regularized
MVL method [Sindhwani & Niyogi, 2005] on each task. The implementation is obtained by setting
the parameter # = 0 in the regMVMT formulation.
Multi-task Relationship Learning (regMT+): We may learn the task relationships among the
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multiple related tasks from the input data when we consider no regularization on different views
in a given task. The implementation is obtained by setting the parameter µ = 0 in the regMVMT+
formulation.
Iterative MVMT (IteM2): We also compare our methods with the state-of-the-art MVMT
method proposed by He et al. [He & Lawrence, 2011]. The authors didn’t release the software, and
we implemented it according to the pseudo-code provided in the IteM2 algorithm in the original
work. This is the most important competing method that our methods will compare with.
8.4.1 Data Sets
We collected three multi-view data sets with multiple tasks. The first one is the WebKB data
set [Blum & Mitchell, 1998] with 1,051 webpages collected from four universities, and the goal
is to classify whether each webpage is course related or not. Here each university is a task, and
we have four tasks. There are three views for each webpage: the bag-of-word features from the
webpage title, from the webpage main text, and from the main text of the webpage with hyperlinks
to the given webpage. There is no missing views in this data set.
The second one is the email spam data set in the ECML 2006 Discovery Challenge 2, and the
goal is to classify if each email is spam or not. There are three email users with 2,500 emails for
each user, and each user is considered a task. Four bag-of-words views are created: one common
view shared by all three tasks, and three task specific views with each for a task. The common
view consists of the common vocabulary that exists in all the three tasks, while each task specific
view consists of the vocabulary unique to each task, as discussed in He et al. [He & Lawrence,
2011]. Each task has two missing views, which are the two views specific to the other two tasks.
The third data set is extracted from the NUS-WIDE Object web image database [Chua et al.,
2009] where each image is annotated by objects such as “book”, “bird”, and etc. We removed all
images that are associated with zero or only one object, resulting in an object data set consisting
of 3,545 samples in 31 tasks. We used a total of 634 features extracted from images [Chua et al.,
2http://www.ecmlpkdd2006.org/challenge.html
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Figure 8.3: Experimental results on the WebKB data set (left) and on the NUS-WIDE Object data set
(right).
2009], which can be considered as five views: 64-dim color histogram, 144-dim color correlo-
gram, 73-dim edge direction histogram, 128-dim wavelet texture, and 225-dim block-wise color
moments. We merged the five types of features for each sample into two views with the 225-dim
block-wise color moments as one view and the rest as the other view. By removing those tasks with
too few positive or negative samples, we obtained a multi-view data set with 11 tasks. Since this
data set consists of a significant portion of negative features, when we applied the IteM2 method to
it, we added a positive constant to the values of negative features of all samples so that all negative
features become non-negative. There is no missing views in this data set.
The three data sets are summarized in Table 8.1, where Np and Nn denote the total number of
positive and negative samples available in each data set. As stated in Section 3, T is the number of
tasks, V is the number of views, and D is the total number of features from all views.
Table 8.1: Statistics of Data Sets Used.
Data Set WebKB ECML2006 NUS-WIDE Object
V 3 4 2 " 5
T 4 3 11
View Missing? No Yes No
Np 230 2,543 389 " 1325
Nn 821 2,929 2220 " 3156
D 2,096 5,597 634
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8.4.2 Model Construction and Evaluation
In each MVMT data set we randomly select the same number n of labeled samples and the same
number m of unlabeled samples for each task, where n is varying in the range [20,80] with the
increment of 10, and m is generally 2 " 4 times of n. For each subset consisting of n labeled
samples and m unlabeled samples for each task, we first randomly selected 20% labeled samples
as the independent testing set, and the remaining 80% labeled and all unlabeled samples are the
training set.
The regularization parameters in our methods allow flexible tradeoffs between different regu-
larization terms. We apply five-fold cross validation on the training set to optimize the parameters
for each method discussed in this chapter: $ , µ and # for regMVMT and regMVMT+, $ and # for
regMT and regMT+, and $ and µ for coMV. For the IteM2 method, we performed five-fold cross
validation to optimize the parameter µ and b, but found not much difference. We simply used the
optimal values of parameter µ = 0.01 and b= 1 that were set in the original work [He & Lawrence,
2011]. We applied grid searching to identify optimal values for each regularization parameter.
After obtaining the optimal parameters for each method, we construct a predictive model us-
ing all the training samples and calculate the classification error for each task on the independent
testing set using the final task functions in Eq.(8.9). Each experiment was repeated for 10 times,
the mean classification error for each task was calculated separately, and the mean and standard
deviation of the classification errors across all tasks in each data set were reported. Here classifica-
tion error = 1% (T P+T N)/N, where T P,T N, and N stand for the number of true positives, true
negatives, and the total number of samples in the testing set, respectively.
8.4.3 Learning with Complete-view Data
We first consider the ideal case that all tasks have complete-view data, i.e. each of the T tasks has
features from all the V views and the indicator matrix Id is a unit matrix. We perform experiments
on the WebKB data set which has four tasks (T = 4) and each task shares all the three views
(V = 3). The left panel in Figure 8.3 shows for each method how the mean classification error
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changes with regard to the number of labeled samples. Note that the standard deviations are marked
as error bars in each curve.
We observe a common trend that the classification errors and the variances for all methods
decrease as the number of labeled samples for training increases. The two MTL baseline methods
(regMT and regMT+ perform marginally better than the MVL baseline method (coMV), but the
performance difference among the three baseline methods is not significant in a two-sample t-test.
We test the significance of the results between regMVMT and the two baselines regMT and coMV
with two-sample t-test, and find that regMVMT significantly outperform regMT and coMV at the
5% significance level. Similarly t-test shows that regMVMT+ is significantly better than the base-
line regMT+. Our proposed inductive MVMT methods (regMVMT and regMVMT+) significantly
outperform the transductive MVMT method (IteM2) by He et al. with the improvement margin of
up to 9 " 12%.
Next we investigate the performance of our MVMT methods on the NUS-WIDE Object data
set. We conduct similar experiments and present the results in the right panel in Figure 8.3. We
observe similar trends to the results of the WebKB data set. Our proposed MVMT methods (reg-
MVMT and regMVMT+) perform better than all the the baselines, especially the IteM2 method,
and the difference is statistically significant with a two-sample t-test.
Different from the previous data set, the regMVMT method with !2 regularization performs
slightly better than the variant MVMT method with task relationship learning (regMVMT+), but
the difference is not significance in the t-test. The performance of the three MTL/MVL baseline
methods are close and their curves are entangled. In this data set the improvement margin of our
MVMT methods is up to 8% over the transductive counterpart.
8.4.4 Learning with Missing-view Data
As we discussed earlier, it is common that the multiple tasks in real-world data sets do not share
all views. We would like to examine the performance of our MVMT methods compared with the
IteM2 method and other baseline methods in this setting. In the WebKB data set, we randomly
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Figure 8.4: Experimental results on the WebKB data set with one missing view for each task (left) and on
the ECML2006 Email data set that has two missing views for each task (right).
select one view in each task and masked it as a missing view. Hence a multi-view data set with
missing views is artificially created. Here we enforce a constraint that no more than two tasks miss
the same view. We perform the same experiments on this new data set using all the methods, and
present the results in the left panel in Figure 8.4. First we observe that the trend of the performance
curves of all methods are very similar to the left panel in Figure 8.3. Due to the information loss in
the missing views, the performance of all methods decreases for about 5%. Our proposed MVMT
methods build accurate models using the existing views in each task, and significantly outperform
the IteM2 method with an improvement margin of up to 12%. In addition, the regMVMT+ method
slightly performs better than the regMVMT method, maybe due to the more flexible modeling of
task relationships.
We then conduct experiments on the ECML2006 Email data set which consists of three task
and four views. There is one common vocabulary view that is shared by all the three tasks, while
each of the other three views is task specific and owned by only a particular task. Since the four
views are not shared by all the three tasks, it is equivalent to the case there are two entire views
missing from each of the three tasks. The experimental results of all methods are plotted in the
right panel in Figure 8.4. Our MVMT methods perform better than the three baseline methods
and the transductive MVMT method IteM2 with the margin of up to 7%, and repeated measures
t-test (paired two-sample t-test) demonstrates that the difference is statistically significant. All
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other similar trends are also observed. Since there are more missing views in each task, the overall
performance of all methods shrinks more significantly.
8.4.5 Task Relationship Modeling
We perform a case study to understand how our methods learn task relationships using the NUS-
WIDE Object data set with 11 tasks. For any two tasks, we calculate the pairwise correlation
using the fraction of samples that are simultaneously active or inactive to the two tasks. For the
regMVMT method, we calculate the learned relationship between any two tasks using the Gaussian
kernel of the !2 norm of the difference between their decision functions as in Eq.(8.5). We make
a 2D plot with each dot representing a pair of tasks, as presented in Figure 8.5. The correlation
coefficient R = 0.8978 reveals the learned task relationships (y-axis) are highly correlated to the
pairwise task correlation from the data (x-axis).

























Figure 8.5: Correlation analysis (regMVMT) on the Object data set.
Looking into the 11 tasks, we find that they form three clusters: animals (5 tasks), vehicles (3
tasks), and plants (3 tasks). We then apply the regMVMT+ algorithm on this data set and obtain the
matrices .v’s that model the task relationships of the 11 tasks. After taking the mean of all task
relationship matrices .v,v = 1,2, we obtain the learned task relationship matrix whose element
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(i, j) indicates the relationship index of task i and j. For each task in the animal cluster, we identify
the four most significantly correlated tasks, which are found mostly also the tasks in the animal
class with only two violations. For the vehicle class and the plant class, we also find two violations
that are not in the same class as the seed task, one in each class. The experiments demonstrate that
the regMVMT+ method can well model the task relationships through the learning process.
8.5 Conclusions
In this chapter, we proposed an inductive multi-view learning algorithm for multiple related tasks.
In our algorithm we developed a co-regularized framework. We utilized several regularization
functions to control the complexity of the learning algorithms. We also developed two extensions.
One handles structured missing views and the other handles non-uniformly related tasks. Experi-
mental results demonstrated that our MVMT methods significantly outperform the state-of-the-art
MVMT method IteM2 and other baseline methods. In the future, we will further extend our work
to different types of missing values.
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Chapter 9
Applying Inductive MVMT Learning for
Jointly Predicting Multiple ADRs
There are two major challenges in constructing effective models for ADR prediction. First, there
are many ADR-causing factors and the molecular mechanism of ADRs are usually not clear. The
adverse reaction profile of a drug depends on not only its chemical structure, but also its functional
groups, binding proteins, interacting drugs, and etc. Models constructed using only part of these
information sources may suffer from low accuracy and overfitting. Second, for each drug, it usu-
ally associates with multiple ADRs. The available data, however, are usually limited and noisy.
For instance, the SIDER database (http://sideeffects.embl.de) is a public digital resource
of adverse drug reactions [Kuhn et al., 2010]. SIDER contains information of 888 drugs and their
connections to 1,385 ADR terms. On average each drug is associated with "69 ADRs, and each
ADR is caused by "44 drugs. In this chapter, we present a unified framework to handel the afore-
mentioned two challenges and jointly predict multiple ADRs using the novel machine learning
approach described in Chapter 8, which we call as multi-view multi-task (MVMT) learning.
116
9.1 Introduction
For learning tasks with multiple sources of data (e.g. drug chemical structures and its interacting
protein profiles), multi-view learning [Sindhwani & Niyogi, 2005, Culp et al., 2009, Krishnapu-
ram et al., 2004] is a technique that aims to improve modeling quality in the presence of multiple
data sources. The underlying assumption is that multiple views present conditionally independent
information and the combination of the two information sources provides better modeling capa-
bility [Amini et al., 2009, Dasgupta et al., 2001]. Handling multiple labels, we utilize multi-label
learning to annotate multiple ADRs that may be associated with a single drug. Technically learn-
ing from multi-label data corresponds to finding a mapping from the feature space to the power
set of all labels, and the multiple labels have latent correlations between one another. In our study
we treat each label as a learning task and hence transform the multi-view multi-label problem as a
multi-view multi-task learning problem.
Little effort has been made toward integrating multi-view and multi-task learning into the same
learning framework so that the benefits provided by both algorithms retain. Cavallanti et al. [Cav-
allanti et al., 2010] proposed linear algorithms for online multi-task learning, but the features of
a single task do not form multiple views. He et al. [He & Lawrence, 2011] developed an effi-
cient graphical framework for transductive MVMT learning problems. However, this method was
mainly designed for text or document mining, and hence imposed a few constraints such as the
signs of features and the fraction of positive samples in training and testing sets. More general and
robust classification algorithms for MVMT learning problems are highly desired.
Here we propose a novel MVMT learning algorithm for predicting multiple ADRs jointly. In
our method one linear mapping function is learned for each view in each task, and the final model
for each task is obtained by averaging the prediction from the decision functions of all its views.
We first adopt a co-regularized multi-view [Sindhwani & Niyogi, 2005, Sindhwani & Rosenberg,
2008] model on each task by optimizing a convex object function that penalizes both the misclassi-
fication on labeled samples, and the disagreement among prediction from different view functions
on unlabeled samples in the same task. We then apply regularized multi-task learning [Evgeniou
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& Pontil, 2004] to enforce the multiple tasks to be similar on the same views, and learn all task
functions jointly. All the steps described above are integrated in a single objective function, and
the analytic solution are derived to optimize the objective function.
The main contributions of this work is the formulation of ADR prediction as a MVMT classi-
fication problem, and we achieve significantly more accurate predictive models. The rest of this
chapter is organized as follows. In Section 2, we briefly review related works on predicting ADRs
and some studies on multi-view learning. We explain our co-regularized MVMT algorithm in
detail and implement an efficient computer algorithm with pseudo code in Section 3. Then we
conduct thorough experimental studies on a data set of adverse drug reactions in Section 4 for
demonstrating the effectiveness of the proposed MVMT method, as compared to baseline learning
methods. Finally we conclude our work in Section 5.
9.2 Related Work
A variety of statistical methods on predicting ADRs have been in literature, such as analysis of
pharmacology data [Bender et al., 2007] or toxicity related proteins [Zhang et al., 2007]. Ursem
et al. applied QSAR and an expert system to FDA post-market reports for estimating the mecha-
nism of action of drug-induced hepatobiliary and urinary tract toxicities [Ursem et al., 2009]. Yang
et al. investigated clinical trial data with adverse event frequencies for kinase inhibition-related ad-
verse events prediction. A mini-review on this class of methods can be found in [Tatonetti et al.,
2009]. In addition, Ji et al. exploited in silico protein docking method (INVDOCK) to search for
putative ADR-related proteins and used these proteins as tools to facilitate adverse effect predic-
tion [Ji et al., 2006], resulting in a valuable collection of ADR-related proteins. Hammann et al.
developed structure-activity relationship analysis of ADRs in the central nervous system (CNS),
liver, and kidney, and also of allergic reactions for identifying drugs suspected of causing adverse
reactions, and then used decision tree modeling to determined the properties of compounds that
predispose them to causing ADRs [Hammann et al., 2010].
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The first MVMT work is proposed by He et al. [He & Lawrence, 2011], where a bipartite graph
of the features and samples is constructed for each view in each task. However, He et al.’s method
can only be applied to MVMT problems whose most (if not all) features have positive signs,
although many real-world data sets have significant amount of negative features. This transductive
learning method requires that the fraction of positive samples in training and testing sets must
be the same, and cannot be used on independent unknown testing sets. He et al.’s method treats
testing samples as unknown data in the training process, and hence the results are only in-sample
prediction. Our experimental study also confirmed the advantage of our methods over et al.’s
method.
Multi-view learning has been applied to many bioinformatics applications. For sample Culp
et al. [Culp & Michailidis, 2009] proposed a co-training algorithm for multi-view data with appli-
cations on drug discovery data fusion, and their aim is to link drug molecules with the diseases.
Sokolov et al. conducted multi-view prediction of protein functions in both a co-training and
transductive structured SVMs framework, incorporating with the structured output learning on the
multiple labels [Sokolov & Ben-Hur, 2011]. Here we report the adaptation of multi-view learning
for drug ADR prediction.
9.3 Methods
In this section, we present a multi-task learning algorithm with multiple view data, i.e., the co-
regularized multi-view learning algorithm that learns multiple related tasks jointly, and denote it
as regMVMT. The diagram of MVMT learning is shown in Figure 9.1. This algorithm has been
previously published in the KDD’12 conference by our group. Our contribution in this work is
to apply this MVMT method for predicting multiple adverse drug reactions jointly. Hence the
introduction and description of our proposed methods (regMVMT and regMVMT+) is omitted for
simplicity. For details of each method present in this chapter, refer to the Methods section in



















































Figure 9.1: Graphical representation of the MVMT learning framework for ADR prediction. FGC: function
group counts, SIG: molecular signature, PRO: protein binding profiles.
9.4 Results
In this section, we conduct a comprehensive experimental study of the regMVMT method and
compare it with three state-of-the-art baseline methods, and present the results in detail. The
baseline methods that we used are introduced below.
Regularized MTL (regMT): If we consider no co-regularization on different views in a given
task, we convert the MVMT learning problem into the single-view MTL problem [Evgeniou &
Pontil, 2004] by concatenating the feature vectors from all views to a single feature vector and
hence merging multiple views into one view. Comparison with this baseline method can help
demonstrate the benefits from using multiple views instead of a single view.
Co-regularized MVL (coMV): By ignoring the multi-task relatedness, we apply the co-regularized
MVL method [Sindhwani & Niyogi, 2005] on each task. The implementation is obtained by setting
the parameter # = 0 in the regMVMT formulation.
Multi-task Relationship Learning (regMT+): We may learn the task relationships among the
multiple related tasks from the input data when we consider no regularization on different views
in a given task. The implementation is obtained by setting the parameter µ = 0 in the regMVMT+
formulation.
Iterative MVMT (IteM2): We also compare our methods with the state-of-the-art MVMT
method proposed by He et al.. We implemented it according to the pseudo-code provided in the
IteM2 algorithm [He & Lawrence, 2011].
120
!2-regularized LSS (regST): If we apply no regularization on different tasks as in [Evgeniou &
Pontil, 2004], we obtain the most basic single-task learning method (!2-regularized least squared
loss): all views are merged into one view, and all different tasks are learned individually one by
one. The implementation is obtained by setting the parameter µ = 0 in the regMT formulation.
9.4.1 Data Sets and Feature Extraction
We collected the data set of adverse drug reactions from the Side Effect Resource (SIDER) database
[Kuhn et al., 2010]. SIDER is a public, computer-readable drug side effect resource with links be-
tween drugs and ADRs, obtained from the Drug Labels provided by the FDA with text mining
tools. We mapped the drugs in SIDER to the DrugBank database [Knox et al., 2011,Wishart et al.,
2008] via PubChem Compound ID and removed those drugs with trivial or too simple structures,
resulting in 797 drugs associated with 1,362 ADR labels, which are represented by the COSTART
controlled vocabulary. It would be difficult for our methods to handle such a large number of ADRs
simultaneously, and also some ADR labels have very few positive samples. We manually selected
12 ADRs which belong to three different classes: five for central nervous system (CNS) injury, four
for liver injury, and three for kidney injury. There are totally 494 drug compounds associated with
these ADRs, and we downloaded their chemical structures from DrugBank. To obtain unlabeled
samples for multi-view learning, we selected 2,400 drug related compounds from the PubChem
database, and these compounds were not found in the DrugBank or the SIDER databases. Here
drug related compounds are defined as the results by searching “drug” in PubChem. There are
no labels for these compounds but they are drug related. The distribution of positive and negative
samples in the 12 ADRs are summarized in Table 9.1.
We computed the descriptors of functional group counts using the DRAGON software (http:
//www.talete.mi.it) and the molecular signature descriptors proposed by Faulon et al. [Faulon
et al., 2004]. The descriptors of functional group counts focus on only a set of predefined func-
tional groups and convert a chemical structure into a vector whose elements are the count of each
functional group. The molecular signature descriptors enumerate all possible substructures with
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Table 9.1: The distribution of compounds associated with the 12 ADRs.
No. ADR Name #Positive #Negative
1 myocardial infarction 196 298
2 cardiac arrest 144 350
3 myocardial ischemia 68 426
4 ventricular tachycardia 85 409
5 congestive heart failure 128 366
6 diabetes mellitus 108 386
7 hepatomegaly 59 435
8 hepatitis 235 259
9 hepatic failure 121 373
10 interstitial nephritis 62 432
11 renal failure 149 345
12 renal insufficiency 56 438
the preset sizes in a chemical and convert each molecule into a vector whose elements are the
count of each such substructure. Refer to related publications for more detailed introduction to
these two feature extraction methods. These two sets of features are weakly correlated, and we
will investigate their contributions to our models when treating each set as a view.
The third set of descriptors that we extract is the protein binding profiles of the 494 drugs.
We extracted the protein binding profiles of these drugs from the STITCH database [Kuhn et al.,
2009]. STITCH is a data repository of interactions of chemicals and proteins. In STITCH, chem-
icals are linked to proteins by evidence derived from experiments, databases and the literature.
Specifically, the protein-chemical interactions present in STITCH are either imported from a set
of existing databases such as DrugBank and PharmGKB, or from text mining onto a consolidated
set of chemicals that has been derived from PubChem with a confidence score for each interaction
assigned. All human proteins in STITCH that are interacting with at least one of the 494 drug
compounds are identified and are merged into the same set. Each drug is converted into a binary
vector whose i-th element is 1 if the drug interact with the i-th protein in our list and 0 otherwise.
In summary, we obtained three set of descriptors for each compound: 116 functional group
counts, 341 molecular signature descriptors, and binding activity with 470 proteins. In the subse-
quent discussion, we call them the FGC view, the SIG view, and the PRO view, respectively.
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9.4.2 Model Construction and Evaluation
In our experimental study, we use different numbers of labeled samples in the range of 100-400
and about four times of labeled samples. For each subset, we first randomly select 20% labeled
samples as the independent testing set, and the remaining 80% labeled and all unlabeled samples
are for the training set. We apply five-fold cross validation and exponential grid searching on the
training set to optimize the parameters for each method discussed in this chapter: $ , µ and # for
regMVMT, $ and # for regMT, and $ and µ for coMV. For the IteM2 method, we simply use the
optimal values of parameter µ = 0.01 and b = 1 that are set in the original paper [He & Lawrence,
2011].
The set of model parameters that return the lowest mean classification error over all ADRs are
selected as the best parameters. We then use the full training data set to train a model and apply it
to the testing set and calculate the testing classification error. We repeat each experiments for 10
times, and report the mean classification errors and standard deviations with different numbers of
labeled samples. Here the classification error is defined as the ratio of the number of misclassified
samples over all samples in the testing set, i.e. 1% (T P+T N)/N, where TP, TN and N stands for
the true positives, true negatives, and total number of testing samples, respectively.
9.4.3 Preliminary Results
We first conduct a brief case study on the MVMT methods, the four baseline methods, and also a
few excellent single-view single-task learning methods such as support vector machines (SVMs),
decision tree (C4.5), and naive bayes. For each multi-view learning method we use 200 labeled
samples and 800 unlabeled samples, while for single-view methods all three views are merged
into one view and no unlabeled samples are used. We report the mean classification errors of each
method on each ADR as in Table 9.2. The regMVMT+ and regMVMT methods perform better
than other methods on almost all ADRs. Since SVM, decision tree, and naive bayes don’t provide
valuable comparison baselines, they are excluded from the subsequent experimental studies.
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Table 9.2: Classification errors using all three views with 200 labeled samples on the 12 ADRs.
Methods ADR1 ADR2 ADR3 ADR4 ADR5 ADR6 ADR7 ADR8 ADR9 ADR10 ADR11 ADR12
regMVMT+ 0.3012 0.2200 0.1020 0.1930 0.2300 0.2017 0.1175 0.2489 0.2100 0.0890 0.2650 0.1215
regMVMT 0.3100 0.2350 0.1150 0.2050 0.2400 0.2100 0.1075 0.2600 0.2050 0.0875 0.2850 0.1075
regMT+ 0.3260 0.2415 0.1321 0.2219 0.2415 0.2430 0.1400 0.2732 0.2525 0.1200 0.3200 0.1155
regMT 0.3300 0.2575 0.1425 0.2350 0.2525 0.2550 0.1400 0.2850 0.2475 0.1250 0.3100 0.1225
coMV 0.3275 0.2563 0.1375 0.2394 0.2750 0.2156 0.1294 0.2531 0.2506 0.1031 0.3000 0.1319
IteM2 0.3125 0.2975 0.1425 0.2650 0.2475 0.2175 0.1425 0.3175 0.2750 0.1325 0.2850 0.1475
regST 0.3550 0.2920 0.1698 0.2545 0.2700 0.2900 0.1720 0.2805 0.2775 0.1450 0.2950 0.1550
SVMs 0.3400 0.2800 0.1600 0.2475 0.2800 0.2925 0.1650 0.2725 0.2675 0.1300 0.3050 0.1450
C4.5 0.4101 0.3715 0.2344 0.3200 0.3623 0.3879 0.2436 0.3900 0.3580 0.2010 0.3775 0.1966
Naive Bayes 0.3588 0.3412 0.2100 0.2946 0.3320 0.3460 0.2202 0.3567 0.3200 0.1830 0.3505 0.1646
9.4.4 Comprehensive Experimental Study
We then conduct comprehensive experiments to compare our proposed MVMT methods with the
three baseline methods. In each experiment, we vary the number of labeled samples nL = 100,
150, ..., 400, and select unlabeled samples from the 2,400 drug related unlabeled samples with the
number nU = 4 ! nL. No unlabeled samples were used for the regMT method. We calculate the
mean and the standard deviation of the mean classification errors of all ADRs, and make plots of
the final mean classification error vs. the number of labeled samples for each method. Note that
the standard deviations are marked as error bars in each figure, and they represent the performance
variances of each method on different ADRs.
There are three views in our data set: functional group counts (FGC view), molecular signatures
(SIG view), and protein binding profiles (PRO view). We use different combinations of these three
views to obtain four subsets. For each subset we conduct experiments according to the protocol
described above with different numbers of labeled samples. First, all three views are used and
the results are presented in the upper left panel in Figure 9.2. Clearly the regMVMT method
achieves the best performance, and it outperforms the baseline methods with a margin of 4-5%
classification errors. When there are more labeled samples, the classification errors of all methods
gradually decrease, though the overall maximal magnitude is only about 3-5%, which demonstrates
that using more labeled samples improves the final models but the improvement is limited. The
regMT method generally performs slightly better than the coMV method. The competing method
IteM2 performs poorly with small and medium numbers of labeled samples, and it performs better
than regMT and coMV with large numbers of labeled samples. The regMVMT method consistently
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Figure 9.2: Mean classification errors using 100-400 labeled samples. Upper left: FGC + SIG + PRO view,
upper right: FGC + SIG view, lower left: FGC + PRO view, and lower right: SIG + PRO view.
outperforms the IteM2 method, and 02-test shows that the improvement is significant (P < 10%3).
Next we examine the three combinations of using two views and perform similar experiments
as above, and the results are plotted in the other three panels in Figure 9.2. As we discussed earlier
that the FGC and the SIG view are both extracted from chemical structures, and they are weakly
correlated. The upper right panel shows the experimental results when using these two views, and
the performance of all methods significantly decrease, and the advantage of the regMVMT method
over baseline methods also shrinks. The results reveal that the two views are not completely
independent and multi-view learning affords only limited performance gain. When we include the
protein binding profile view in our models, the performance of the regMVMT method also increases
and become comparable to the results when using all three views, as shown in the two lower
panels in Figure 9.2. Furthermore, we conduct experiments on the same data set of 12 ADRs using
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the extended MVMT method (regMVMT+) and the extended baseline method (regMT+). The
extended MVMT method slightly performs better than the counterpart method regMVMT for about
2% accuracy improvement. Though the improvement is marginal, it demonstrates the effectiveness
of task relationship learning. These experimental results show that the PRO view is critical for
ADR prediction. Nevertheless, the experimental results using all the three views are the best, which
demonstrates the causation of ADRs is related to functional groups, important substructures, and
protein binding profiles jointly.
9.4.5 Recovery of ADR Clusters
When we select the 12 ADRs, we intentionally collect them from three groups, and we aim to
examine if our MVMT method can effectively recover the three groups via cluster analysis. We
conduct experiments using 200 labeled 800 unlabeled samples, and repeat the experiments for 20
times. We calculate the mean decision function for each of the 12 ADRs, and perform K-means
clustering on the 12 ADRs using the coefficients in the decision functions as features for each
ADR. Results show that our MVMT method can successfully recover all three ADRs in the kidney
injury cluster, four of the five ADRs in the CNS cluster, and two of the four ADRs in the liver
injury cluster. Three ADRs (congestive heart failure, diabetes mellitus, and hepatomegaly) are
incorrectly clustered into the kidney injury cluster, resulting in a 75% accuracy of clustering.
We perform literature survey to investigate the three seemly misplaced ADRs, and results show
that all these three ADRs are also related to and/or cause kidney injury (cluster 3). Agrawal et
al. [Agrawal & Swartz, 2000] showed that acute renal failure in patients with congestive heart
failure occurs because of decreased renal blood flow caused by the latter, which confirmed that
congestive heart failure also causes kidney damage. Clinical studies [Soläng et al., 1999] predicted
that diabetes and congestive heart failure are highly correlated and there will be a considerable
increase in diabetes-related cardiovascular disease in the near future [Clark & Perry, 1999]. In the
kidney, damage resulting in the development of diabetic nephropathy (kidney damage secondary to
diabetes) may lead to kidney failure in extreme cases [Newman, 2005], and minor kidney damage
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in patients with type 1 diabetes leads to increased mortality. In addition, Nachar et al. [Nacher et al.,
2001] demonstrated that hepatomegaly is associated with jaundice with acute renal failure. All
these literature results verify that the three misclassified ADRs (congestive heart failure, diabetes
mellitus, and hepatomegaly) are not really classified in the wrong cluster (kidney injury) by using
the results of our MVMT methods. Due to the fact that the three ADRs cause injury on multiple
organs, clustering them into the kidney injury cluster using our MVMT method reveals the hidden
mechanisms.
9.4.6 Significant Features
From the results of the 20 repeated experiments above, we calculate the mean and the variance of
the decision functions for each ADRs. The Z-score of a feature is defined as the mean to variance
ratio of its coefficient, and it can be used to evaluate the significance of this feature to the final
models [Hastie et al., 2009]. A feature with the absolute value of the Z-score greater than 2.0 is
generally considered significant. Specifically, a positive (negative) Z-score means that it is more
statistically probable for a molecule with (without) the feature to have the ADR. We identify 19
such features that are significant to at least one ADR, including four functional groups and eight
human binding proteins. The five positively significant features are listed in Table 9.3.
Table 9.3: Some features significant to the ADR models.
Feature Z-score Adverse Drug Reaction
Ar-OR(functional group) 2.020 congestive heart failure
Brain-derived neurotrophic 2.194 hepatitis
factor precursor(BDNF)
DNA topoisomerase(TOP2B) 2.206 hepatic failure
Arginine vasopressin(AVP) 2.008 renal failure
Prostaglandin E(PTGES2) 2.236 myocardial infarction
Existing literature confirm the correlation of the identified significant features to their target
ADRs. For instance, protein TOP2B is found a commonly upregulated gene in intrahepatic cholan-
giocarcinomas [Obama et al., 2005]. Schrier et al. [Schrier & Wang, 2004] postulate that arginine
vasopressin (AVP) may have a protective effect on kidney function in patients with sepsis in their
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review acute renal failure and sepsis. Literature also show that congestive heart failure is highly re-
lated to prostaglandin E synthase 1 and 2 via unknown mechanisms [Wang & FitzGerald, 2010,Gi-
annico et al., 2005]. By identifying significant features using our MVMT learning models, we can
map adverse drug reactions into both chemical space (e.g. functional groups and molecular sub-
structures) [Scheiber et al., 2009] and biological space (e.g. protein binding profiles), and achieve
more insightful results.
9.5 Conclusions
Multi-view learning has been applied to many challenging machine learning and data mining ap-
plications, but almost all of them learn a single task at a time and are for binary classification.
There is a gap between our current understanding and the need of solving the more challenging
multi-view multi-task learning problem. Here we first formulate ADR prediction as a multi-view
multi-task learning problem, and then apply the previously described inductive MVMT algorithm
(regMVMT) and develop an effective algorithm to optimize the convex objective function. We con-
duct regularized MTL learning [Evgeniou & Pontil, 2004] by treating each ADR as a task, while
within each task one decision function is learned on each view and the co-regularized MVL [Sind-
hwani & Niyogi, 2005] approach is applied to the task. We further extend the regMVMT method
by learning task relationship from data, which allows the task relationships to positively or nega-
tively correlated, or uncorrelated. Experimental results show that the regMVMT+ and regMVMT
method outperform all the state-of-the-art baseline methods, while regMVMT+ is slightly better
than regMVMT due to learning task relationships. Moreover, recovery of ADR clusters and sig-
nificant feature identification reveals interesting hidden mechanisms underlying the causation of
ADRs. Note that the regMVMT+ and regMVMT algorithms become very inefficient and may use
up all memory when the number of tasks is large. Handling a large number of tasks in the MVMT
learning framework could be our future work plan.
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Chapter 10
Conclusions and Future Work
Adverse drug reactions represent a huge burden to the national public health care system, a lead-
ing cause of deaths to patients, and a major obstacle in drug development. Hundreds of billions
of dollars are spent on drug-related morbidity and mortality, over 100,000 deaths are caused by
ADRs, and about one third of late stage drug failures are due to adverse effects. Although ADRs
are not preventable, they can be anticipated and predictable. Effective prediction of ADRs is highly
challenging due to the fact that there are so many factors related to the causation of ADRs, includ-
ing drug chemical structures, functional groups, their interacting protein profiles, protein binding
sites, ADME/PK properties, and etc. In this thesis, we investigated the prediction of ADRs using
advanced machine learning techniques systematically from multiple perspectives.
We first analyzed a variety of feature extraction methods for chemical descriptors and com-
pared their performance, and then proposed a set of protein features extracted from human protein-
protein interaction networks. These network topological features are proven very effective for
identifying potential drug targets and off-targets. A further analysis of the BioAssay network
existing in PubChem data revealed some important observations for protein-chemical interaction
data (chapter 4). Although the chemical structures of all approved drugs are known, the links be-
tween ADRs and drugs are, however, highly noisy and sparse with errors, biases, and uncertainty,
as shown in online databases such as Arizona CERT (http://www.azcert.org/) and SIDER
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(http://sideeffects.embl.de/, which provide annotation links between approved drugs and
ADRs. As one of the most important ADR causing factors, the interacting protein profiles of most
drugs are incomplete. Hence we proposed two supervised learning methods for protein-chemical
interaction prediction using efficient multi-task learning techniques, and their performance is sig-
nificantly better than the state of the arts (chapter 5).
For effective ADRs prediction, we proposed a sparse multi-view learning method for predicting
a single ADR at a time (chapter 6). The ADR picked is drug-induced QT prolongation, which is
caused by the blockage of some important ion-channel proteins. We use features extracted from
drug chemical structures as the first view, and the ion-channel binding profiles of drugs as the
second view. The sparse MVL method outperformed many existing methods on predicting QT
prolongation using the noisy data set. The general binding protein profiles of drugs were also used
as the alternative second view, but the performance decreased. The work is the first attempt to
apply multi-view learning for ADR prediction, and our method is novel by introducing sparsity in
our models and hence improves the performance.
We further extend the MVL method to the multi-task learning framework so that multiple re-
lated ADRs can be predicted jointly (chapter 8). Three views were used: substructures, functional
groups, and interacting protein profiles (human protein only). A set of ADRs were selected and
each was treated as a task. The MVL method was applied to each ADR, and the decision func-
tions of all ADRs are enforced to be similar by regularized multi-task learning. Using a small
number of labeled samples and a large number of unlabeled samples, the MVMT learning method
outperformed all existing state of the arts significantly. We then improved our method to a more
generalized inductive MVMT learning algorithm that can handle missing views and more com-
plex task relationships, applied the new method to other real-world application, and also achieved
outstanding performance. This extension represents a significant contribution on methodology
development and has been published in a top conference (KDD’12).
There are also some limitations in our methods and implementations. First, our proposed
methods are all linear methods, which might be a reasonable approximation when the decision
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boundaries of the learning problems are not linear separable. Second, our MVMT methods can
only handle a relatively small number of tasks (up to 20) in the multi-view learning framework,
and learning a large number of tasks is challenging in this MVMT framework. Finally, there are
still some ADR-causing factors that are not included in the current models due to data availability.
All the limitations will be our future work plans.
In summary, this thesis represents the systematic efforts on effective ADRs prediction and
novel method development of relevant multi-task and multi-view learning in the past five years
of my Ph.D. study. The methods and results should be beneficial to the future research on ADR
prediction, and the tough training will be helpful to my future career.
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